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Thesis Abstract  
The Life Marker Chip (LMC) instrument is an antibody assay-based system which will 
attempt to detect molecular signatures of Life in the Martian subsurface as part of the 
payload on board the European Space Agency (ESA) ExoMars mission rover, currently 
scheduled for launch in 2018. The LMC will have the ability to detect up to 25 different 
molecular targets of different origins that are associated with meteoritic in-fall, extinct 
or extant Life, prebiotic chemistry and spacecraft contamination. Regolith / crushed 
rock samples will be collected for the LMC by the rover and subjected to solvent 
extraction to extract organic molecules for analysis by the immunoassays.   
One of the key stages in the development of the LMC is the selection of antibodies to be 
used in the flight instrument. The challenge lies in the nature of the molecules or classes 
of molecules that are LMC targets and the need for antibodies that remain functional in 
the extreme conditions during a planetary exploration mission, especially the radiation 
environments. 
The work described within focuses on two main aspects of the search for LMC-relevant 
antibodies; the effect of space radiation on antibody performance [in the form of both 
ground-based and Low Earth Orbit (LEO)-set studies] and the development of 
―customised‖ antibodies against some of the molecules that are being investigated as 
potential LMC targets. 
The need to study the effects of space radiation on antibodies arose due to lack of any 
heritage of their use in interplanetary missions. For all the antibodies in the LMC, the 
ability to resist inactivation due to space radiation seen during a Mars mission will be a 
prerequisite. The objective of the ground-based radiation studies was to expose a 
number of LMC-relevant antibodies to simulated Mars mission radiation in the form of 
proton and neutron radiation which are the components of the mission radiation 
environment that are expected to have the dominant effect on the operation of the LMC.  
Various combinations and multiples of the nominal mission fluence values that had 
been calculated via modelling of the radiation environment for a mission to Mars were 
used to demonstrate the effects of radiation on antibody activity, both at the actual 
radiation levels envisaged for the ExoMars mission and at much higher levels. Five 
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antibodies were freeze-dried in a variety of protective molecular matrices and exposed 
to various radiation conditions. After exposure, the antibodies‘ ability to bind to their 
respective antigens was assessed. At radiation levels equal to 1x times the mission dose, 
four antibodies out of the five maintained the majority of their binding activity, while at 
10x and 250x times the mission dose, the same four out of five antibodies maintained 
considerable amounts of their binding activity. The preparation and treatment 
(lyophilisation/rehydration) of the antibody samples were found to have a detrimental 
impact on their performance. These experiments indicate that the expected radiation 
environment of a Mars mission does not pose a significant risk to antibodies packaged 
in the form anticipated for the LMC instrument. 
The LEO radiation studies that are described were part of ESA‘s 2007 BIOPAN-6 Low-
Earth Orbit space exposure platform. Two representative LMC antibodies were used in 
the form of lyophilised samples integrated in glass fibre pads, loaded into a custom-
made sample holder unit which was mounted on the BIOPAN-6 platform. BIOPAN-6 
went into orbit for 12 days, after which all samples were recovered and their binding 
performance was measured via ELISA. The factors expected to affect antibody 
performance were the physical conditions of a space mission and the exposure to space 
conditions (i.e. the radiation environment in LEO). Both antibodies survived complete 
inactivation due to these factors. 
Phage display technology offers the possibility to rapidly generate high affinity 
recombinant antibodies against small molecules with poor immunogenic potential 
(haptens), like a number of prospective LMC target molecules. In the present work, a 
naive and an immunised phage antibody library have been employed in the production 
of recombinant antibodies against phytane and β-carotane. The naive library gave 
extremely poor results for both targets. The immunised library had been constructed 
after animal immunisation with a mixture of LMC targets, and resulted to the 
identification of phage clones that appeared able to recognise target conjugated to a 
carrier protein, without presenting cross-reactivity with the carrier proteins alone. 
Therefore phage display technology with the use of immunised libraries was considered 
an appropriate method to pursue for obtaining antibodies for the Life Marker Chip 
instrument. 
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Thesis Preamble – The Life Marker Chip Instrument 
The driving force behind the experiments that make up the present work has been the 
undertaking of the development of an instrument called the Life Marker Chip (LMC) by 
an international scientific consortium, lead by the University of Leicester and Cranfield 
University. The LMC is an antibody-based biosensor that will be part of the ExoMars 
mission, a joint initiative between the European Space Agency (ESA) and NASA, 
currently scheduled for launch in 2018. The mission belongs to a greater framework for 
Mars planetary exploration that has recently been announced by ESA and NASA. 
The LMC will be part of the Pasteur payload on board the ExoMars rover and it will 
have the ability to detect up to 25 different molecular targets of different origins that are 
associated with meteoritic in-fall, extinct or extant Life, prebiotic chemistry and 
spacecraft contamination. Regolith / crushed rock samples from up to four different 
locations can be collected for the LMC, which is designed to integrate sample 
processing and analysis into what is essentially an analytical laboratory in miniature. 
The Life Marker Chip reflects a rise in the interest in the use of immunoassays in Life 
detection experiments in extreme environments, with antibodies being considered very 
promising tracers of molecular signatures of Life (biomarkers) in the field of 
Astrobiology (Steele et al., 2001, Parro et al., 2005; 2011). The target selection for the 
LMC instrument was the result of an international biomarker workshop held in 2006 
(Parnell et al., 2007), where an attempt was made to compose a list of molecules that 
could constitute proof of the presence of Life, past or present, in light of the ExoMars 
mission. This list of potential targets included markers of present (extant) Life, markers 
of fossil (extinct) Life, molecules of meteoritic origin and contamination markers. For a 
more comprehensive description of some candidate LMC targets (including their 
chemical structures), see Appendix 1. 
One of the key challenges that had to be addressed in the LMC development process has 
been the selection of antibodies that have a combination of characteristics (sensitivity, 
specificity, resilience, etc.) that make them appropriate for use in the final (flight) model 
of the instrument. In contrast to antibodies that are developed for laboratory 
experiments, the LMC antibodies must not only detect their respective targets even at 
extremely low amounts in a sample, they must also maintain their performance quality 
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in the array of conditions envisaged for a planetary exploration mission, primarily in 
terms of space radiation. 
Within the LMC development framework, and given the factors that must be taken into 
account in order to acquire antibodies that can be used for the instrument, the present 
work focused on two main areas; the effect of space radiation on LMC candidate 
antibodies and the production of bespoke antibodies against LMC targets using phage 
display technology. The radiation studies were further separated in ground-based and 
Low Earth Orbit (LEO)-set experiments, the latter in the form of BIOPAN-6, an ESA-
sponsored experimental platform for the exposure of biological material to LEO 
conditions.  
Experimental Work Overview and Thesis Structure 
1.1 Ground-based Radiation studies (Chapter 2) 
During the course of these studies, the radiation environment envisaged for a mission to 
Mars was simulated using a cyclotron facility in Sweden. The proton and neutron 
components of the mission radiation environment are those that are expected to have the 
dominant effect on the operation of the LMC, and for this reason they were the radiation 
environment components that were used in these irradiations. A total of five LMC 
candidate antibodies were freeze-dried in a variety of protective molecular matrices and 
were exposed to the various combinations and doses of proton and neutron radiation. 
After exposure, the antibodies‘ ability to bind to their respective antigens was assessed 
using enzyme-linked immunosorbent assays (ELISA).  
 
1.2 Radiation studies in Low Earth Orbit (LEO) – BIOPAN-6 (Chapter 3) 
In September of 2007, various components of the LMC instrument, including two 
representative antibodies in lyophilised format, were put in LEO for a period of 12 days, 
as part of ESA‘s BIOPAN-6 platform for direct exposure of biological material to space 
conditions. This was an opportunity to test the antibodies‘ performance after exposure 
to a natural (non-simulated) space environment, as well as the combination of 
conditions that compose an actual space mission (launch, operation, re-entry where 
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applicable). After recovery of the samples, their ability to recognise and bind to their 
respective targets was assessed via ELISA.  
The BIOPAN experiments, though not directly comparable to the ground-based studies 
for a number of reasons (including the heterogeneity of a natural radiation environment, 
the doses of radiation the samples were exposed to and the addition of all ―actual 
mission factors‖), helped form a more complete view of the behavior of antibodies in a 
hypothetical planetary exploration mission setting.  
 
1.3 Development of recombinant antibodies using phage display technology (Chapter 
4) 
Phage display was used to explore its potential to produce recombinant antibody 
molecules against two of the ―difficult‖ LMC targets (phytane and carotane). This 
method offers the possibility to generate high affinity recombinant antibodies against 
small molecules with poor immunogenic potential (haptens). As a number of potential 
LMC targets are haptens, there is a need to have a standard method of anti-hapten 
antibody generation, and the traditional routes proved insufficient from an early stage of 
the LMC development. 
Two phage antibody libraries were used in these experiments; a naive library (which 
had not been constructed following animal immunisation with our particular targets) 
and an immunised library which had been specifically constructed against a mixture of 
LMC targets. The screening of the naive library for binders against phytane and 
carotane was performed initially, followed by screening of the immunised library. The 
quality of the results of the screening process was assessed using ELISA. 
1.4 Additional Notes on the Thesis Structure 
A final ―Discussion‖ section (Chapter 5) at the end of chapters 1-4 summarises the 
findings of the research work, along with conclusions that were drawn after 
consideration of these results.  
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It is important to note that instead of a separate chapter presenting a review of the 
literature and a standalone ―Materials and Methods‖ chapter, these sections for each of 
the three sets of experimental work were incorporated into the individual chapters (2-4), 
aiming to give the reader a better understanding of each cluster of experiments, their 
theoretical background and the details of their execution, before bringing all the data 
together in Chapter 5. 
 
 
Thesis Aims and Objectives 
1.5 Aims  
The main aim of the thesis was to consider aspects of antibodies within the early stage 
developments of the LMC. In particular, to contribute to the development of the LMC 
via (i) de-risking the concern that the radiation environment to be encountered by the 
LMC instrument would degrade the antibodies at the heart of the LMC or require 
additional radiation shielding mass that would make the overall LMC unviable and (ii) 
exploring the possibility of phage display recombinant antibody technology as a viable 
tool to produce antibodies against potential targets within the development schedule 
context of the LMC. 
 
1.6 Objectives 
Given the limited amount of data concerning the effects of particle radiation on proteins 
(antibodies), there was a need to study the effects of simulated space radiation on 
representative LMC candidate antibodies in order to confirm that they would be able to 
survive radiation conditions relevant to a Mars mission, provided they are appropriately 
packaged.  
The main objective of the ground-based studies was to expose a number of lyophilised 
antibodies to various combinations and doses of proton and neutron radiation, produced 
by a cyclotron source, at levels that would closely simulate those calculated via 
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modelling of the radiation levels expected during a mission to Mars. A further objective 
was to assess a number of lyophilisation matrices for their ability to retain antibody 
function during lyophilisation, storage, radiation exposure and rehydration. The antigen 
binding functionality of the antibodies was measured post-radiation exposure using a 
simple immunoassay approach and compared to a number of control samples that 
allowed correction for any effects of shipping (from Cranfield University to the 
Swedish cyclotron facility) and/or storage conditions on the exposed samples. 
The LMC experiment on BIOPAN-6 was complementary to the series of ground-based 
irradiations and offered additional information about the ability of antibodies to 
recognise and bind to their respective antigens after exposure to space radiation. By 
exposing antibodies to a heterogeneous (in composition and particle energy levels) 
radiation environment, the objective was to obtain a more accurate representation of the 
radiation situation of an actual mission to Mars. In addition to the primary radiation 
(protons, electrons, heavy ions), an additional LMC on BIOPAN objective was to 
evaluate the effect (if any) of secondary radiation and any spacecraft radiation sources 
on antibody performance.  
Given that the LMC antibodies had no history of space flight, another objective of the 
BIOPAN experiment was to assess the importance of the physical aspects of a space 
mission. These included the conditions during launch and re-entry (shock loadings, 
acoustic energy during launch etc.) and the general ground handling of samples, from 
the point of sample preparation all the way to recovery and analysis.  
In order to determine whether phage display could be the main method of acquiring 
antibodies against high priority LMC target haptens within the LMC development 
programme, the final cluster of work aimed to demonstrate the generation of 
recombinant antibodies against two potential LMC targets (phytane and β-carotane) 
with the employment of phage display technology. 
By using both a naïve and an immunised phage antibody library, their potential could be 
directly compared; the use of naïve libraries does not involve the construction cost and 
time delay of obtaining an immunised library, and could therefore prove more resource-
efficient if successful. Additionally, the naïve library which was used had been 
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constructed as an immunised library against another mixture of small molecules 
(lactone-type haptens), and this was seen as a chance to examine whether there would 
be any kind of positive bias in acquiring binders against our own haptens. 
Given that this was the first time that phage display technology was to be used in the 
context of the LMC development, the present work was also an opportunity to adjust 
and optimise the protocols related to the screening of the libraries to fit the requirements 
of specific targets, in order to isolate high-quality binders against them. 
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Effects of Simulated Space Radiation on 
Immunoassay Components for Life Detection 
Experiments in Future Planetary Exploration 
Missions 
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Introduction 
2.1 Use of immunoassays in Life detection experiments on the surface of Mars 
The driving force behind the radiation studies described in the present chapter is the on-
going development of the Life Marker Chip (LMC) instrument, which is part of the 
Pasteur instrument payload of the European Space Agency‘s (ESA) ExoMars rover 
mission. The ExoMars rover mission‘s primary goal is the search for evidence of past 
and/or present life on Mars and is currently scheduled to launch to Mars in 2018. The 
mission belongs to a greater framework for Mars planetary exploration that has recently 
(2009) been announced by ESA and NASA (Brown, 2009).  
The LMC is frequently described in the general media as a ―pregnancy test for Mars‖, a 
term which hails from the fact that both the LMC and commercial off-the-shelf 
pregnancy tests are based on lateral flow immunodiagnostic technology (Wilson and 
Howell, 2002). Thus the LMC uses (i) multiple dried-down fluorescently-labelled 
antibodies that (ii) dissolve into an aqueous-based liquid extract of a Martian regolith / 
crushed rock sample containing extracted organic molecules, and (iii) this initiates a 
multiplexed inhibition immunoassay before (iv) being flowed over a microarray 
composed of immobilised copies of the various multiplexed immunoassay targets. For a 
given antibody, (v) if the corresponding target molecule is present in the liquid extract, 
the antibody binding site is occupied and thus inhibited from binding to the 
corresponding microarray spot which (vi) subsequently does not fluoresce. Conversely, 
if the relevant target molecule is not present in the liquid extract, the antibody binding 
site is left vacant and therefore able to bind to the corresponding microarray spot which 
fluoresces. The immunoassay target molecules that are being chosen as LMC targets are 
those representative of ancient, preserved biomarkers of extinct life, biomarkers of 
extant life, those representing meteoritic input and other abiotic organic molecules as 
well as organic molecular markers of rover / instrument borne Earth contamination 
(Parnell et al., 2007).  
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2.2 Radiation environment during a mission to Mars 
All space missions inside and outside the Earth‘s magnetosphere are subject to a 
radiation environment harsher than that found at sea-level on Earth. Space radiation is 
therefore of concern as it could have a detrimental effect on antibodies and other 
molecular assay reagents which form part of instruments like the LMC; with this in 
mind, the radiation environment during a mission to Mars has been recently modelled 
using Monte Carlo simulations (Le Postollec et al., 2009a). A vital stage in the 
development of the LMC has been the study of the effects of space radiation on the 
biological, and chemical, assay components.  
The radiation field within the Earth‘s magnetosphere, despite being far from negligible 
for missions in Low Earth Orbit (LEO), is not significant in the context of a planetary 
exploration mission, as the payload will only be exposed to it for a very short period of 
time. The key radiation environments are limited to the radiation en route to a planet 
(cruise phase) and the radiation environment on the planet‘s surface (surface phase).  
Over a two-year cruise period to Mars, which was the transit duration for the original 
ExoMars mission circa 2006 (cruise phase duration is expected to be nine-months for 
the current mission design), the radiation environment to which all mission instruments 
are exposed is mainly due to Galactic Cosmic Rays (GCR) and Solar Particle Events 
(SPE). GCR exposure is expected to be approximately constant, while radiation 
associated to SPE will be more sporadic. (Hands and Rodgers, 2006). Modelling of the 
radiation environment during the transit phase using standard tools (SPENVIS and 
CREME96), determined that the dominant radiation threat would come from the SPE 
protons, followed by protons and high energy ions present in GCR (Hands and Rodgers, 
2006). 
On the surface of Mars, the radiation environment is composed of four types of directly 
ionising radiation; ultraviolet (UV), solar energetic particles (SEP) composed mainly of 
protons, galactic cosmic rays (GCR) mainly composed of stripped ions from hydrogen 
to uranium, and mineral radiation (MR). Estimations have been made for the surface 
radiation environment, as well as the one en route to Mars, and the findings suggest that 
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the proton dose received on the surface is very small compared to the dose while in 
transit, due to attenuation from the Martian atmosphere.  
An additional component of the Martian radiation environment, in the context of the 
operation of the LMC instrument, is the neutron environment. The neutron flux at the 
Martian surface is considerably higher than the proton flux and dominates over the 
previously mentioned radiation types (Hands, 2008). The Martian surface neutrons are 
produced as cosmic rays penetrate the thin Martian atmosphere, a process exacerbated 
by the lack of a magnetosphere like the Earth‘s, and reach the surface thereby 
interacting with elements in the upper layer of regolith and scattering secondary 
neutrons back towards space. 
 
2.3 Previous studies on the effects of radiation on biological systems  
The majority of recent studies on irradiation-induced alterations in biomolecules focus 
on the effects of gamma irradiation (usually from a 
60
Co source), since gamma ray 
treatment has applications in the sterilisation of medical supplies (Grieb et. al, 2002, 
Caballero et. al, 2004), the immobilisation of bioactive materials, food irradiation and a 
number of other uses, like the modification of antigenicity of certain proteins (Kume 
and Matsuda, 1995, Caproni et. al, 2007). The latter studies showed that radiation was 
able to affect the antigenicity of certain proteins as it resulted to conformational 
(denaturation) and physicochemical (aggregation) changes to the molecules. 
Additionally, the studies on the use of gamma irradiation for sterilisation purposes 
highlight the need for the use of radioprotective excipients, i.e. compounds that can 
increase stability prior, during and after irradiation (e.g. ascorbate – Grieb et. al, 2002). 
On a structural level, the effects of gamma irradiation on proteins have been extensively 
studied (Kempner, 2001), and the mechanism of damage can be either direct via rupture 
of covalent bonds in the protein molecules as a result of a photon depositing energy into 
the molecule, or indirect, with the participation of water molecules. In the second case, 
the production of free radicals and other non-radical reactive oxygen species (ROS) is 
responsible for the majority (99.9%) of the protein damage. Gamma irradiation of 
aqueous solutions in the presence of oxygen results in formation of hydrated electrons, 
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hydrogen atoms, hydrogen peroxides, and the most damaging hydroxyl radicals (SOH). 
Exposure of proteins to such generated ROS can alter the physical and chemical 
structure of the target causing consequent oxidation of side-chain groups, protein 
scission, backbone fragmentation, cross-linking, unfolding, and formation of new 
reactive groups (Zbikowska et al., 2006). 
 
A number of studies on the effects of ionising radiation on various proteins, carried out 
mainly in the 1980‘s, were reviewed by Kempner in 1993. Some of the main 
conclusions from this review were that exposure to high energy electrons or gamma 
rays results in covalent bond ruptures within proteins and that there is observable loss of 
protein activity after irradiation, regardless of the location of primary ionisation. 
Another issue was that irradiation itself may not directly disrupt the conformational 
relationships of complex protein structures, which are only affected when chemical or 
physical stress is applied to the system. In the context of the LMC development, where 
antibodies are always flown and stored in a lyophilised condition, this effect could 
manifest itself after they have been rehydrated.    
High-energy and high atomic number ions (HZE particles) have also been a subject of 
interest with regards to their effects on biological systems in light of future manned 
space missions. HZE particles as part of the GCR have been used in studies to assess the 
potential dangers to manned space missions (Hada et al, 2007, also reviewed by Held, 
2009). Their potential carcinogenic role has been investigated (Alpen et. al, 1994), as 
well as the ways they affect gene expression and cause DNA damage. The studies on 
the effects of HZE on the molecular level imply the presence of unique patterns of 
damage, depending on the identity and energy of the particles involved (Nelson, 2003), 
and there seem to be no data on the effect of high energy ions on the functionality of 
antibodies. 
A review of publications on irradiation of isolated / purified biomolecules, especially 
antibodies, exposed a general lack of research on the effects of particle irradiation 
especially when considering protons and neutrons, given their importance in the 
composition of the space radiation environment. We attribute this to the lack of medical 
and/or environmental applications driving the implementation of such studies and 
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therefore their current sole relevance appears to be driven by astrobiological questions. 
This topic has recently been addressed in the form of research on the effects of particle 
radiation on biological materials, given their potential importance to planetary 
exploration missions (Le Postollec et al., 2009b). This study examined the effect of 
neutron radiation on polyclonal antibodies and fluorescent dyes, and the conclusion was 
that this type of radiation does not result to loss of antibody functionality and has no 
effects on the intensity of the dyes. An additional step in the collection of information 
about the effects of particle radiation is being attempted in light of future manned 
planetary missions in the form of publications on potential cell damage due to space 
radiation (Durante and Manti, 2008, Hellweg et al., 2008, Held, 2009).  
2.4 Biological material integration in the context of the LMC 
For the LMC, two classes of molecular materials are of interest within the context of 
their stability to the cumulative radiation environment of a Mars mission. One class, 
fluorescent dyes, has been studied initially elsewhere (Thompson et al., 2006). The 
second class, antibodies, is the focus for the current work. For a number of reasons, an 
early decision within the design of the LMC was to integrate the core molecular 
materials of the immunoassays in dried or lyophilised (freeze-dried) state.  
In terms of molecular stability, antibodies are not considered extremely sensitive, as the 
disulfide bonds and intimate domain-domain interactions within the molecule make 
them more stable (e.g. to thermal stress) than other proteins They are, however, prone to 
a variety of physicochemical instabilities like aggregation, denaturation, deamidation, 
oxidation etc. (reviewed by Wang et al., 2007). For this reason, lyophilisation has been 
widely employed in antibody technology, in combination with a variety of protective 
excipients that are expected to increase antibody stability and resistance to denaturation. 
Among the protective additives, sucrose and NaCl are very common, with sucrose being 
considered preferable due to its tendency to form intimate H-bonds with the antibody 
and increase the glass transition temperature of formulation, making lyophilisation more 
effective (Wang et al., 2007). 
Lyophilisation is expected to increase storage life, especially where storage 
temperatures can include transient exposure to temperatures up to and above +40°C.  
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Furthermore, increased radiation resistance when compared to antibodies stored in 
hydrated formats is expected due to the elimination of radiolytic products of water 
molecules that can chemically degrade proteins.  
 
2.5 Study objectives 
Given the limited amount of previous experimental work on particle radiation effects on 
proteins, we were faced with the need to study the effects of simulated space radiation 
on the key biological components of the LMC (antibodies) in order to confirm that these 
materials would be able to survive radiation conditions relevant to a Mars mission, 
provided they are appropriately packaged.  
Thus, the primary objective of the present work has been to expose a number of 
lyophilised antibodies to various combinations and doses of proton and neutron 
radiation, produced by a cyclotron source, at levels that would closely simulate those 
calculated via modelling of the radiation levels expected during a mission to Mars. A 
further objective was to assess a number of lyophilisation matrices for their ability to 
assist in the preservation of antibody function during lyophilisation, storage, radiation 
exposure and rehydration. As a significant over test, a number of samples were 
irradiated at ten and 250 times the estimated mission doses with the objective to assess 
their ability to survive extreme radiation stress. The antigen binding functionality of the 
antibodies was measured post-radiation exposure using a simple immunoassay approach 
and compared to a number of control samples that allowed correction for any effects of 
shipping (from Cranfield University to the Swedish cyclotron facility) and storage 
conditions on the exposed samples. 
In summary, this study is aiming to provide experimental data that support the 
assumption that when suitably packaged, antibodies can survive exposure to the 
radiation environment expected to be encountered during a Mars mission and therefore 
de-risk this aspect of the LMC development. 
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Experimental Design, Materials and Methodology 
2.6 Experimental Design  
2.6.1.1 Estimation of radiation exposure during a Mars Mission 
The initial stage in the design of the experimental approach has been the calculation of 
radiation doses that would simulate the radiation environment en route to and on the 
surface of Mars. The calculated radiation doses for a Martian mission arose during a set 
of initial exposure experiments, carried out at the Paul Scherrer Institute (PSI) in 
Switzerland in 2007 (data not shown). 
As described previously, the dominant radiation threat to the LMC molecular reagents 
during a mission to Mars will be high energy protons during the mission cruise phase 
and neutron radiation during surface operations. Using standard modelling tools 
(SPENVIS and CREME96), the proton fluence for a two-year transfer phase was 
calculated with a 95% upper confidence limit at 2 x 10
10
 protons/cm
2
 (taking into 
consideration the proton attenuation due to a 4mm aluminium shield thickness which 
corresponds to the estimated shielding level within the ExoMars structure.) This fluence 
is polyenergetic; the protons have a variety of different energies and therefore in order 
to simulate this fluence with available cyclotron resources, normalisation of the energy 
spectrum to a single energy equivalent is required. Therefore the equivalent 60 MeV 
monoenergetic fluence was calculated at 5 x 10
10
 protons/cm
2
 (Hands, 2006). At 
approximately 50 MeV (which was the proton energy that would be used at the facility 
for the proton irradiations) this fluence is reduced [due to higher Linear Energy Transfer 
(LET) of the lower energy protons] to 4 x 10
10 
protons/cm
2
. This figure was doubled to 
provide a suitable minimum ―overtest‖ fluence of 8 x 1010 protons/cm2, corresponding 
to a total ionising dose of approximately 14 Krads (140 Gy) (Hands, 2008a).  
The neutron irradiation of the biological samples was introduced after modelling of the 
Martian radiation environment raised the issue of the effect of surface radiation (where 
the total secondary neutron flux is substantially greater than the proton flux) on the 
biological components of ExoMars. Modelling of the radiation environment on the 
surface of Mars was performed with the use of a Monte Carlo simulation. For a six-
month long operation on the Martian surface, the neutron dose was calculated, after 
15 
 
normalisation, at ~20 milliSieverts (mSv), which is equivalent to a fluence of 1.8 x 10
7
 
peak neutrons/cm
2
 (at the test facility used in these experiments), rounded at 2 x 10
7
 
neutrons/cm
2
 and doubled to give an experimental minimum test fluence of 4 x 10
7
 
neutrons/cm
2
 (equivalent to a one-year exposure period) (Hands, 2008a).  
In conclusion, the choice for the radiation doses that would be used in the present 
studies to simulate the relevant space radiation environments was based on modelling of 
the Martian radiation environment and a set of preliminary experiments, and in the case 
of proton irradiation the nominal mission dose was set at 8 x 10
10
 protons/cm
2
, while for 
neutron irradiation the nominal mission dose was set at 4 x 10
7
 neutrons/cm
2
. Wherever 
―mission dose‖ is mentioned from this point onwards, it corresponds to these values for 
proton and neutron irradiation respectively.  
 
2.6.1.2 Phased Ground-based Radiation Exposure Campaign  
The simulated Mars mission radiation studies were planned to take place in two stages, 
Phase I (February 2008) and Phase II (September 2008). The overall design for both 
phases was, as mentioned previously, based on a preliminary radiation study that took 
place at the PSI in 2007. The reasons for having two rounds of irradiations included the 
availability of antibodies against biomarkers of interest (availability of sample 
antibodies), the need for additional exposure time at the host facility and an increasing 
volume of information on improved lyoprotection and radioprotection methods for the 
antibodies. 
 
2.6.1.3 Choice of Radiation Levels  
The antibodies were to be exposed to various multiples of mission doses and 
combinations of proton and neutron radiation. The radiation levels that were chosen 
aimed to duplicate the doses calculated for the ExoMars mission and determine whether 
proton or neutron radiation would have the most significant effects on antibody 
functionality. 
In Phase I, the irradiations focused on investigating the effects of combined proton and 
neutron irradiation, both in doses simulating the ―mission dose‖ for ExoMars, and at 10 
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times these values, as an overtest aiming to test the antibodies‘ survival limits. Some 
samples would also receive the ―mission dose‖ of protons or neutrons in isolation to 
clarify, as mentioned, if either type of radiation would dominate the damage caused to 
the samples.  
Phase II was designed to provide further information about irradiation damage to a 
number of antibodies that were not available during Phase I, in addition to confirming 
the findings of the previous round for all antibodies that were used in Phase I. A further 
test during Phase II was the irradiation of antibody samples at 250 times the mission 
dose for protons, an extreme dose that would allow us to determine the higher threshold 
of exposure for antibody inactivation. Neutron irradiation at 250 times the ExoMars 
dose were not performed at this stage, as the effect of neutron radiation had been 
deemed negligible, after analysis of the results from Phase I. 
 
2.6.1.4 Selection of Antibodies for Study  
The decision on which antibodies would be used in the radiation tests was based on two 
main criteria; they had to be representative of the broad range of types of antibodies that 
could be included in the final format of the LMC and they had to be part of existing 
working assays within the lead authors‘ group. Consequently, priority was given to 
those antibodies that had been proven to function in immunoassay format, recognising 
and binding to their respective antigens with considerable sensitivity. Availability was 
another factor that affected the choice of antibodies for each round of experiments. 
Table 2-1 provides a list of the antibodies used in the present study and represent 
antibodies against a broad range of antigens – whole cell, protein and small molecule – 
as well as IgG antibody types – polyclonal, monoclonal and recombinant fragments and 
derived from a range of animal species. 
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Table 2-1:  Antibodies used in the ground-based radiation experiments (details given in Materials and 
Methodology section) 
Antibody Abbreviation Antigen/Target Production Method 
Rabbit IgG antibody against Chaperonin 
60 (GroEL) 
Anti-GroEL Chaperonin 60 (GroEL) Polyclonal 
Mouse IgG antibody against 
Staphylococcus aureus 
Anti-S. aureus 
Peptidoglycan from S. 
aureus 
Monoclonal 
Rabbit IgG antibody against Fluorescein 
Isothiocyanate (FITC) 
Anti- FITC 
Fluorescein 
Isothiocyanate (FITC) 
Polyclonal 
Rabbit IgG antibody against Phytanic Acid 
Anti-phytanic 
acid 
Phytanic Acid/BSA 
conjugate 
Polyclonal 
Sheep IgG derived antibody against 
Atrazine 
Anti-atrazine Atrazine 
Recombinant single-chain antibody 
fragment (scAb) 
 
2.6.1.5 Strategy for Sample Preparation 
From the initial stages of the LMC instrument development, it was decided that the 
antibodies would be integrated into the instrument as freeze-dried preparations and 
freeze-dried directly into laser-cut glass fibre pads. This format, in addition to the 
stability and radioresistance advantages it was expected to offer (mentioned earlier), 
facilitated antibody handling and integration during LMC assembly – i.e. assembly 
involved only handling a dry glass fibre pad containing pre-dosed and quality assured 
antibodies. This format was maintained during the radiation studies as it eased antibody 
handling and more importantly allowed radiation exposure in a flight-model 
representative format. Each antibody sample was freeze-dried into a separate pad and 
for each set of experimental conditions, three replicates of each antibody pad were used 
to confirm the reproducibility of the results. 
In order to increase the resistance of the antibodies to inactivation prior, during or after 
exposure to radiation, three protective lyophilisation matrices (solute mixtures) were 
used in the freeze-drying process, in addition to samples that were freeze-dried in the 
buffer solutions they were provided in by their manufacturers. These matrices were 
mixtures of sugars, proteins and free radical scavengers, which allowed us to assess the 
effectiveness of these additives on the stability and post-rehydration activity of the 
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antibody samples. The disaccharide (sucrose) and polymer (Blue Dextran) used in these 
mixtures were added as lyoprotectants, bovine serum albumin (BSA) served as an anti-
aggregation agent and Tween 80 is considered protective during freezing and thawing, 
and has been suggested to prevent protein adsorption to ice/water interfaces during 
freezing and assist protein refolding during thawing. Ascorbate is an effective radical 
scavenger (Niki, 1991). A detailed list of the reagents used in each matrix can be found 
in Table 2-2: The lyophilisation matrices used in the ground-based radiation studies and 
their respective components in detail.  
To ensure a uniform exposure of the pads to the radiation source, and further facilitate 
handling and shipping, the pads were loaded into 384-well microtitre plates, over an 
area that did not exceed the few cm diameter of the particle beam. Figure 2-1 shows a 
microtitre plate loaded with antibody sample pads.  
 
Figure 2-1: 384-well microtitre plate with antibody sample pads loaded in the central square area of 32mm x 
32mm (plate area is 12.5cm x 8cm) 
 
The antibody sample pads were stored in ambient atmosphere at ambient temperature. 
After being loaded, the microtitre plates were covered by a layer of aluminium foil. The 
plates‘ plastic lids were placed over the layer of aluminium foil and the lids sealed in 
place using masking tape. 
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In addition to the microtitre plates with samples for exposure to radiation, a number of 
control antibody pads were prepared and packed identically to the samples for exposure, 
i.e. antibodies freeze-dried into pads, loaded in microtitre plates. One set of controls was 
kept at Cranfield University, in ambient temperature and atmosphere, for the duration of 
the study prior to final analysis (―storage‖ controls). A second set of control pads were 
prepared and packed identically to the samples for exposure, and were shipped 
alongside them to the radiation facility, but not irradiated (―shipping‖ controls). Both 
sets of control pads were analysed in parallel with the radiation-exposed samples to 
determine differences in antibody functionality caused solely by exposure to radiation, 
after subtraction of the effects of the storage and shipping process on the samples.  
 
Materials and Methodology 
2.7 Antibodies and Lyophilisation Matrix Components 
The anti-GroEL antibody used in the radiation studies was purchased from Sigma-
Aldrich (cat. No G6532) at a stock concentration of 10 mg/ml and the single-chain 
antibody fragment against atrazine was provided by Immunosolv Ltd. (Aberdeen, 
Scotland) at a stock solution of 0.3 mg/ml. The mouse monoclonal antibody to 
peptidoglycan from Staphylococcus aureus was purchased from Abcam (cat. No 
ab20002) at a stock concentration of 1 mg/ml; as was the rabbit polyclonal antibody 
against phytanic acid (ab51309), at a stock concentration of 1 mg/ml. The rabbit-raised 
polyclonal anti-FITC antibody was purchased from Abcam (cat. No ab19491-100), at a 
stock concentration of 1 mg/ml  
The lyophilisation matrices were an important component of the radiation tests. Two 
matrices were used in Phase I; one of the mixtures included the dye Blue Dextran (‗Blue 
Dextran-based matrix‖) and the second mixture included sucrose (―Sucrose-based 
matrix‖) (Table 2-2). A third matrix was added during Phase II, a mixture including the 
dye Allura Red (―Allura Red-based matrix‖). The Allura Red matrix was included due 
to co-development of the LMC instrument, where Blue Dextran was found to interfere 
optically with the fluorescence-based immunoassay format used and the high molecular 
weight nature of Blue Dextran affected the viscosity of the resulting assay solution. 
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Hence, Allura Red was used as a visual low molecular weight tracer dye for microfludic 
development reasons and did not interfere with the fluorescence-based immunoassay 
format used. The list of components for the lyophilisation matrices included the bovine 
serum albumin (BSA) which was used in all three lyophilisation matrices and was 
purchased from Sigma-Aldrich (cat. No A4503), the HEPES buffer was also from 
Sigma-Aldrich (cat. No H7523), as was the sucrose (cat. No S7903), the Blue Dextran 
(cat. No D5751), Allura Red (cat. No 458848) and the ascorbate (Fluka - cat. No 
95210). Tween 80 was purchased from SAFC (cat. No W29, 170-6-K).  
Table 2-2 shows the components of each of the three lyophilisation matrices used in 
these studies. 
 
Table 2-2: The lyophilisation matrices used in the ground-based radiation studies and their respective 
components in detail 
Component 
Function 
Blue Dextran-based 
Lyophilisation Matrix 
Sucrose-based 
Lyophilisation Matrix 
Allura Red-based 
Lyophilisation Matrix 
Anti-aggregation 
agent 
1% w/v BSA 1% w/v BSA 0.05% w/v BSA 
Lyoprotectant 0.1% w/v Blue Dextran 1% w/v sucrose 10% w/v sucrose 
Free radical 
scavenger 
0.34 % w/v ascorbate 0.34% w/v ascorbate - 
Cryoprotectant - 1% v/v Tween 80 - 
Dye - - 0.005% w/v Allura Red 
Preservative - - 2% v/v Thiomersal 
Buffer solution 100 mM HEPES 
(pH 7.4) 
100 mM HEPES 
(pH 7.4) 
100 Mm HEPES 
(pH 7.4)  
For the ELISA reagents, the majority came from Sigma-Aldrich, including chaperonin 
60 (GroEL) (cat. No C7688), an inactivated S.. aureus cell suspension (cat. No S2014), 
an anti-mouse secondary antibody for the S.. aureus assay (cat. No A6782), phosphate 
buffered saline (PBS) tablets (cat. No P4417), Tween 20 (cat. No P7949), anti-rabbit, 
HRP-labelled polyclonal IgG (cat. No A6154), citrate-phosphate buffer with sodium 
perborate (cat. No P4922) and 3,3′,5,5′-Tetramethylbenzidine dihydrochloride (TMB) 
tablets (cat. No T3405). A phytanic acid/BSA conjugate was acquired from Abcam (cat. 
No ab51309). The FITC/BSA conjugate used in the FITC assay was from Sigma-
Aldrich (cat. No A9771), and the streptavidin/HRP conjugate used at the end of this 
assay was from Zymed Laboratories (cat. No 43-4323) at a stock concentration 0f 1.25 
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mg/ml; the secondary antibody used in this assay was a goat anti-rabbit Fc-specific 
biotinylated antibody from QED Biosciences (cat. No. 84400). An anti-rabbit, Fc region 
specific, HRP-labelled secondary antibody which was used in the phytanic acid assays 
was purchased from Novus Biologicals (cat. No NB7179). The blocking buffer for the 
ELISA was prepared with the use of skimmed milk from Marvel, while the 1M 
sulphuric acid was purchased from Fisher (cat. No J/8420/17).  
 
2.8 Preparation of glass fibre pads and sample integration 
The material for the glass-fibre pads was GF/D glass microfibre filters (47 mm ø) from 
Whatman. The 2 x 4 x 0.6 mm
3
 rectangular pads were laser-cut using a Fenix CO2 Laser 
Marker from SYNRAD. 6 μl of each antibody in buffer or in the lyophilisation matrices 
were allowed to fill each glass fibre pads by ejecting a drop from a pipette and allowing 
this to wick into a pad. This volume appeared to fully saturate a pad, as assessed by 
visual inspection. All the antibodies were used at the stock concentrations they were 
provided at by their manufacturers in the buffer-only pads, and at 50% dilution of the 
stock concentration in the pads where added matrices were present (3 μl stock antibody 
solution & 3 μl protective mixture). After the sample solution was added to each pad, 
the pads were immediately frozen by immersion into liquid nitrogen. Due to the pads‘ 
small size and little thermal inertia, it was observed that removing them from liquid 
nitrogen prior to the freeze-drying step of the process resulted in rapid thawing. The 
problem was overcome by keeping the frozen pads in liquid nitrogen, inside 20 ml 
plastic beakers which were then placed in the vacuum chamber of a bench top freeze-
drier (Coolsafe 55-4 bench-top freeze drier from ScanVac). Upon establishment of the 
vacuum inside the chamber, the liquid nitrogen quickly boiled away. The samples were 
dried overnight (approx. 12 hours). The lyophilised samples were then loaded into 384-
well microtitre plates from Nunc (cat. No 242765) within a central square area of 32mm 
x 32mm.  
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2.9 Radiation Exposure  
2.9.1.1 Exposure Facilities and Sample Transportation 
The two radiation test campaigns took place at the Theodor Svedberg Laboratory (TSL) 
in Uppsala, Sweden. The accelerator of the laboratory is the Gustaf Werner cyclotron. 
In addition to a mono-energetic proton beam which is capable of reaching energies up to 
nearly 200 MeV, the Blue Hall of the TSL has a neutron facility, devoted to component 
testing performed by customers from the private sector and departments of Uppsala 
University. The neutron beams are generated by the 
7
Li + p  ->  
7
Be + n  reaction, from 
which neutron beams are obtained that have particle energy spectra with a narrow-band 
high-energy flux-peak region, and a significant wide-band flux-tail region that extends 
from the peak region towards zero MeV (Prokofiev et al, 2007).  
The proton beam is collimated and the diameter is stable at 8 cm, with a top hat radial 
distribution. The neutron beam, which originates from a source point (a lithium target) 
is best described as cone-shaped, with a diameter of approximately 10 cm at the 
samples‘ distance from the source. With this data in mind, the samples‘ exposure to 
both radiation beams was considered uniform (in the case of the neutron beam, exposure 
is not uniform in theory, but given the samples‘ dimensions and distance from the 
source, this was considered a reasonable approximation). 
Given the calculated mission fluence of 4x10
10
 protons cm
-2
, which was doubled to 
8x10
10
 protons cm
-2
 to provide the minimum sample fluence, the minimum irradiation 
time would only be half a minute, given the fluence capacities of the TSL facility. This 
was viewed as impractical for this type of facility – where the beam control was indirect 
and remote – so during the experiments the flux was reduced by at least an order of 
magnitude to give a more manageable irradiation time per sample. For the neutron 
irradiations, the minimum exposure time was three minutes, taking into consideration 
the facility‘s capacity, but once again, the irradiation time was prolonged by decreasing 
the beam intensity. 
Phase I experiments were carried out between the 20
th
 and the 22
nd
 of February 2008 
and Phase II experiments between the 3
rd
 and 6
th
 of September 2008. The microtitre 
plates with the antibody samples were hand-carried (in passenger aircraft carry-on 
luggage; also subjected to security X-ray scanning) to TSL and returned the same way, 
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in order to avoid any physical or chemical alterations to the samples due to unknown 
storage conditions during transport that could occur with checked-in luggage or via 
couriers or other freighting methods. 
 
2.9.1.2 Details of radiation exposure  
In Phase I four sample loaded microtitre plates were exposed to various combinations 
and doses of radiation; ―Test Plate 1‖ received the combined ―mission dose‖ for protons 
and neutrons, ―Test Plate 2‖ received the proton mission dose only, and ―Test Plate 3‖ 
was irradiated at the mission dose for neutrons only. Finally, ―Test Plate 4‖ received 10 
times the combined proton and neutron mission dose. 
In Phase II, three radiation test plates were prepared and once again irradiated with 
different combinations and levels of radiation; ―Test Plate 1‖ receiving the combined 
mission dose for protons and neutrons, ―Test Plate 2‖ received 20 times the combined 
proton and neutron mission dose, and ―Test Plate 3‖ was irradiated at approximately 
250 times the calculated ExoMars mission dose for protons only. Table 2-3 and Table 
2-4 show a detailed description of the samples used in each Phase and each 
level/combination of radiation exposure. 
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Table 2-3: Outline of antibody samples used in Phase I of the ground-based radiation studies and the 
doses/combination of radiation each sample was exposed to 
Phase I: Plate Description and Radiation Dose 
Antibody Sample 
Anti-atrazine scAb 
Anti-GroEL 
ab 
Ab to 
S. aureus 
Control Plate 1 
Cranfield University Storage Control Plate 
3 pad replicates 3 pad replicates 3 pad replicates 
Control Plate 2 
Shipping Control Plate 
3 pad replicates 3 pad replicates 3 pad replicates 
Radiation Test Plate 1 
combined 2x ExoMars proton dose & 2x ExoMars neutron dose 
3 pad replicates 3 pad replicates 3 pad replicates 
Radiation Test Plate 2 
2x ExoMars proton dose 
- 3 pad replicates - 
Radiation Test Plate 3 
2x ExoMars neutron dose only 
- 3 pad replicates - 
Radiation Test Plate 4 
Combined 10x ExoMars proton dose &10x ExoMars neutron dose 
- 3 pad replicates - 
 
 
During both phases of the radiation studies, in the case of the proton irradiations, the 
energy range of the beam extended a few MeV around its peak value of 50 MeV. 
 
Table 2-4: Outline of antibody samples used in Phase II of the ground-based radiation studies and the 
doses/combination of radiation each sample was exposed to  
Phase II: Plate Description and Radiation Dose 
Antibody Sample 
Anti-GroEL 
ab 
Ab to 
S. aureus 
Ab to Phytanic 
acid 
Anti-FITC ab 
Control Plate  
Storage Control Plate 
3 Pad 
Replicates 
3 Pad 
Replicates 
3 Pad Replicates 
3 Pad 
Replicates 
Control Plate  
Shipping Control Plate 
3 Pad 
Replicates 
3 Pad 
Replicates 
3 Pad Replicates 
3 Pad 
Replicates 
Radiation Test Plate 1 
combined 2x ExoMars proton dose & 2x ExoMars 
neutron dose 
3 Pad 
Replicates 
3 Pad 
Replicates 
3 Pad Replicates 
3 Pad 
Replicates 
Radiation Test Plate 2 
combined 20x ExoMars proton dose & 20x ExoMars 
neutron dose 
3 Pad 
Replicates 
3 Pad 
Replicates 
3 Pad Replicates 
3 Pad 
Replicates 
Radiation Test Plate 3 
250x ExoMars proton dose 
3 Pad 
Replicates 
3 Pad 
Replicates 
3 Pad Replicates 
3 Pad 
Replicates 
 
25 
 
In the consideration of the possible errors during irradiation of the samples, their plastic 
casing, within the microtitre plates, should be taken into consideration, as it is thought 
to have a small degrading effect on the incident energy. Other potential errors included 
beam uniformity, beam control dosimetry, scattering effects and background radiation, 
although these factors were considered to be of negligible effect (Hands, 2008). Figure 
2-2 shows a sample-loaded microtitre plate about to be exposed to the neutron beam, in 
the TSL‘s Blue Hall. 
 
 
Figure 2-2: Sample-loaded microtitre plate (circled), clamped in place, about to be exposed to neutron 
radiation. Beam enters from the right side of the image. 
 
2.10 Radiation dose measurement  
In order to calculate the actual radiation dose that corresponds to each sample-loaded 
pad (2 x 4 mm
2
), the data used were those provided by the TSL facility and comprised 
the ―reference fluence‖ (which is the particle fluence at the beam exit point) and the 
―sample fluence‖ (which is the particle fluence at the mounted sample‘s distance from 
the beam exit point). Table 2-5 and Table 2-6 give the total doses per pad for the proton 
and neutron irradiations in Phase I and II. 
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Table 2-5: Proton and neutron fluences recorded for each radiation test plate during Phase I and calculated 
sample doses (reference fluence: measured at the beam’s exit point, sample fluence measured at approximately 
the test plate’s distance from the beam source, total number of particles per pad calculated using the pad’s 
dimensions 2x4 mm2)  
Phase I 
Proton 
Reference 
Fluence (p.cm-
2) 
Proton 
Sample 
Fluence 
(p.cm-2) 
Total 
Protons per 
Pad 
Neutron 
Reference 
Fluence (n.cm-
2) 
Neutron 
Sample 
Fluence 
(n.cm-2) 
Total 
Neutrons 
per Pad 
Relation 
to 
“mission 
dose” 
TEST 
PLATE 
1 
8.01E+10 8.01E+10 6.40E+09 6.11E+07 4.02E+07 3.20E+06 2x 
TEST 
PLATE 
2 
8.04E+10 8.04E+10 6.40E+09 - - - 
2x 
TEST 
PLATE 
3 
- - - 6.11E+07 4.02E+07 3.20E+06 
2x 
TEST 
PLATE 
4 
4.01E+11 4.01E+11 3.20E+09 3.03E+08 2.00E+08 1.60E+07 10x 
 
 
Table 2-6: Proton and neutron fluences recorded for each radiation test plate during Phase II and calculated 
sample doses (reference fluence: measured at the beam’s exit point, sample fluence measured at approximately 
the test plate’s distance from the beam source, total number of particles per pad calculated using the pad’s 
dimensions 2x4 mm2) 
Phase II 
Proton 
Reference 
Fluence (p.cm-
2) 
Proton 
Sample 
Fluence 
(p.cm-2) 
Total 
Protons per 
Pad 
Neutron 
Reference 
Fluence (n.cm-
2) 
Neutron 
Sample 
Fluence 
(n.cm-2) 
Total 
Neutrons 
per Pad 
Relation 
to 
“mission 
dose” 
TEST 
PLATE 
1 
8.01E+10 8.01E+10 6.40E+09 5.37E+07 3.63E+07 2.90E+06 2x 
TEST 
PLATE 
2 
8.07E+11 8.07E+11 6.40E+09 5.74E+08 3.89E+08 3.11E+07 20x 
TEST 
PLATE 
3 
1.00E+13 1.00E+13 8.00E+11 - - - 250x 
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2.11 Assessment of Remaining Antibody Binding Activity Post Radiation Exposure 
Once the irradiations were completed, the radiation test plates were hand-carried back to 
Cranfield University, where they were stored in the dark, at room temperature until their 
rehydration and ELISA testing, which for all samples took place within a three-month 
period after irradiation.  
 
2.12 Antibody Recovery from glass fibre pads 
For both Phase I and II the antibodies in the pads were rehydrated by being initially 
removed from the microtitre plate wells and each pad placed inside a 10 μl plastic 
pipette tip. This step provided a stable position for the pad (inside the internal taper of 
the tip) during the rehydration and wash-out process and prevented the pad from coming 
in contact with any pooled wash-out liquid. The 10 μl tips were then put inside 1.5 ml 
Eppendorf tubes. This facilitated the centrifugation step that followed and provided a 
means to collect the rehydrated material.  The rehydration protocol involved placing 6 
μl of PBS solution on the surface of each pad which wicked into the pad, followed by a 
centrifugation step using an MSE MicroCentaur centrifuge from DJB Labcare to allow 
collection of the rehydrated material from the pad. The procedure consisted of ten 
centrifuge runs of approximately one minute each, using 6 μl of PBS in each run, 
yielding a ~60 μl solution with an expected antibody dilution factor of 10, assuming 
100% wash-out efficiency.  
 
2.13 ELISA for assessment of remaining antibody binding activity 
The rehydrated solutions were used immediately in an ELISA, since preliminary 
experiments had shown they are unstable, even after a 24-hour storage period at +4
°
C. 
The enzyme-linked immunosorbent assays (ELISA) applied in the analysis of samples, 
followed the same protocol in all cases, the only variable being the antibodies and 
antigens used in each assay. The ELISAs were all binding assays, aiming to test the 
antibodies‘ ability to recognise and bind to their respective targets – no competition or 
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inhibition assays with free antigens was attempted. Table 2-7 shows the reagents used in 
each of the five different immunoassays performed at this stage. 
 
Table 2-7: Analytic overview of the reagents used in each of the immunoassays used to assess the antibodies' 
post-exposure performance 
 Immunoassays 
 GroEL S. aureus Phytanic Atrazine FITC 
Coating Antigen GroEL 
Inactivated S. 
aureus cells 
Phytanic acid/BSA 
conjugate 
Atrazine/BSA conjugate 
FITC/BSA 
conjugate 
Coating 
Concentration 
10 μg/ml 1 mg/ml 10 μg/ml 10 μg/ml 0.5 μg/ml 
Primary Antibody 
Dilution 
Dilution range 
of 1:20 to 
1:2x105 
Dilution range of 
1:100 to 1:1x106 
Dilution range of 
1:200 to 1:2x106 
Dilution range of 1:100 
to 1:1x106 
Dilution range of 
1:400 to 1:4x106 
Secondary 
Antibody 
anti-rabbit HRP-
labeled 
anti-mouse HRP-
labelled 
anti-rabbit Fc region-
specific HRP-
labelled 
anti-human kappa light 
chain, HRP-labelled 
goat anti-mouse 
biotinylated  
 
More specifically, ninety six-well polystyrene microtitre plates from Nunc were coated 
with antigen and incubated for one hour at room temperature. This comprised 100 μl of 
antigen solution added to each well and after the coating step the plates were emptied 
and tap-dried and unbound sites at the walls of the wells were blocked using a 1% (or 
5%) blocking buffer of Marvel skimmed milk in phosphate buffer saline (PBS). This 
comprised 200 μl of blocking buffer added to each well and the plates incubated for one 
hour at room temperature. Once the blocking was complete, the plates were emptied and 
tap-dried. The sample antibody solutions were then split in triplicate wells, serially 
diluted in accordance to each assay‘s working range, and a control assay was run in 
parallel using stock antibody solutions. This comprised 100 μl of sample/control 
antibody solution added to each well and the plates incubated for one hour at room 
temperature. Upon completion of this step, the plates were washed using a BW 50 plate 
washer from BioHit, and the washes consisted of three 200-μl 0.05% Tween 20 in PBS 
(PBST) washes. Then the enzyme (HRP) labeled secondary antibody was added, in an 
appropriate dilution, at 100 μl per well and the plates were incubated for one hour at 
room temperature. Another washing step of three 200 μl PBST washes followed. The 
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final stage of the ELISA consisted of the colour development reaction, using an HRP 
substrate of TMB in phosphate-citrate buffer. One hundred μl of this solution were 
added to all wells and colour was allowed to develop over 5-7 minutes (according to 
colour intensity). The reaction was stopped using 50 μl of 1M sulfuric acid, and the 
optical density of the samples was measured at a wavelength of 450 nm, using a 
VarioSkan Flash reader from ThermoScientific.  
 
Experimental Results  
Upon completion of the two radiation test campaigns, the ELISA results were collected 
and plotted with standard curves that were obtained from ELISAs using fresh stock 
solutions of all antibodies, i.e. in addition to the various sample sets including shipping 
and storage controls, in order to determine the degree of activity loss in each case. Each 
sample was represented in triplicate throughout the experiments; in the following 
figures, each data point corresponds to the average value of the three replicates.  
 
2.14 Phase I Results 
2.14.1.1 Effect of lyophilisation matrix on retention of antibody binding activity 
In Phase I of the radiation studies, the antibodies available for testing were the 
polyclonal antibody against the protein GroEL, the monoclonal antibody against S. 
aureus and the recombinant antibody against atrazine. All three antibodies were freeze-
dried in three formats: in buffer solution, in the Blue Dextran-based lyophilisation 
matrix and in the sucrose-based lyophilisation matrix. Due to availability limitations, 
only the anti-GroEL antibody was used in radiation plates 2 to 4. Figure 2-3 shows the 
ELISA results for all three antibodies, with the varying factor being the lyophilisation 
matrix used in each case (3A: anti-atrazine, 3B: anti-GroEL, 3C: anti-S. aureus). 
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Figure 2-3: Binding performance of the anti-atrazine (3A), anti-GroEL (3B) and anti-S. aureus (3C) antibody 
in various lyophilisation matrices measured at λ450 (“100% efficiency” refers to wash-out efficiency) 
 
From Figure 2-3 it becomes obvious that the monoclonal antibody to S. aureus (Figure 
3C) had the poorest overall performance, regardless of the lyophilisation matrix used. In 
the case of the anti-atrazine antibody (Figure 3A), there appears to be no significant 
differences between the controls and radiation-exposed samples, while the anti-GroEL 
antibody (Figure 3B) presents a clearer distinction of binding activity between controls 
and irradiated samples.  
 
2.14.1.2 Effect of varying radiation dose on retention of antibody binding activity 
As far as the effects of radiation are concerned, Figure 2-4 shows the performance of the 
anti-GroEL antibody in the sucrose-based matrix, after being exposed to various doses 
and combinations of proton and neutron radiation (for details, see Table 2-3). 
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Figure 2-4: Binding performance of the anti-GroEL antibody after exposure to various doses/combinations of 
radiation measured at λ450 (“100% efficiency” refers to wash-out efficiency) 
 
 
In Figure 2-4, the storage controls seem to be more active than the shipping controls and 
irradiated samples, a fact that could be attributed to transit X-ray scanners (airport 
scanners) and/or cosmic rays; another possible explanation would be any drastic 
changes in temperature during transportation that could result to decreased activity of all 
samples except the storage controls. 
 
2.14.1.3 Summary of antibody binding activity for Phase I 
In order to quantify the differences in each antibody‘s binding activity due to the use of 
specific protective matrices and/or irradiation, the data is summarised in Table 2-8. 
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Table 2-8: Binding activity retention (%) for all antibodies used in Phase I of the ground-based radiation 
studies (n/a: not available) 
 
Anti - Atrazine Antibody Anti - GroEL Antibody Anti - S. aureus Antibody 
Assay mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity (%) 
Assay mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity (%) 
Assay mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity (%) 
standard curve 0.16 100.0% 0.23 100.0% 0.12 100.0% 
buffer - storage plate n/a 0% n/a 0% n/a 0% 
buffer - shipping plate n/a 0% n/a 0% n/a 0% 
buffer - radiation plate 1 n/a 0% n/a 0% n/a 0% 
buffer - radiation plate 2 n/a 0% n/a 0% n/a 0% 
buffer - radiation plate 3 n/a 0% n/a 0% n/a 0% 
buffer - radiation plate 4 n/a 0% n/a 0% n/a 0% 
Blue Dextran - storage plate 8.65 1.9% 0.75 30.8% n/a 0% 
Blue Dextran - shipping 
plate 
7.53 2.1% 2.33 9.9% n/a 0% 
Blue Dextran - radiation 
plate 1 
8.38 1.9% 2.36 9.7% n/a n/a 
Blue Dextr n - radiation 
plate 2 
n/a n/a 3.69 6.2% n/a n/a 
Blue Dextr n - radiation 
plate 3 
n/a n/a 3.91 5.9% n/a n/a 
Blue Dextr n - radiation 
plate 4 
n/a n/a 4.47 5.1% n/a n/a 
sucrose - storage plate 11.11 1.4% 1.20 19.1% n/a 0% 
sucrose - shipping plate 24.81 0.6% 5.99 3.8% n/a 0% 
sucrose - radiation plate 1 18.69 0.9% 5.31 4.3% n/a n/a 
sucrose - radiation plate 2 n/a n/a 5.68 4.0% n/a n/a 
sucrose - radiation plate 3 n/a n/a 6.61 3.5% n/a n/a 
sucrose - radiation plate 4 n/a n/a 5.20 4.4% n/a n/a 
 
2.15 Phase II Results 
An important factor in the choice and preparation of samples for Phase II experiments 
was the availability of the various antibodies that would be used. The anti-GroEL 
antibody, which was available in considerable amounts and high concentration stocks, 
was used in Phase II in order to confirm the results obtained from Phase I, in addition to 
testing the protective effect of the Allura Red-based lyophilisation matrix which was 
being used in other aspects of the LMC development at the time. The monoclonal 
antibody to S. aureus was also used, albeit only lyophilised in the sucrose-based matrix 
(allowing further result comparison between Phase I and II). Two antibodies that were 
not used in Phase I were added to the sample set during Phase II; a polyclonal antibody 
against phytanic acid and a polyclonal antibody against FITC. Both antibodies were 
available in limited amounts, and priority was given to samples lyophilised in the 
sucrose-based matrix, which was considered the most efficient at the time of studies. An 
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error in the handling of the storage control samples rendered them unusable
1
; for this 
reason they are not included in the results of Phase II. Given the difficulty in repeating 
the experiments to replace the storage controls, and judging by the results in Phase I 
were the storage and shipping controls gave similar results, the shipping controls were 
considered adequate as variation control sample set. 
 
2.15.1.1 Effect of lyophilisation matrix on retention of antibody binding activity 
Figure 2-5 shows the ELISA results for the anti-GroEL (5B) and anti-phytanic acid 
(5A) antibodies; the former was freeze-dried in three different matrices (Blue Dextran-
based, sucrose-based and Allura Red-based), while the latter was lyophilised in the 
sucrose and Allura Red-based matrices only. 
 
                                                 
1 The storage controls were accidentally transported to Sweden with the shipping control samples. 
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Figure 2-5: Binding performance of the anti-phytanic acid (5A) and anti-GroEL (5B) antibody after 
lyophilisation in various protective matrices measured at λ450 (“100% efficiency” refers to wash-out efficiency) 
 
From Figure 2-5 it is obvious that the use of the Allura Red-based matrix resulted to 
higher signals than those obtained from the use of the sucrose-based matrix, while the 
Blue Dextran-based matrix appeared to result to the lowest signals out of the three 
matrices.  
 
2.15.1.2 Effect of varying radiation dose on retention of antibody binding activity 
Figure 2-6 shows the ELISA results for the same two polyclonal antibodies, anti-GroEl 
(6B) and anti-phytanic acid (6A), but this time the varying factor is the dose and 
combination of radiation that each sample was exposed to.  
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Figure 2-6: Binding performance of the anti-phytanic acid (6A) and anti-GroEL (6B) antibody after exposure 
to various doses/combinations of radiation measured at λ450 (“100% efficiency” refers to wash-out efficiency) 
 
The different reaction of antibodies to radiation-related stress is obvious in Figure 2-6, 
where the anti-GroEL antibody seems to maintain its binding activity even after 
exposure to 250 times the ExoMars envisaged proton radiation dose, while the anti-
phytanic acid antibody shows visibly reduced activity after being exposed to the same 
dose of radiation. 
Figure 2-7 shows the ELISA results obtained for the anti-S. aureus and the anti-FITC 
antibodies. Both of them were only freeze-dried in the sucrose-based matrix, so the 
varying factor in Figure 2-7 is the level of radiation to which each sample was exposed 
to. 
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Figure 2-7: Binding performance of the anti-S. aureus (7A) and anti-FITC (7B) antibody after exposure to 
various doses/combinations of radiation measured at λ450 (“100% efficiency” refers to wash-out efficiency) 
 
From Figure 2-7 it is clear that the two antibodies showed different levels of activity 
retention (compared with the standard curves which serve as an indication of the 
―maximum‖ antibody activity), with the anti-S. aureus antibody being heavily affected, 
similarly to Phase I.  
 
2.15.1.3 Summary of antibody binding activity for Phase II 
In order to quantify the loss of activity for all antibodies used in Phase II, the data was 
summarised in Table 2-9. 
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Table 2-9: Binding activity retention (%) for all antibodies used in Phase II of the ground-based radiation 
studies (n/a: not available) 
 
Anti - Phytanic Acid 
Antibody 
Anti - GroEL Antibody 
Anti - S. aureus 
Antibody 
Anti - FITC Antibody 
Assay 
mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity 
(%) 
Assay 
mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity 
(%) 
Assay 
mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity 
(%) 
Assay 
mid-
point 
(µg/ml) 
Retained 
Antibody 
Activity 
(%) 
standard curve 0.01 100.0% 0.23 100.0% 0.42 0.0% 1.49 100.0% 
Blue Dextran - 
shipping plate 
n/a n/a 37.37 0.6% n/a n/a n/a n/a 
Blue Dextran - 
radiation plate 1 
n/a n/a 38.38 0.6% n/a n/a n/a n/a 
Blue Dextran - 
radiation plate 2 
n/a n/a 52.18 0.4% n/a n/a n/a n/a 
Blue Dextran - 
radiation plate 3 
n/a n/a 80.81 0.3% n/a n/a n/a n/a 
sucrose - 
shipping plate 
0.07 14.5% 10.61 2.2% n/a 
0.0% 
2.68 55.6% 
sucrose - 
radiation plate 1 
0.07 13.5% 12.16 1.9% n/a 
0.0% 
5.19 28.7% 
sucrose - 
radiation plate 2 
0.06 15.6% 12.22 1.9% n/a 
0.0% 
4.95 30.1% 
sucrose - 
radiation plate 3 
0.64 1.5% 22.86 1.0% n/a 
0.0% 
76.70 1.9% 
Allura Red - 
shipping plate 
0.03 33.2% 2.56 8.9% n/a n/a n/a n/a 
Allura Red - 
radiation plate 1 
0.03 32.0% 2.66 8.6% n/a n/a n/a n/a 
Allura Red - 
radiation plate 2 
0.03 30.4% 2.58 8.9% n/a n/a n/a n/a 
Allura Red - 
radiation plate 3 
2.53 0.4% 4.95 4.6% n/a n/a n/a n/a 
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Discussion  
2.16 Limitations of chosen conditions to simulate a Mars mission 
The simulated conditions of a Martian mission, in this case the radiation environment, 
are subject to a number of limitations and approximations and can never be an entirely 
accurate representation of the events during a real mission.  
Thus in the present study, it is assumed that SPE-related proton radiation is the 
dominant threat en route to Mars, ignoring the radiation hazard by GCR ions, despite 
the fact that the heavy ion bombardment that is related to GCR is expected to be 
constant, while the presence of SPE protons will be more sporadic – the modelling 
assumed a worst case scenario with the ―worst week‖ case in the CREME96 model 
used. Similarly, the composition of the radiation environment on the surface of Mars 
was simplified to include only the dominant secondary neutrons, not taking into 
consideration the other types of radiation which are present (UV, mineral radiation, 
SPE-related protons, GCR). Some of these other types of radiation are blocked by the 
thin Martian atmosphere and others by the rover‘s outer shielding, making them 
secondary to the effect of neutron radiation. 
Mission duration is another factor to consider; for the purpose of modelling of the 
radiation environment is was assumed that the Earth-Mars transit phase would take 
place over a 2-year period, with an additional 6-month period of surface operation. This 
estimation was based on the early ExoMars mission design and is a significant over test 
of the current (circa 2010) ExoMars mission design which has a 9-month transit period. 
 
2.17 Assumptions and limitations of the estimated mission dose 
The present experiments were designed around estimated radiation doses during a 
mission to Mars that were the result of modelling of the radiation environment based on 
―worst case scenarios‖ for every type of radiation that forms part of this environment. 
Consequently, they do not necessarily offer a representation of the actual levels of 
radiation that will be encountered by the ExoMars mission. The advantage of this 
simulated environment is that it takes into account the maximum doses of radiation that 
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could be deposited on the mission instruments – it is therefore a suitable over test of the 
expected conditions. 
Dose deposition rates should also be mentioned, since in terms of an actual mission the 
total dose of radiation would be accumulated over the mission‘s duration period, while 
in the present experiments the samples were exposed to the same dose of radiation in a 
period ranging over some minutes, rather than months or years. The assumption is that 
the difference in the rate of deposition will not affect the outcome of the experiments.  It 
is however possible that a longer exposure time (for the same fluence) would result in 
reduced effects due to annealing of any radiation damage. 
 
2.18 Limitations of realisation of estimated mission dose via cyclotron facility 
The use of the Gustav Werner cyclotron at the TSL facility allowed the generation of 
high-energy particles that can be used in simulated space radiation experiments. 
However, the use of these facilities introduces additional limitations to the exposure 
conditions; space radiation is composed of particles of various energies (polyenergetic) 
and this cannot be duplicated easily with the use of the cyclotron, as the resulting beam 
is monoenergetic (or quasi-monoenergetic in the case of neutrons). For this reason, the 
entire spectrum of energies is narrowed down to a single representative value and the 
exposure time/runs are set based on this figure. This was a necessary compromise for 
both the proton and neutron irradiations, and was deemed a satisfactory way to simulate 
the radiation environment in question. 
Other issues with the use of the cyclotron had to do with a level of uncertainty 
concerning beam intensity, beam uniformity, beam control dosimetry, back-scattered 
effects and background radiation (Hands, 2008). These errors were considered 
negligible, compared to uncertainties related to calculation of mission doses and the 
safety margin which was introduced by doubling the modelled dose as an over test. 
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2.19 Choice of antibody integration method  
As mentioned in the Introduction and Experimental Design sections, antibodies were 
used throughout the radiation test campaigns in a lyophilised format. This decision was 
based on extensive data in the literature about the increase in shelf life and stability of 
antibodies when freeze-dried, compared to molecules in solution and was in accordance 
with the general strategy for antibody integration to the LMC instrument. Lyophilisation 
was also expected to increase resistance to inactivation due to radiation exposure, by 
eliminating, for instance the presence of radiolytic products due to the presence of water 
in a sample. The importance of an optimised procedure for lyophilisation, taking into 
account the physical and chemical degradations that samples are exposed to during and 
after freeze-drying, became obvious from preliminary studies with simulated space 
radiation (Paul Scherrer Institute, 2007 – results not shown), prompting significant 
changes in the freeze-drying protocols, and the addition of protective matrices.  
 
2.20 Lyophilisation matrix and glass fibre pads 
The antibodies were lyophilised into glass fibre pads in accordance to the envisaged 
final design format in the LMC instrument and in order to facilitate handling and 
exposure to the radiation source 
As far as the matrix that the antibodies were freeze-dried in, in addition to samples 
freeze-dried into the buffer solutions they were originally in (i.e. from their 
manufacturers), samples were lyophilised in various protective matrices, the 
components of which were chosen to offer both lyo- and radioprotection.  
It became obvious that samples that were lyophilised in buffer solutions handled the 
drying and recovery process very poorly, showing practically zero binding activity in 
subsequent ELISA (Figure 2-3). This data lead to a better understanding of the 
importance of the use of protective matrices, which have since then been integrated to 
all levels of sample preparation for the LMC instrument. 
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2.21 Sample rehydration and pad washout 
The rehydration of antibodies in order to assess the retention of binding activity after 
lyophilisation and radiation exposure was a process that was optimised in parallel to the 
design of the ground-based radiation studies. The importance of an efficient method for 
sample recovery lies in differentiating the effects of handling/freeze-drying from the 
standalone effect of radiation in many cases. Out of all lyophilised samples, the storage 
controls provided the most immediate measure of comparison to non-lyophilised 
antibody activity (standard curves), and the fact that an efficient wash-out protocol (pad 
washout studies demonstrated an efficiency of at least  40% - data not shown) was in 
place allowed us to assess the effect of the lyophilisation process alone, which, as can 
be seen in Table 2-8 and Table 2-9 is by no means negligible (the overall maximum 
activity retention was observed in the case of the anti-FITC antibody shipping control in 
the sucrose-based matrix at 55.6% of the activity of the non-lyophilised antibody). For 
the remaining antibodies, the anti-phytanic acid shipping control in Allura Red-based 
mixture showed the maximum retention of activity at 33.2%, the maximum activity for 
the anti-GroEL antibody was at 30.8% (Blue Dextran – storage control), for the anti-
atrazine antibody the maximum observed activity was at 2.1% (Allura Red matrix – 
shipping control) and finally the anti-S. aureus antibody appeared not to be active after 
recovery. A number of factors affecting wash-out efficiency may be associated with 
these results, e.g. basic instability of the proteins to freeze-drying and non-specific 
binding of antibodies to the various surfaces they interact with during handling. The 
dominant factor among the possible causes for these observations has not been clarified 
in the present study. 
 
2.22 Lyophilisation matrix effects 
Of the three protective lyophilisation matrices used in the present studies, the Allura-
Red based mixture was considered the most successful protectant (Figure 2-5) wherever 
used, based on the ELISA results obtained in each case, followed by the sucrose-based 
mixture. The Blue Dextran-based matrix gave poorer results than the other two matrices 
when it was used with the anti-GroEL antibody in Phase II (Figure 2-5A), but appeared 
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to offer more protection than the sucrose-based mixture in samples from Phase I (Figure 
2-3). This discrepancy could be due to slight differences in the preparation of the 
samples for the two different test campaigns (e.g. the use of different batches of matrix 
components and anti-GroEL antibody). The high efficiency of the Allura Red matrix 
could be attributed to the combination of compounds used in the mixture, e.g. the 
presence of Thiomersal as an antibiotic agent (not present in the Sucrose-based and 
Blue Dextran-based matrices). The absence of ascorbate from the mixture did not lead 
to any problems, implying that it is not essential for the preservation of antibody 
functionality. 
 
2.23 Radiation 
Without taking the effects of handling/recovery into consideration, the standalone effect 
of radiation exposure can be seen in Figure 2-4 (anti-GroEL antibody), Figures 2-6A 
and 2-6B (anti-phytanic acid antibody and anti-GroEL antibody) and Figure 2-7B (anti-
FITC antibody). For the anti-GroEL antibody, which was the one sample which was 
used in all combinations of experimental conditions, what can be said is that radiation 
exposure alone does not seem to affect its ability to bind to its respective antigen, 
provided a lyophilisation matrix was used in the sample preparation. Even at 250 times 
the proton radiation dose envisaged for the ExoMars mission, the majority of the 
antibody binding activity remains, compared to samples exposed to 2x and 20x 
ExoMars proton dose (>50% activity retention). Exposure to proton or neutron radiation 
(not combined) revealed that one type of radiation does not seem to have a more 
observable effect than the other; this is primarily because no significant effects were 
observed following any of these independent exposures and it confirms the conclusions 
of Le Postollec et al. (2009) about the effects of neutron radiation on antibody 
performance. 
In the case of the anti-phytanic acid antibody, significant loss of activity was observed 
at 250 times the proton dose, but no significant reduction of signal for the 20 times 
mission dose of protons. The behaviour of the anti-FITC antibody was very similar, 
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suggesting that the selected ―maximum‖ experimental proton dose (250 times) was 
close to the most intense radiation stress that these antibodies can handle. 
 
2.24 Antibodies 
The five antibodies that were used in the present experiments were both of polyclonal 
and monoclonal origin and also a recombinant single chain antibody fragment, as far as 
the production method was concerned. One of the initial questions raised was whether 
antibodies of the same type would react similarly to radiation exposure.  
Excluding activity loss due to sample preparation and handling, the three polyclonal 
antibodies (anti-GroEL, anti-FITC and anti-phytanic acid) proved radioresistant, with 
deactivation appearing at very high levels of radiation (250 times the nominal mission 
dose for protons). This was seen both for the anti-phytanic acid antibody (Figures 2-5A, 
2-6A) and the anti-GroEL antibody (Figures 2-5B, 2-6B). The anti-FITC antibody was 
not especially sensitive to the lyophilisation process (the ELISA results from the 
shipping controls showed less than 50% loss of binding activity) and maintained high 
levels of binding activity for 1x and 10x times the ExoMars combined dose of radiation, 
with activity loss observed at 250x times the ExoMars levels of protons (Figure 2-7B).  
For the monoclonal antibodies (anti-S. aureus and anti-atrazine scAb), the monoclonal 
antibody to S. aureus was very sensitive to lyophilisation and/or recovery from the glass 
fibre pads, and this concealed any standalone effects of radiation (Figure 2-7A). In the 
case of the anti-atrazine recombinant antibody fragment (Figure 2-3A), the 
lyophilisation process resulted to over 90% loss of activity, judging from the ELISA 
results for the storage controls. 1x combined ExoMars mission dose of radiation did not 
result to further loss of binding activity, suggesting that this single-chain antibody 
fragment is able to survive irradiation. 
From the ELISA results it is obvious that there is no stable pattern or trend in the way 
antibodies react to radiation exposure, even among antibodies of the same type 
(monoclonal/polyclonal). Despite these differences in performance, it was observed that 
all antibodies suffered various degrees of activity loss at extremely high doses of proton 
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radiation; the exact mechanism of this effect is not fully understood at this point, but a 
number of speculations can be made based on the combination of the design and 
outcome of the experiments. It is, for instance, believed that the lyophilisation of the 
antibodies prior to irradiation resulted to the elimination of water in the proximity of the 
proteins and reduced potential for secondary effects of radiation via the radiolysis of 
water molecules. Therefore it can be concluded that the major radiation effects on the 
antibodies were direct ones, after energy deposition on the molecule, either in the form 
of bond breakage or by the production of various reactive radical species. The loss of 
activity that was observed after irradiation with high doses of proton radiation can 
consequently be attributed to the higher probability of bond breakage in the presence of 
higher numbers of energetic particles (protons). 
 
2.25 Future studies 
The evolution of the present study will lead to a better understanding of the effects of 
space radiation on immunoassay components for future planetary exploration missions. 
The number of antibodies used in these radiation campaigns was a sub-set of the total 
library planned for the flight model of the LMC instrument. New antibody assays are 
under development and further representative antibodies should undergo similar testing 
to determine the effects of space radiation on their ability to bind their targets. 
Another set of experiments to consider for future testing could be ion irradiations of 
immunoassay components, in an attempt to simulate the effect of GCR ions on the 
operation of the LMC. The dose levels would be much lower than those for protons, but 
the damage coefficient is expected to be much higher. 
An area that requires further optimisation is the lyophilisation process. It became 
obvious from the results obtained from the irradiation studies that the majority of 
antibody activity is lost due to freeze-drying and/or recovering functional protein (>80% 
activity loss in most cases). Overcoming these issues will not only be beneficial for the 
following rounds of irradiation studies, but the overall development of the LMC 
instrument. 
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The ground-based radiation campaigns took place in parallel to an experiment to assess 
the antibodies‘ activity to survive exposure to actual space conditions in Low Earth 
Orbit (LEO). BIOPAN-6 was an experimental platform onboard ESA‘s Foton M3 
mission (2007), which went into LEO for 12 days and allowed direct exposure of 
biological material to space conditions. Two of the antibodies used in the present 
studies (anti-GroEL and anti-atrazine) were also used in the BIOPAN experiment and 
neither was deactivated due to exposure to these conditions – estimated to be one 
fifteenth of a total Mars mission dose for the BIOPAN-6 flight (see Chapter 3).  
 
Summary and Conclusions 
Overall, the ground-based irradiations of immunoassay reagents - specifically 
antibodies - at simulated radiation levels envisaged for the ExoMars mission to Mars, 
and also at much higher levels, have given valuable information and data input for the 
LMC development. It is apparent that the dominant effect on the loss of activity of five 
representative antibodies studied was the processing and packaging of the antibodies as 
freeze-dried preparations in glass fibre pads and their subsequent retrieval from the pads 
for use in ELISAs. The subsequent steps of international shipping of the samples to an 
irradiation facility and their irradiation typically contribute far less to the loss of 
antibody activity. Therefore, it is apparent that further studies of the freeze-drying, 
packaging and sample recovery process are required. Initial studies of varying the 
solutes co-freeze dried with the antibodies have displayed promise in improving the 
recovery efficiency. For the radiation effects, the important observation is that at a 
representative Mars mission dose, none of the antibodies studied exhibit any evidence 
of loss of activity due to the radiation. This therefore achieves a key de-risking step for 
the LMC instrument development process of demonstrating that the core antibody 
reagents will survive the radiation environment to be encountered on the ExoMars 
mission. Whilst this study de-risks the use of antibody-based assays in the exploration 
of the Red Planet, the noticeable loss of antibody activity at higher radiation levels 
(x250 Mars mission dose) does suggest that further shielding or alterative radiation 
protection approaches will need to be considered for some other astrobiology targets 
such as future Europa missions. 
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using the ESA BIOPAN-6 experimental platform 
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Introduction 
3.1 Preamble and Relationship to Ground-Based Radiation Studies 
The Life Marker Chip (LMC) instrument is an antibody assay-based sensor which will 
attempt to trace molecular signatures of Life in the Martian subsurface as part of the 
payload on board the ExoMars mission rover. The ExoMars mission, a collaboration 
between the European Space Agency (ESA) and NASA, is ESA‘s flagship mission to 
Mars, currently scheduled for launch in 2018. The LMC will be part of the Pasteur 
payload on board the ExoMars rover and it will have the ability to detect up to 25 
different molecular targets of different origins that are associated with meteoritic in-fall, 
extinct or extant Life, prebiotic chemistry and spacecraft contamination. Regolith / 
crushed rock samples from up to four different locations can be collected for the LMC, 
which is designed to integrate sample processing and analysis into what is essentially an 
analytical laboratory in miniature.   
The molecular reagents at the core of instruments such as the LMC have no heritage of 
interplanetary mission use. Therefore, the design of such instruments for space missions 
must take into account a number of risk factors, among which the intense radiation 
environment that will be encountered en route to, and on the surface of, planets. In order 
to study the effects of space radiation on lyophilised immunoassay reagents, primarily 
antibodies, a number of ground-based and space studies were carried out, the latter in 
the form of ESA‘s 2007 BIOPAN-6 Low-Earth Orbit (LEO) space exposure platform. 
The ground-based studies confirmed that representative LMC antibodies, pre-treated 
and packaged in the LMC-intended format, remain functional after exposure to levels of 
proton and neutron radiation that closely simulate those envisaged for a mission to Mars 
and even up to 250 times the ExoMars dose for proton radiation (Derveni et al., 
unpublished data – see chapter 2). Nevertheless, ground-based simulations of space 
radiation have their limitations. In an actual space mission, a body is exposed to a low 
flux of particles of a broad spectrum of atomic mass and energy, moving in various 
directions. In ground-based studies where accelerators are used, high fluxes of a single, 
monoenergetic source of particles are produced in a narrow, unidirectional beam 
(Horneck, 1992). In addition to the issues related to the composition of the simulated 
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radiation environment, ground-based studies offered no information concerning the 
performance of antibodies after exposure to the physical aspects of a space mission in 
terms of ground handling, launch, flight and possible atmosphere re-entry/recovery. 
This means that in order to study the effect of the full range of conditions that comprise 
a planetary exploration mission, ground-based simulations should ideally be combined 
with actual exposure to the environment in space. 
 
3.2 Biological Experiments in Low Earth Orbit 
Low Earth Orbit (LEO), which can generally be defined as the orbit between 0 and 2000 
km from the Earth‘s surface, is characterised by extreme environmental conditions 
(significant radiation field, high vacuum and extreme temperatures), which, aided by the 
advances in space technology, render it an important location for in situ space studies. 
Chemical and biological experiments in Earth Orbit have been taking place for the past 
40 years (reviewed by Horneck, 1998b & 1999), aiming to answer questions related to 
the molecular evolution of the interstellar medium, the possibility of interplanetary 
transfer of life and the importance of solar UV radiation in terms of pre-biotic and 
biological evolution. The majority of biological studies in LEO have focused on the 
physiological, genetic and biochemical response of a variety of microorganisms after or 
during exposure to space conditions. In the past, biological experiments in Earth Orbit 
have been part of a number of missions, including Gemini, Spacelab, LDEF, MIR and 
EURECA. The focal points of the European activities in this field include the 
experimental platforms BIOPAN (for short-term exposure to space conditions) and 
EXPOSE (for long-term exposure to space conditions on the ISS) (Schulte et al. 2007).  
One of the most recent reviews of microbiology in LEO points out that presently 
representatives of all three domains of life have been exposed to the environment in 
Earth Orbit (Olsson-Francis and Cockell, 2010) as part of experiments with a wide 
range of applications in future space exploration, including life support systems, energy 
sources and planetary protection. The materials for these experiments were whole active 
cells or spores, and even individual cellular constituents (plasmid DNA, amino acids, 
urea and purple membranes) (Dose et al., 1995), depending on the nature of the 
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experiment. With new planetary exploration missions underway, like ExoMars, new 
instruments are being developed, with components that have no history of exposure to 
space conditions, like the antibodies in the core of the LMC. The performance of 
lyophilised antibodies after exposure to a combination or even individual elements of 
the space environment has not been studied before and no data existed on their 
subsequent performance as molecular tracers. Given that the LMC antibodies will be 
effectively shielded from all aspects of a planetary mission (temperature extremes, 
space vacuum etc.) except for ionising radiation, it was considered an important early 
development issue to investigate their response to the radiation environment in LEO. 
This was to complement a series of ground-based studies of simulated ExoMars levels 
of proton and neutron radiation (Derveni et al., unpublished data – see chapter 2).  
 
3.3 The Radiation Environment in Low Earth Orbit 
The natural radiation environment in LEO is composed of charged particles of cosmic 
and solar origin and particles in the radiation belts trapped by the Earth‘s geomagnetic 
field (Stassinopoulos, 1988). Additionally, secondary radiation is produced from the 
interaction of cosmic rays with spacecraft shielding material, in the form of proton 
recoils, neutrons and other by-products (Wilson et al., 1993). The composition of the 
radiation environment is not constant; spatial and temporal variations are observed 
(Reitz, 2008). The intensity of the radiation exposure is also variable and closely related 
to a number of orbital (altitude, trajectory etc.) and technical (spacecraft shielding) 
aspects of a mission in LEO.  
The radiation exposure in LEO was described in detail by Reitz (2008), both inside and 
outside the spacecraft structure, i.e. in the presence or lack of, protective shielding. 
Radiation exposure inside the spacecraft is the result of the proton and heavy ion 
components of Galactic Cosmic Rays (GCR) and the protons inside the South Atlantic 
Anomaly (SAA), which is an area where a displacement of the axis of the geomagnetic 
field with respect to the axis of the geoid results to the radiation belt coming closer to 
the Earth‘s surface. This region is responsible for up to 90% of the total exposure in 
LEO (Horneck, 1992). Neutrons are also present, produced from the interaction of GCR 
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particles with atoms in the Earth‘s atmosphere. Outside the spacecraft, the dominant 
radiation elements are the electrons in the horns of the radiation belts located at a ±60
o
 
latitude at the Polar Regions (Reitz, 2008). 
 
3.4 The ESA BIOPAN platform for exposure of biological experiments to Low Earth 
Orbit conditions 
3.4.1.1 Current status of BIOPAN 
The BIOPAN multi-user experimental platform for the exposure of scientific 
experiments to space conditions in LEO was designed in 1990-1991 (Demets et al., 
2005). BIOPAN is a circular, pan-shaped aluminium structure (38 cm in diameter, 23 
cm in height, 27 kg mass) with a hinged lid that can open to 180
0
 in orbit. A number of 
experimental modules can be mounted on two experiment support plates (top and 
bottom layer) (Figure 3-1).  
 
 
Figure 3-1: Opening of BIOPAN-6 loaded with experiments at ESTEC in the Netherlands after flight and 
recovery (October 2007) 
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Once in orbit, the structure opens by telecommand to expose the experiments to space 
radiation and vacuum, microgravity and extreme temperatures, as well as unfiltered 
solar light. BIOPAN can carry a variety of experiments (typically 10 different 
experiments) of up to 3.5 kg in combined weight. The platform is mounted on the 
exterior of a FOTON retrievable capsule (Figure 3-2) and is thermally insulated from 
the capsule. During launch and re-entry BIOPAN is hermetically sealed and secured 
with a locking ring, while the whole structure is covered by an ablative shielding 
material to protect the experiments from the heat generated during launch and re-entry 
(Schulte et al., 2007). 
 
Figure 3-2: The retrievable FOTON capsule in LEO with BIOPAN exposing its contents to space conditions 
(red circle, top right) 
 
In order to monitor the environmental conditions during the mission in detail, BIOPAN 
is equipped with a suite of built-in sensors (in addition to researcher-provided detectors 
of various types), including thermometers, a broadband radiometer, UV-B and UV-C 
sensors and pressure sensors. All data is recorded and stored onboard. BIOPAN 
provides thermal control between +15ºC and +25ºC, with temperatures normally never 
exceeding the biologically critical limit of +30 to +35ºC. In addition to temperature 
consistency, the orbital parameters selected for FOTON missions are fairly similar, 
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allowing experiments to be repeated under comparable conditions (Demets et al., 2005). 
After landing and recovery, all the experimental samples are returned to their owners for 
analysis at their respective laboratories.  
 
3.4.1.2 History of the BIOPAN missions 
Between 1992 and 2007, six BIOPAN missions had been completed successfully on 
FOTON missions on board Soyuz rockets, with an additional one (BIOPAN-4) on board 
FOTON M1 being lost due to launcher failure in 2002. BIOPAN 1-4 were launched 
from the Plesetsk Cosmodrome in Russia, while BIOPAN 5 and 6 were launched from 
the Baikonur Cosmodrome in Kazakhstan. 
The BIOPAN platforms have each carried 4-9 experiments so far, covering four areas of 
research; astrobiology, chemical evolution, radiation biology and radiation dosimetry 
(Demets et al., 2005). In addition to the biological experiments carried on the BIOPAN 
platforms, the mission setup provides an opportunity to perform experiments in other 
fields or test new technologies to determine their performance in space and their 
resistance to the environmental extremes in LEO. Examples include a variety of 
electronics and diagnostic systems, sensors for ionising or UV radiation and the various 
components (antibodies, microarrays, fluorescent dyes) of the LMC (biosensor 
technology) (Schulte et al., 2007). 
 
3.4.1.3 Details and Description of BIOPAN-6 
BIOPAN-6 on board the FOTON M3 mission went into LEO on the 14
th
 of September 
of 2007 and was retrieved on the 26
th
 of September 2007. The unit used in BIOPAN-6 
was the refurbished unit from BIOPAN-5, after light modifications to accommodate the 
9 experiments (7 single-module and 2 multi-module experiments) it would carry. Table 
3-1 and Figure 3-3 provide details about the experiments on BIOPAN-6 and their 
location within the unit. 
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Table 3-1: List of experiments on BIOPAN-6 
Experiment Location Description/Subject 
UV-OLUTION I Unit Lid Chemical Evolution 
UV-OLUTION II Unit Lid Chemical Evolution 
LITHOPANSPERMIA Unit Lid Microbiology 
TARDIS Unit Bottom Microbiology 
ROTARAD Unit Bottom Microbiology 
MARSTOX & HIGHRAD Unit Lid Microbiology 
LIFE MARKER CHIP Unit Bottom Biosensor Technology 
YEAST Unit Bottom Radiation Biology 
RADO DEPTH DOSE Unit Bottom Radiation Dosimetry 
RADO NEUTRON DOSE Unit Bottom Radiation Dosimetry 
RADO PLASTIC Unit Bottom Radiation Dosimetry 
R3D-B Unit Bottom Radiation Dosimetry 
 
As with previous missions, the suite of instruments on board BIOPAN-6 corresponded 
to experiments of different nature and scientific context; some experiments had been 
included in previous BIOPAN missions (Marstox, RADO and R3D-B had also been 
flown in BIOPAN-5), while others, like the LMC experiment, had no previous LEO 
history. 
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Figure 3-3: Location of the various BIOPAN-6 experiments in the flight unit 
 
3.4.1.4 Space Radiation on BIOPAN  
The experiments inside BIOPAN are exposed to the radiation environment in LEO, 
predominantly solar radiation trapped in the inner radiation belt and in the SAA (South 
Atlantic Anomaly). The composition of this radiation field is dominated by electrons in 
the range of 100 keV to 5 MeV and protons in the range of 1 MeV to 30 MeV which 
have been captured by the Earth‘s magnetic field and form a uniform radiation 
environment due to gyration movement in the magnetic field (Taken from document 
titled Space Radiation in Biopan (author not given) downloaded from the ESA Biopan 
FTP server on 5
th
 June 2006). 
The radiation in LEO, with the exception of the SAA where anisotropic fluxes are 
observed, is isotropic; for this reason the slow rotation of the FOTON capsule along its 
longitudinal axis does not influence the irradiation of BIOPAN. The irradiation of 
BIOPAN depends on how the spacecraft trajectory intersects the magnetosphere of the 
Earth and on the timing of the mission within the 12-year solar cycle. The way the 
FOTON spacecraft crosses the magnetosphere depends on the orbital parameters 
selected for that mission (inclination, altitude and flight duration). Those parameters for 
FOTON are highly consistent: the orbital inclination is always close to 63º, the 
spacecraft always cruises at an altitude around 300 km and the flight duration is always 
62 
 
close to two weeks. This consistency is particularly important whenever repetition of 
experiments is required; experiments can be performed under conditions that are quite 
similar, with the exception of solar cycle events.  
As far as the absorbed dose of radiation is concerned for the experiments on BIOPAN, 
it was determined that shielding levels play a very important part in the protection of 
samples. It was observed that small changes in shielding density resulted to massive 
differences in the radiation dose received by samples. Over the first 0.05 g/cm
2
 of 
shielding mass the radiation dose falls steeply down by one order of magnitude, over the 
first 0.25 g/cm
2
 by two orders of magnitude, over the first 1g/cm
2
 by three orders of 
magnitude, while at shielding densities beyond 2.25 g/cm
2
 the absorbed radiation dose 
is more stable. For cosmic rays, it was observed that around 99.9 % was blocked by the 
first 1 g/ cm
2 
of shielding mass. This 99.9 % consists of the softer components of the 
space radiation spectrum (belt electrons and low-energy protons). The residual 0.1 % 
consists of high-energy belt & solar protons, high-energy heavy ions (HZE) and 
secondary particles like neutrons. 
Among the findings from BIOPAN-5 was the observation that the two parts of the 
BIOPAN unit (lid and bottom) did not receive the same dose of radiation, with the 
bottom part exposed to a lower dose (approx. 30% less), presumably due to partial 
―shading‖ by the cooling panels of the power supply unit (Fehér and Pálfalvi, 2008). 
The same authors reported that when the lid of BIOPAN is closed, more than 4.2 g per 
cm
2
 of additional shielding mass is placed in front of the experiment packages 
pertaining to the heat shield and parts of the lid structure. The closed lid results to a 
dose reduction by more than 99.9 %, whereby the influx of electrons and low-energy 
protons is completely blocked. This means that when BIOPAN is closed, the exposure 
to cosmic rays is comparable to the dosage received by experiments inside the satellite.  
 
3.5 Aims and Objectives 
The objective of the present work was to de-risk the employment of LMC-related 
immunoassay reagents – especially antibodies – in a planetary exploration mission 
instrument. The LMC experiment on BIOPAN-6 was complementary to a detailed 
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series of ground-based irradiations (see Chapter 2) and offered additional information 
about the ability of antibodies to recognise and bind to their respective antigens after 
exposure to space radiation. 
 By exposing antibodies to the radiation environment in LEO, which is not uniform in 
composition and particle energy levels, we were aiming to achieve a more accurate 
representation of the radiation situation of an actual mission to Mars. In addition to the 
primary radiation (protons, electrons, heavy ions), LMC on BIOPAN allowed the study 
of the effects of secondary radiation (a result of the interaction of primary radiation 
particles with the spacecraft structure) and any spacecraft radiation sources.  
The LMC on BIOPAN-6 experiment was also an opportunity to factor in the physical 
aspects of a space mission, as the LMC antibodies had no history of space flight. These 
included the conditions during launch and re-entry (shock loadings, acoustic energy 
during launch etc.) and the general ground handling of samples, from the point of 
sample preparation all the way to recovery and analysis. 
 
Materials and Methodology  
3.6 Experimental Design 
3.6.1.1 Selection of antibodies and strategy for sample preparation 
Two representative antibodies were used in the LMC experiment on BIOPAN; among 
the antibodies available at the time of studies (mid-2007), priority was given to those 
that existed within the lead authors‘ research group and had been confirmed to function 
in immunoassay format and recognise and bind to their targets with high sensitivity. 
The antibodies used were a polyclonal antibody against chaperonin 60 (GroEL) and a 
recombinant antibody fragment (scAb – single chain antibody) against atrazine. 
Chaperonin 60 and atrazine are both representative LMC targets and among the first 
assays to be developed from an extensive list of potential molecules that were of interest 
for the LMC instrument (Parnell et al., 2007) 
In accordance with the sample preparation strategy throughout the development of the 
LMC, the antibodies were packaged and exposed in a lyophilised state, freeze-dried into 
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laser-cut glass fibre pads. This format, in addition to the stability and radioresistance 
advantages it was expected to offer, facilitated handling during various steps of the 
LMC assembly, and was used both in the BIOPAN experiment and the parallel ground-
based radiation studies. Each antibody was freeze-dried into a separate pad and multiple 
replicates of each antibody pad were prepared, aiming to confirm the reproducibility of 
the results obtained. 
The strategy concerning the preparation of control samples that was used in the ground-
based experiments was also employed in the LMC on BIOPAN experiment; two sets of 
control sample pads were prepared, identical to the flight samples. These were a storage 
control set (kept at Cranfield University for the duration of the BIOPAN mission) and a 
shipping control set, transported to the Baikonur Cosmodrome in the same way as the 
flight samples but not flown on board the mission. The shipping control set was 
returned to Cranfield University along with the flight sample set at the end of the 
mission. All three sample sets were analysed in parallel in Cranfield University. 
 
3.6.1.2 Exposure of antibodies to space conditions 
The antibodies that were used in the LMC on BIOPAN-6 experiment had to be tested in 
a realistic simulation of the ExoMars mission. To this end, they were pre-treated and 
packed in an LMC-intended format and sealed in an inert gaseous atmosphere (no 
exposure to space vacuum). The gas chosen was argon, which would minimise the H2O 
and O2 content of the sample container and the gas pressure was constant at 1 atm.  
Temperature during launch and re-entry was not expected to be extremely high, due to 
BIOPAN‘s heat shielding and temperature controls on board, while low temperatures 
(in orbit) were not expected to be an issue for the LMC antibodies. 
Finally, as radiation exposure was the high-priority factor to investigate (except solar 
UV radiation, which is expected to be fully blocked by the structure of the ExoMars 
rover), it was decided that the antibodies would be exposed to space radiation under 
three different shielding thicknesses/materials. One of the shielding levels was deemed 
―zero shielding‖, blocking only UV radiation and helping to maintain the argon 
atmosphere around the samples, the second shielding level was labelled ―ExoMars 
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shielding‖, as it corresponded to the level of shielding provided by the ExoMars rover 
and the final shielding level was ―infinite shielding‖, which was expected to fully block 
all kinds of radiation, allowing the study of all other flight variables. The three shielding 
levels in detail can be seen in Table 3-2.  
Table 3-2: Types of shielding of the antibody samples in the LMC on BIOPAN-6 experiment 
Shielding Level Description Radiation Protection 
“Zero” shielding 125 μm Kapton ® foil 
Minimal (blocks UV radiation, 
maintains atmosphere) 
“ExoMars” shielding 
4 mm of aluminium & 125 μm 
Kapton ®  foil 
ExoMars rover equivalent 
“Infinite” shielding 
Stacked 4 mm of aluminium & 2 
mm of stainless steel & 125 μm of 
Kapton ® foil 
Maximises shielding within the size 
and mass constraints of the 
experiment (blocks all types of 
radiation) 
 
 
3.6.1.3 Dosimetry 
In addition to the radiation measurements performed by other instruments on board 
BIOPAN-6 (RADO, R3D-B), the LMC sample antibody pads were each loaded in the 
sample holder unit with an individual Al2O3 Optically Stimulated Luminescence (OSL) 
dosimeter, which would offer supplementary data on the radiation levels the samples 
were exposed to. By contrast to the RADO experiment, the operation of which is based 
on thermoluminescent dosimetry (TLD) where readout is based on heating, in OSL 
dosimeters the readout is performed by controlled illumination of the dosimeter.  
The operation principle of OSL dosimeters is based on electron/hole pairs created by 
exposure to ionising radiation and a fraction of these pairs elevated to the conduction 
band via ionisation becoming trapped in the OSL dosimeter structure. The subsequent 
recombination process leads to the emission of a light signal which can be detected. 
OSL dosimeters offer highly sensitive measurements, mainly due to the carbon doped 
aluminium oxide (Al2O3: C), which is their core component (Yukihara et al., 2006). The 
same authors report the use of OSL dosimeters (OSLDs) in space radiation 
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measurements for heavy charged particles (HCPs), where the OSL data combined with 
Linear Energy Transfer (LET) measurements are a practical way of characterising the 
radiation profile (total absorbed dose and dose equivalent) of a space mission.   
The dosimeters used in the LMC on BIOPAN-6 experiment were hand-cut Luxel+
® 
Al2O3: C dosimeters (2 x 4 x 0.3 mm
3
) from Landauer Inc, provided by the Oklahoma 
State University (OSU).  
 
3.7 Preparation of the LMC experiment for BIOPAN-6 
3.7.1.1 Provision of LMC experimental hardware  
A custom-made sample holder unit was prepared for the LMC on BIOPAN experiment 
by DLR (Germany). The machined aluminium (grade ISO 4762- M3x9-10.9) unit had 
two main parts; the base plate, with a number of cylindrical wells to accommodate the 
antibody-loaded glass fibre pads and a number of printed microarrays (not reported in 
this paper), and a top plate with areas of varying thickness (zero, 4mm Al and 4mm Al 
+ 2mm stainless steel) to correspond to the different shielding levels of the various 
samples.  The aluminium parts of the structure were passivated with an Alodine 1200 
treatment, while the stainless steel inserts were bonded in place with a two-part epoxy 
adhesive (Araldite AV 100/HV100). Sandwiched between the two plates was a 125 μm 
thick Kapton
® 
foil (grade HN polyimide film), aiming to seal the sample wells and offer 
a minimal level of radiation protection. Between the Kapton
® 
foil and the bottom plate 
of the unit, a Viton
®
 elastomer sheet gasket (grade GLT, 0.5 mm thickness) served as a 
gas-tight seal after mechanical clamping of the two parts with assembly bolts also 
provided by DLR. A schematic overview of the LMC on BIOPAN sample unit and a 
picture of the Development Model (DM) can be seen in Figure 3-4A and Figure 3-4B. 
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Figure 3-4: A. Design and B. Development Model of the sample holder unit for the LMC on BIOPAN-6 
experiment (latter prior to Alodine treatment) (image credits: DLR Germany) 
 
The final mass of the sample holder was 37.2 g prior to sample loading, at a volume of 
41 x 38 x 12 mm
3
.   
In addition to the flight model, a second identical unit was constructed and used as a 
shipping control sample holder. A machining oversight on the shipping control sample 
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holder resulted in the shielding level of one of the microarray sample wells being much 
lower than the correct thickness of 4mm.  
 
3.7.1.2 Preparation of glass fibre pads and sample integration 
The antibodies used in the LMC on BIOPAN experiment were an anti-GroEL 
polyclonal antibody from Sigma Aldrich (cat. no. G6532) (stock concentration: 10 
mg/ml) and a recombinant scAb against atrazine from Immunosolv Ltd. (Aberdeen, 
Scotland) (stock concentration: 5 mg/ml). The material for the glass-fibre pads was 
GF/D glass microfibre filter (47 mm ø) from Whatman. The 2 x 4 x 0.6 mm
3
 
rectangular pads were laser-cut using a Fenix Laser Marker from SYNRAD. Using a 
protocol identical to the one used in the preparation of samples for the ground-based 
studies, 6 μl of each antibody (in the buffer solution it was provided in by its 
manufacturer) were dispensed using pipettors and allowed to wick into the glass fibre 
pads. Assessed by visual inspection, this volume appeared to fully saturate the pad. 
Both antibodies were used at the stock concentrations they were provided in by their 
manufacturers. After the sample solution was added to each pad, the pads were 
immediately frozen by immersion into liquid nitrogen. Due to the pads‘ small size and 
practically no thermal inertia, it was observed that removing them from liquid nitrogen 
prior to the drying step of the process resulted in rapid thawing. The problem was 
overcome by keeping the frozen pads in liquid nitrogen, inside 20 ml plastic beakers, 
which were then placed in the vacuum chamber of a bench top freeze-drier (Coolsafe 
55-4 bench-top freeze drier from ScanVac). Upon establishment of the vacuum inside 
the chamber, the liquid nitrogen quickly boiled away. The samples were freeze-dried 
overnight (approx. 12 hours). 
The lyophilised samples were stored in Petri dishes secured with masking tape, in 
ambient conditions (ambient temperature and atmosphere) and kept in the dark until the 
assembly of the flight and storage control unit. 
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3.7.1.3 Assembly of flight model and shipping control unit  
The assembly of the flight sample holder unit and shipping control unit were performed 
in parallel in a class 100,000 clean room at Cranfield University on the 28
th
 of August 
2007. The assembly protocol was provided by DLR. The Luxel+
®
 dosimeters (Figure 
3-5A) were loaded in the cells at the bottom part of the unit first (1 dosimeter/well), 
followed by all the lyophilised samples (Figure 3-5B) and the printed microarrays.  
 
 
Figure 3-5: A. Hand-cut Luxel+ dosimeters (2 x 4 x 0.3 mm3) and B. Laser-cut glass fibre pad (2 x 4 x 0.6 mm3) 
for the LMC on BIOPAN-6 experiment 
 
For the antibody samples, three replicates of each antibody type were loaded into wells 
(one glass fibre pad per well) of the same level of shielding (3x ―zero‖ shielding, 3x 
―infinite‖ shielding and 3x ―ExoMars‖ shielding), in order to confirm the 
reproducibility of the results obtained. Once the sample loading was complete (Figure 
3-6A), the Viton
®
 gasket (Figure 3-6B), followed by the Kapton
®
 foil (Figure 3-6C) 
were put in their place over the sample area, before the cover plate was screwed in place 
(Figure 3-6D).  
B A 
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Figure 3-6: FM of the LMC on BIOPAN-6 experiment (A. unit loaded with samples, B. addition of Viton 
gasket, C. addition of Kapton foil, D. cover plate screwed in place). Note the “blue” squares at the top of A and 
B are microarrays printed on silicon nitride coated chips and the dark and light blue coloured glass fibre pads 
contain fluorescent dyes (Both fluorescent dyes and microarrays are not considered further in this paper). 
 
An important step in the assembly was the establishment of an argon atmosphere in all 
the sample-loaded wells in the unit, which was handled by assembling the sealing 
covers for the unit inside an argon-filled box. The progress of the assembly process was 
recorded in detail – both photographically and via video capture. The Shipping Control 
(SC) was assembled identically and both units were kept at Cranfield University prior to 
being transported to ESTEC in the Netherlands and finally Baikonur in Kazakhstan.   
 
 
D C 
B A 
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3.8 The flight of the LMC experiment on BIOPAN-6 
3.8.1.1 Transport from Cranfield to ESTEC 
After assembly, the FM and SC of the sample holder unit were hand-carried via ground 
transport (although subjected to security X-ray scanning due to use of the Eurostar / 
Channel Tunnel) from Cranfield University to ESTEC in the Netherlands, where all the 
BIOPAN-6 experiments were integrated on the exposure platform (5
th
 to 8
th
 September 
2007). The integration laboratory was a class 100,000 cleanroom and the room 
temperature was kept constant at +19ºC. Once the integration was completed, BIOPAN 
was stored in the TTC (Thermal Transport Container) at +13ºC between the 8
th
 and 10
th
 
of September 2007, before being transported to Kazakhstan (Schulte and Faulstilch, 
2008). 
 
3.8.1.2 Transport from ESTEC to Kazakhstan  
On the 11
th
 of September 2007, after 20 hours of transport, BIOPAN arrived at the 
Baikonur Cosmodrome in Kazakhstan, where it would be mounted on the descent 
module of the FOTON capsule. BIOPAN was integrated onto the FOTON capsule 
under ambient conditions (T inside BIOPAN after mounting and payload testing = +26 
to +29°C) (Figure 3-7). 
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Figure 3-7: The FOTON-M3 capsule prior to mounting on the Soyuz rocket at Baikonur Cosmodrome 
(September 2007) (BIOPAN-6 in the red circle) 
 
3.8.1.3 Launch of FOTON-M3 
The FOTON-M3 mission was launched from the Baikonur Cosmodrome on the 14
th
 of 
September 2007 at 13:00 (CEST) (Figure 3-8), with the lid opening in orbit 
approximately 3 hours later via a pre-programmed automatic mode (all mission timeline 
data from the BIOPAN-6 Mission Report, Kayser-Threde 2008). 
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Figure 3-8: Launch of the Soyuz rocket carrying the FOTON-M3 capsule with BIOPAN-6 (14th September 
2007) 
 
3.8.1.4 Orbit Phase 
In total, BIOPAN was in LEO for 11 days, 20 hours and 25 minutes (14
th
 to 26
th
 
September 2007). During orbital flight, the lid of BIOPAN remained open for 9 days, 
23 hours and 44 minutes, before the lid was closed by telecommand on 24
th
 September 
2007. For the duration of the flight, FOTON completed a full Earth orbit every 90 
minutes, at an altitude of 300 km (≈ 190 miles) from the Earth‘s surface.  
 
3.8.1.5 Re-entry and landing 
On 26
th
 September 2007, the re-entry capsule with BIOPAN-6 landed 150 km south of 
Kostanay in Kazakhstan (Figure 3-9). Shortly before landing, the FOTON capsule was 
separated from the service module, resulting to a power cut-off of BIOPAN‘s external 
supply until FOTON landed and BIOPAN was retrieved and connected to the constant 
temperature TTC. 
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Figure 3-9: Landing site of the FOTON capsule in Kazakhstan 
 
3.8.1.6 Platform recovery and transport to ESTEC 
Shortly after landing, the re-entry capsule was retrieved and BIOPAN-6 was 
disconnected from it and connected to the TTC (T = +12 to +13°C). Figure 3-10 shows 
the re-entry capsule at the landing site with BIOPAN-6 (red circle). 
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Figure 3-10: FOTON re-entry capsule at the landing site (BIOPAN-6 can be seen in the red circle, bottom 
centre)  
 
After retrieval, BIOPAN-6 was transported back to ESTEC in the Netherlands, where, 
between the 1
st
 and 2
nd
 of October 2007 the unit was disconnected from the TTC, the 
data from the various sensors on board were downloaded and the experiments were 
removed from BIOPAN-6.  
 
3.9 Sample recovery from the LMC experiment on BIOPAN-6 
3.9.1.1 Transport ESTEC-Cranfield 
After disassembly from BIOPAN-6, the LMC experiment was collected from ESTEC 
and hand-carried back to Cranfield University in the same manner it had been 
transported to the Netherlands. The SC unit was also collected and transported to 
Cranfield University, after having travelled to the Baikonur Cosmodrome and remained 
there for the duration of BIOPAN‘s orbital flight.  
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3.9.1.2 Opening of the FM and SC units and sample recovery at Cranfield University 
After arrival at Cranfield University, the FM and SC sample holder units were opened 
in a class 100,000 clean-room and the dosimeters and samples inside were recovered 
and stored until analysis. The dosimeters were removed first, in the dark, to prevent any 
illumination-induced alteration of the radiation data recorded (Figure 3-11A), followed 
by the antibody pads and microarrays (Figure 3-11B). Each pad and dosimeter was 
placed in a separate labelled container until their subsequent analysis.  
 
 
Figure 3-11: A. removal of dosimeters from FM and B. removal of glass-fibre pads from FM 
 
The glass fibre pads, after being removed from the sample holder units, were stored in 
separate labelled Eppendorf tubes, in argon atmosphere, in an attempt to maintain a 
stable environment, similar to that of the FM and SC wells. 
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3.10 Analysis of samples from the LMC experiment on BIOPAN-6 
3.10.1.1 Visual inspection 
The first step in the data recording from the LMC experiment on BIOPAN-6 was the 
visual inspection of the sample holder units during their disassembly and sample 
recovery. The assembly process, with the loading of samples and the sealing of the 
units, had been recorded in detail, allowing a direct before/after comparison of the 
visual condition of the hardware and samples. 
 
3.10.1.2 Sample Rehydration and ELISA 
The antibodies in the glass fibre pads were rehydrated using a protocol which was 
developed during the ground-based radiation studies; initially, each was placed inside a 
10 μl plastic pipette tip. This step prevented the pad coming in contact with any surface 
that could retain the newly-rehydrated antibodies and provided a stable position for the 
pad during the rehydration process. The 10 μl tips were then put inside 1.5 ml 
Eppendorf tubes. This facilitated the centrifugation step that followed and provided a 
means to collect the rehydrated material.  The rehydration protocol involved placing 6 
μl of phosphate buffered saline (PBS) (Sigma Aldrich – cat. no. P44I7) on the surface of 
each pad and allowing this to wick into each pad, followed by a centrifugation step 
using an MSE MicroCentaur centrifuge from DJB Labcare to flush out and recover the 
buffer. The procedure consisted of ten centrifuge runs of approximately one minute 
each, using 6 μl of PBS in each run, yielding a ~60 μl solution with an expected 
antibody dilution factor of 10, assuming 100% wash-out efficiency.  
These solutions were used in Enzyme Labelled Immunosorbent Assays (ELISA). The 
ELISAs were all binding assays, aiming to test the antibodies‘ ability to recognise and 
bind to their respective targets.  
Ninety six-well polystyrene microtitre plates from Nunc (Microplate Immuno 
Maxisorp, cat. no. DIS-971-030J) were coated with antigen with a working 
concentration of 10 μg/ml and incubated for one hour at room temperature. The antigen 
was Chaperonin 60 (GroEL) (Sigma Aldrich – cat. no. C7688) for the anti-GroEL 
antibody and an atrazine/BSA conjugate (purchased from GBC – Aberdeen, Scotland) 
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for the anti-atrazine antibody. 100 μl of antigen solution were added to each well. After 
the coating step the plates were emptied and tap-dried and unbound sites at the walls of 
the wells were blocked using a 1% (or 5%) blocking buffer of skimmed milk powder 
(Marvel brand) in phosphate buffer saline (PBS). 200 μl of blocking buffer were added 
to each well and the plates were incubated for one hour at room temperature. Once the 
blocking was complete, the plates were emptied and tap-dried. The sample antibody 
solutions were then split in triplicate wells, serially diluted in accordance to each 
assay‘s working range. 100 μl of sample antibody solution were added to each well and 
the plates were incubated for one hour at room temperature. Upon completion of this 
step, the plates were washed using a BW 50 plate washer from BioHit, and the washes 
consisted of three 200-μl 0.05% Tween 20 (Sigma Aldrich - cat. No P7949) in PBS 
(PBST) runs. Then the secondary antibody was added, in an appropriate dilution, at 100 
μl per well and the plates were incubated for one hour at room temperature. The 
secondary antibody in the case of the GroEL assay was an anti-rabbit, HRP-labelled 
polyclonal antibody (Sigma Aldrich - cat. no. A6154) and the secondary antibody in the 
atrazine assay was an anti-human kappa light chain HRP labelled antibody (Sigma 
Aldrich - cat. no. A7164) (the recombinant single chain antibody was constructed with a 
human kappa light chain framework domain). Another washing step of three 200 μl 
PBST washes followed. The final stage of the ELISA consisted of the colour 
development reaction, using an HRP substrate of TMB (3,3′,5,5′-Tetramethylbenzidine 
dihydrochloride tablets – Sigma Aldrich - cat. no. T3405) in phosphate-citrate buffer 
(Sigma Aldrich – cat. no. P4922). 100 μl of this solution were added to all wells and 
colour was allowed to develop over 5-7 minutes (according to colour intensity). The 
reaction was stopped using 50 μl of 1M sulphuric acid (Fisher Scientific - cat. no. 
J/8420/17), and the optical density of the samples was measured at a wavelength of 450 
nm, using a VarioSkan Flash reader from ThermoScientific. 
 
3.10.1.3 Dosimeter Readout 
All dosimeters from the LMC on BIOPAN experiment were removed from the sample 
wells in the sample holder units and stored in individual Eppendorf tubes wrapped in 
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aluminium foil to avoid accidental exposure to light and data alteration. They were then 
shipped to the Oklahoma State University for their controlled illumination readout. 
 
 
Results 
3.11 General mission sensor data 
The various sensors on board BIOPAN stored data throughout the mission, which were 
collected after the unit‘s retrieval. A set of data collected by these sensors are shown in 
Table 3-3, reflecting the environmental conditions in which the LMC on BIOPAN-6 
experiment with all the antibody samples was exposed to (Schulte and Faulstich, 2008).  
The temperature measurements for the experiments at the top lid and the bottom of the 
BIOPAN platform were considerably different; the temperature values presented in 
Table 3-3 correspond to the experiments at the bottom part of BIOPAN, where LMC 
was situated. 
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Table 3-3: General mission sensor data for BIOPAN-6 (data taken from the post-flight review by Schulte and 
Faulstich, 2008) 
Accumulated dose of Solar Radiation (Radiometer) 24 SCh 
Accumulated dose of Solar Radiation (UV-B Sensor) 36 SCh 
Accumulated dose of Solar Radiation (UV-C Sensor) 29 SCh 
Average Temperature during orbit (for bottom experiments where 
LMC was placed) – note that lid experiments saw av. temp of -2°C  
+ 15°C 
Temperature change between sunlight and darkness (for bottom 
experiments where LMC was placed) 
± 2.5°C 
Temperature change during the entire orbital flight (for bottom 
experiments where LMC was placed) 
± 12.5°C 
Range of Temperature change during orbital flight (for bottom 
experiments where LMC was placed) 
+ 25°C 
Minimum / maximum Temperatures (for bottom experiments 
where LMC was placed) 
+ 10
o
C / +35
 
°C 
Pressure during orbital flight and after landing/recovery < 3 mbar 
 
As far as the shipping controls for the LMC samples were concerned, temperature data 
from the 12
th
 of September to the 2
nd
 of October of 2007 show that the maximum 
temperature the samples were exposed to was approximately +30°C (for a very brief 
period of time, during transport to Samara), while the minimum temperature recorded 
was approximately +5°C (once again very briefly, during landing in Rotterdam).  
 
3.12 Visual Inspection 
The pictures taken during the assembly and disassembly of the LMC on BIOPAN 
hardware lead to a series of observations on the physical condition of the experiment 
before and after the BIOPAN mission. The first thing that was noted during disassembly 
was a slight colour alteration of the Kapton foil used in the FM compared to that used in 
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the SC (Figure 3-12) and where there is a difference in colour for the FM foil where 
unshielded and shielded by the metal cover. 
 
 
Figure 3-12: Comparison of Kapton foil used in the FM (left) and SC (right) unit. The FM component 
appeared darker than the SC one in areas unprotected by the metal cover (round spots) 
 
Another physical observation was related to the position of the samples inside the unit 
wells; some pads and dosimeters had noticeably moved from their initial positions 
inside the wells (Figure 3-13). 
 
Figure 3-13: Movement of samples inside wells in the FM sample holder unit before (left) and after (right) the 
BIOPAN mission - insert picture shows the FM unit after the mission, prior to removal of the Viton gasket 
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The visual inspection revealed no alterations or visible damage to the antibody sample 
pads/dosimeters/microarrays inside the units.  
 
3.13 ELISA results for the anti-GroEL and anti-atrazine antibodies 
ELISA provided the most definitive set of data concerning antibody performance after 
the BIOPAN mission. All the ELISA that were run on the LMC on BIOPAN samples 
were binding assays, aiming to test the antibodies‘ ability to recognise and bind to their 
respective targets. The assays were run in parallel for the samples from the FM unit, the 
SC unit and the set of storage controls which had remained in Cranfield University for 
the duration of the mission.  
 
3.13.1.1 Anti-GroEL Antibody 
The ELISA results for the anti-GroEL antibody can be seen in Figure 3-14. Figure 
3-14A shows the comparison in the binding performance of anti-GroEL antibody 
storage and shipping control samples against a standard curve which was produced 
using an anti-GroEL antibody stock solution (not lyophilised). Figure 3-14B-D show 
the binding performance of the anti-GroEL antibody (compared to storage and shipping 
controls, the latter corresponding to the same shielding level as the FM samples) from 
the FM unit for the three levels of shielding. 
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Figure 3-14: Binding performance of the anti-GroEL antibody samples in the LMC on BIOPAN-6 experiment 
– “efficiency” refers to pad wash-out efficiency (A. comparison of shipping and storage controls, B. "Infinite" 
shielding samples, C. "Zero" shielding samples, D. "ExoMars" shielding samples). Error bars reflect the 
standard deviation among the three replicates of each type of pad that were analysed. 
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From the figures above it is apparent that, despite a considerable loss of activity 
compared to the standard curves, the FM samples behave very similarly to the control 
samples.  
In order to simplify the visualisation of the effect of the three different shielding levels, 
the ELISA signals of the samples from all three pads of each shielding level were 
averaged and drawn against each other in Figure 3-15.  
 
Figure 3-15: Binding performance comparison for the three levels of shielding in the LMC on BIOPAN-6 
experiment. Error bars reflect the standard deviation among the three replicates of each type of pad that were 
analysed 
 
From Figure 3-15 it is apparent that the different levels of shielding of samples have no 
significant effect on their subsequent binding performance, and therefore the 
―ExoMars‖ level of shielding appears not to have a detrimental effect on the activity of 
the anti-GroEL antibody. 
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3.13.1.2 Anti-atrazine antibody 
Similarly to the anti-GroEL antibody results, the ELISA signals for the anti-atrazine 
samples from the FM unit can be seen in Figure 3-16A-D. Figure 3-16A provides a 
comparison of control samples (storage and shipping), and once more, all curves are 
drawn against standard curves from stock antibody solutions. Figure 3-16B-D show the 
binding performance of the anti-atrazine antibody samples for the three different levels 
of shielding, compared to a standard curve and storage and shipping controls (the latter 
once again corresponding to the same level of shielding). 
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Figure 3-16: Binding performance of the anti-atrazine antibody samples in the LMC on BIOPAN-6 
experiment – “efficiency” refers to pad wash-out efficiency (A. comparison of shipping and storage controls, B. 
"Infinite" shielding samples, C. "Zero" shielding samples, D. "ExoMars" shielding samples). Error bars 
reflect the standard deviation among the three replicates of each type of pad that were analysed. 
 
From Figure 3-16B-D, it is obvious that the storage controls for the anti-atrazine 
antibody showed reduced activity compared to SC and FM pads.  
Similarly to the anti-GroEL samples, the visualisation of the effect of the three different 
shielding levels was made possible by averaging the ELISA signals of the samples from 
all three pads of each shielding level and plotting them against each other in Figure 
3-17.  
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Figure 3-17: Binding performance comparison for the three levels of shielding in the LMC on BIOPAN-6 
experiment. Error bars reflect the standard deviation among the three replicates of each type of pad that were 
analysed 
 
From Figure 3-17 it became obvious that in the case of the anti-atrazine antibody, the 
level of shielding of the sample pads had practically no effect on the subsequent activity 
of the antibody in binding ELISA. 
 
3.13.1.3 Data analysis 
In order to quantify the changes in the antibodies‘ binding activity after recovery from 
the BIOPAN/FOTON mission,  
 
Table 3-4 shows the percentage of activity retention in all samples for both antibodies. 
The remaining activity percentage was calculated by using the assay mid-points 
(subtracting an assay‘s mid-point value from the mid-point value of the standard curve). 
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Table 3-4: Binding activity retention (%) for the LMC on BIOPAN-6 antibodies  
 
Anti - Atrazine Antibody Anti - GroEL Antibody 
Assay mid-
point 
Retained Antibody 
Activity (%) 
Assay mid-
point 
Retained Antibody 
Activity (%) 
Standard curve 0.029 100% 0.079 100% 
Storage control 0.835 4% 1.116 7% 
Shipping control 
“Zero” shielding 
0.118 25% 2.718 3% 
Shipping control 
“Infinite” 
shielding 
0.133 22% 1.538 5% 
Shipping control 
“ExoMars” 
shielding 
0.068 43% 1.496 5% 
Flight model  
“Zero” shielding 
0.117 25% 1.598 5% 
Flight model 
“Infinite” 
shielding 
0.123 24% 3.000 3% 
Flight model 
“ExoMars” 
shielding 
0.083 35% 0.843 9% 
 
 
3.14 Dosimetry results 
The OSL dosimeters from the LMC on BIOPAN experiment were shipped to the 
Physics Department of the Oklahoma State University in order to read out via controlled 
illumination the radiation data they had recorded. This type of dosimeters can be reset 
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by light, making it crucial to keep them in the dark at all times until analysis. Table 3-5 
shows the radiation data collected by the dosimeters. The data from dosimeters of the 
same shielding level and sample unit have been averaged to facilitate data presentation. 
 
Table 3-5: Accumulated radiation dose recorded by the dosimeters from the LMC on BIOPAN-6 experiment 
Shielding Level/Sample Type Accumulated radiation dose (mGy)
1 
 
“Zero” shielding / SC dosimeters   0.01 ± 0.1  
“Infinite” shielding / SC dosimeters  0.05 ± 0.1  
“ExoMars” shielding / SC dosimeters  0.13 ± 0.1  
“Zero” shielding / FM dosimeters  2.2 ± 0.1  
“Infinite” shielding / FM dosimeters  2.4 ± 0.1 
“ExoMars” shielding / FM 
dosimeters 
 2.4 ± 0.1 
1values are presented in each case accompanied by the standard deviation (n=2)  
 
As the dosimeters were all hand-cut, slight variations in size and mass were inevitable. 
This variation was taken into account during the readout, and normalisation was 
necessary, in the form of weighing each dosimeter and normalizing results based upon 
dosimeter mass.  
From Table 3-5, it is obvious that the radiation dose recorded for dosimeters coming 
from the same sample holder unit is very similar. All FM dosimeters appear to have 
recorded roughly twenty times the dose recorded by the SC dosimeters, and one 
interesting observation is that for the FM dosimeters, the dose from the ―Zero‖ shielding 
dosimeters is almost identical to that from the ―ExoMars‖ and ―Infinite‖ shielding ones.  
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Discussion 
3.15 Missions in LEO as planetary exploration mission analogues 
Missions in LEO do not provide entirely accurate representations of an actual planetary 
exploration mission; some environmental conditions in LEO (temperature extremes, 
high vacuum) are very similar to what such a mission would encounter, while others, 
like the radiation environment are not direct analogues. LEO radiation is a mixture of 
trapped particles (electrons, heavy ions, protons etc.) of various fluxes and individual 
energies, that is mainly isotropic; this is not expected to be the case during the ExoMars 
mission.  
The radiation environment for the ExoMars mission, which was modelled prior to the 
ground-based radiation studies (see Chapter 2), was simplified to be composed of Solar 
Particle Event (SPE)-related protons en route to Mars and back-scattered neutron 
radiation on the surface of the planet. This facilitated simulating it via a cyclotron and 
studying the individual and combined effect of these particles on components of the 
LMC. The radiation environment in LEO is more complex in the context of its effect on 
antibody performance. However, exposure of experiments to the environment in LEO is 
practically the most effective way to test response to a naturally-occurring radiation 
environment, free from the limitations posed by ground-based simulations.  
Mission duration is also an important factor to consider, especially in terms of radiation 
dose deposition on the LMC components. Based on the current configuration of the 
ExoMars mission (circa 2010), the transit phase is expected to last nine months, 
followed by a minimum of six months of surface operations. The BIOPAN-6 mission 
lasted 12 days in its entirety, only 10 of which corresponded to full exposure to the 
radiation field in LEO (while the lid was fully open). Radiation data from BIOPAN-5 
gave an overall radiation dose of 2.4 krad, which corresponds to roughly 1/3 of the total 
radiation dose expected for ExoMars (6.6 krad – calculation based on earlier estimations 
of a 2-year transit phase), while BIOPAN-6 ―saw‖ much lower levels of radiation at 0.4 
krad, primarily due to the low solar activity during the flight compared to previous 
BIOPAN flights. Therefore, despite being much shorter than an actual mission to Mars, 
the BIOPAN missions manage to provide antibody performance data based on 
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significant fractions of the radiation levels envisaged for ExoMars (1/3 ExoMars level 
on BIOPAN-5 and 1/16 ExoMars level on BIOPAN-6).  
Where missions in LEO prove faithful to planetary exploration missions are the 
―physical‖ conditions of a space mission. The setting during payload transportation to 
the launch site and the exposure to all aspects of launch (and re-entry, for future 
sample/instrument recovery) are expected to be very similar, and offer valuable 
information on the potential -or lack of- of using certain materials in such missions.  
Concerning the ―physical‖ results – i.e. the visual observations of the condition of the 
LMC components upon sample recovery, it was observed that the movement of the pads 
inside the sample holder wells was minimal (Figure 3-13), as most of the pads did not 
appear to move whilst others did but without any obvious damage; this suggests that the 
disturbance of the pads during the mission was minimal. The harsh vibration and shock 
conditions during launch and re-entry therefore did not appear to cause any damage to 
the pads, rendering them an appropriate platform for antibody packaging.  
As far as the protective Kapton foil was concerned, mild colour alterations were 
observed in areas which were not protected by the metal cover (Figure 3-12). Given the 
patterns seen on the flight foil, the colouration change is most likely due to the effects of 
the solar UV radiation that the Kapton foil saw through the zero shielding holes.  
 
3.16 Choice of antibody integration method 
The antibodies were used in the LMC on BIOPAN-6 experiment in a lyophilised 
format. This decision was based on literature data about the increase in shelf life and 
stability of antibodies when freeze-dried, compared to molecules in solution and was in 
accordance with the general strategy for antibody integration to the LMC instrument. 
Lyophilised samples were expected to resist the environmental conditions during 
transportation and storage before and after the BIOPAN-6 mission. Lyophilisation was 
also expected to increase resistance to inactivation due to radiation exposure in LEO, by 
eliminating, for instance the presence of radiolytic products due to the presence of water 
in a sample. The importance of an optimised procedure for lyophilisation, taking into 
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account the physical and chemical degradations that samples are exposed to during and 
after freeze-drying, became obvious from the ground-based experiments. 
As far as the sample packaging format was concerned, the antibodies were lyophilised 
into glass fibre pads in accordance to the envisaged final design format in the LMC 
instrument and in order to facilitate handling and integration to the sample holder unit 
and subsequently the BIOPAN-6 platform. 
It is noted that the flight of BIOPAN-6 took place prior to the majority of the results 
obtained from the ground-based irradiations (Chapter 2) and therefore no specific 
lyophilisation matrix was used, whereas in latter studies for the ground-based testing, 
sophisticated lyophilisation matrices were explored, as other work within the LMC team 
indicated that additional lyophilisation matrix features required study. 
 
3.17 The effects of ground handling 
After all the LMC on BIOPAN-6 samples had been prepared and loaded into the sample 
holder units, they left the controlled laboratory environment and were exposed to 
various environmental conditions and outside factors that could have an effect on the 
quality of their performance during the final ELISA analysis. Transportation from one 
place to another meant that the samples inside the FM and SC unit were not only 
physically handled and shaken (this could be the reason for the sample movement inside 
the wells that was observed during the visual inspection after recovery, an assumption 
which is further encouraged by inspection of the pads in the SC unit, which appear to 
have moved no less than the FM pads), but also subjected to X-ray scanning at airports. 
The latter is expected to have a negligible effect on samples as the doses are extremely 
low due to health and safety concerns [data from Aviation Online mention doses <1 
mSv (Mitchell, 2010)].  
After integration in the BIOPAN platform, the journey of the LMC samples was no 
longer directly monitored by our group, but the transportation conditions were 
documented in detail by the mission personnel and the values recorded for all the crucial 
factors (primarily the sample temperature) were not considered harmful to antibody 
95 
 
activity. The same principles applied to the transportation back to Cranfield University 
after the end of the BIOPAN-6 mission. 
The consequent sample analysis via ELISA showed no significant difference in the 
binding activity of the FM and SC samples, compared to storage controls (this is clearly 
illustrated in Figure 3-14A and Figure 3-16A, with the comparison between storage 
controls and shipping controls from the SC unit), leading to the conclusion that the 
ground handling did not have a damaging effect on the LMC antibodies.  
3.18 Sample rehydration 
The rehydration of antibodies in order to assess the retention of binding activity after 
recovery from the BIOPAN mission was a process that was optimised during the 
ground-based radiation studies (the preparation of the BIOPAN samples took place 
before the majority of the ground-based studies while the analysis of the samples took 
place after the ground-based experiments, taking advantage of the optimised handling 
and analysis protocols that were developed during the latter). The importance of an 
efficient method for sample recovery lies in differentiating the effects of sample 
preparation/handling from the effects on performance due to exposure to the conditions 
of a space mission. 
 
3.19 Effect of LEO on antibody performance 
Overall, the two LMC-representative antibodies that were used in the LMC on 
BIOPAN-6 experiment were observed to maintain their binding functionality after 
exposure to space radiation and the physical conditions of the FOTON mission.  
The antibody against atrazine appeared to retain higher levels of activity compared to 
the antibody against GroEL (Table 3-4). 
Assuming that the binding activity of stock solutions of both antibodies corresponds to 
100%, the anti-atrazine antibody showed almost 50% of activity retention after 
lyophilisation and ground handling (SC samples) and around 40% activity retention 
after exposure to the previous conditions plus space radiation (FM samples), compared 
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to the less than 10% activity retention for SC and FM samples of the anti-GroEL 
antibody.  
The results obtained for the anti-atrazine antibody show a very close similarity between 
the SC and FM samples, as far as activity levels are concerned (Figure 3-16 and Table 
3-4). This implies that the orbital flight phase of the mission, including shock loadings 
during launch and landing, did not have a damaging effect on the antibody. Activity loss 
compared to the standard assay (carried out using stock solutions) seems to be due to 
the lyophilisation and/or sample rehydration process. The effect of ground handling, 
which was not expected to have been harmful, could be assessed by comparing the 
shipping control (SC) samples to the storage controls. Unfortunately, the ELISA results 
for the storage controls revealed very low activity retention compared to the SC and FM 
samples (Figure 3-16B-D and Table 3-4), an issue that could be attributed to errors 
during the preparation of this particular batch of sample pads, handling errors (pad 
wash-out) or, in a less likely scenario, alterations to the storage control pads that 
occurred between their production and their analysis. 
The effect of the three different shielding combinations can be observed in Figure 3-17. 
It is clear that, taking into account the error margins, the different shielding levels have 
no observable effect on antibody functionality, which leads to the conclusion that the 
degree of shielding provided by the ExoMars rover is sufficient from protection against 
inactivation, at least inactivation due to LEO levels of radiation. In conclusion, the anti-
atrazine antibody was able to survive complete inactivation after participation in a space 
mission in LEO with exposure to 0.4krad of radiation and is considered a suitable 
candidate molecule for the LMC instrument. Note that an inhibition immunoassay for 
atrazine within the LMC context is considered a positive control assay, as atrazine, 
being a manmade molecule, is unlikely to be found on Mars. 
As far as the anti-GroEL antibody is concerned (Figure 3-14A-D), the results from the 
storage controls seem to agree with the SC and FM samples, in terms of the effect of 
lyophilisation and rehydration (Table 3-4). The freeze-drying process alone appears to 
significantly affect the subsequent performance of the antibody, stripping it of around 
90% of its binding activity. Lyophilisation aside, the ground handling seems to have no 
considerable effect on antibody activity, after comparison of the storage controls with 
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the SC samples (Figure 3-14A). Comparing the values obtained for the FM samples and 
the SC samples, the effect of the mission itself and the space radiation in LEO can be 
assessed (Table 3-4). The performance of both samples sets is similar, implying that this 
effect is not destructive to the anti-GroEL antibody.  
Figure 3-15 allows the comparison of the effect of the three shielding combinations on 
the anti-GroEL antibody; the observations here are very similar to what was seen in the 
case of the anti-atrazine antibody, with the different shielding levels leaving antibody 
activity essentially unaffected. Therefore, the shielding level within the ExoMars rover 
has proven sufficient to protect the anti-GroEL antibody against inactivation due to 
LEO levels of radiation. The conclusion from the analysis of the anti-GroEL samples is 
that this antibody is another suitable tracer for the LMC instrument. 
The LMC on BIOPAN-6 experiment was viewed as an important step in de-risking the 
use of antibodies in a space mission context, despite being exposed to much lower 
levels of ionising radiation (approximately 1/16) of those envisaged for the ExoMars 
mission. The different response of the two antibodies to treatment (lyophilisation) and 
exposure to the mission parameters highlighted the need to test all potential LMC 
antibodies in order to assess their lyo- and radio-resistance levels, prior to use in the 
final (flight) LMC module. This will naturally not be possible in a LEO environment, 
but ground-based experiments can provide comprehensive data sets. Ground-based 
testing, which involves the same sample preparation steps, ground handling and 
exposure to some elements of a space mission (i.e. components of space radiation). 
 
3.20 Dosimetry Results 
The radiation levels recorded by the dosimeters from the FM and SC sample holder 
units (Table 3-5) were the most accurate values that corresponded to the radiation levels 
encountered by samples from the LMC on BIOPAN-6 experiment. As it was expected, 
the radiation values that came from dosimeters from the SC unit were very low (≈0.5 
mGy), in agreement with the normal radiation exposure on the Earth‘s surface. The data 
from the FM unit were approximately 20 times higher than the SC dosimeter data. The 
―zero‖ shielding dosimeter values from the FM unit were the only abnormal ones, i.e. it 
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was expected that these would be higher values, and the most likely interpretation is that 
the dosimeters were reset for the zero-shielding samples due to solar light being able to 
pass through the Kapton foil cover, albeit at a reduced level. It is also noted that the 
levels seen by the dosimeters were different from those seen by the dosimeters using an 
alternative and more established technology elsewhere in BIOPAN, i.e. 400 rad 
(equivalent to 4000mGy) versus 2.4 mGy. This discrepancy will require further study 
and may be due to inappropriate calibration of the OSL dosimeters or inappropriate 
handling pre- or post flight that allowed partial resetting of the dosimeters. The 400 rad 
data provided by other experiments which were previously flown on BIOPAN is 
therefore taken as the more reliable value. 
 
3.21 Future Work 
Presently, the European Space Agency has expressed no intention to go forward with 
another BIOPAN mission in the immediate future. Nevertheless, there is a need to study 
the performance of LMC-related immunoassay (and potentially hardware) components 
after exposure to space radiation. This issue will be resolved, at least to some extent, 
with more ground-based testing. Additional rounds of irradiations are currently being 
planned, following the development of more assays of interest to the LMC. Ground-
based experiments, despite their limitations, allow studies with controlled levels of 
radiation and conclusions on the effects of combined or individual elements of space 
radiation.   
 
Summary and Conclusions 
The experiment that was designed in order to be part of the BIOPAN-6 platform 
onboard the FOTON-M3 mission lead to a number of conclusions concerning the ability 
of antibodies to form components of an instrument on a planetary exploration mission. 
Using this mission in LEO as an analogue of a mission to another planet, a variety of 
factors that could have a detrimental effect on antibody functionality were examined, 
including sample preparation, principally the lyophilisation of the antibodies into glass 
fibre pads, ground handling of the samples, orbital flight and sample recovery. The 
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analysis that took place at the end of the mission revealed that, aside from the effect that 
lyophilisation has on the ability of antibodies to recognise and bind to their respective 
targets, the effect of all physical conditions during the mission and exposure to LEO 
level of radiation are not destructive to these antibodies.   
Within the context of the development of the LMC, it is important to note that the 
radiation levels measured for the Foton M3 mission were considerably lower than the 
radiation levels envisaged for an actual mission to Mars; the radiation environment was 
also different (more heterogeneous) than the radiation used in the ground-based studies 
(composed exclusively of proton and neutron radiation). Nevertheless, the results from 
the BIOPAN-6 experiment agreed with the results of the ground-based experiments in 
that they showed that antibodies did not undergo inactivation due to exposure to 
radiation, even after exposure to a broad spectrum of radiation like the one expected in 
LEO. Additionally, the BIOPAN-6 results showed that the antibodies used in this 
experiment remained functional after exposure to the combination of physical factors 
associated with a space mission (launch and re-entry conditions), which is another 
encouraging step in their use within a planetary exploration mission context. 
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4 . 
Development of recombinant antibodies against 
haptens with biosignature properties with the use 
of naïve and immunised phage antibody libraries 
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Introduction 
4.1 Chapter Preamble: the LMC instrument 
The Life Marker Chip (LMC) instrument is an antibody assay-based system which will 
attempt to detect molecular signatures of Life in the Martian subsurface as part of the 
payload on board the ExoMars mission rover (Sims et al., 2005, Cullen and Sims, 
2007). The ExoMars mission, a collaboration between the European Space Agency 
(ESA) and NASA, is ESA‘s flagship mission to Mars, currently scheduled for launch in 
2018. The mission belongs to a greater framework for Mars planetary exploration that 
has recently been announced by ESA and NASA (Brown, 2009). 
The LMC is frequently described in the general media as a ―pregnancy test for Mars‖, a 
term which hails from the fact that both the LMC and commercial off-the-shelf 
pregnancy tests are based on lateral flow immunodiagnostic technology (Wilson and 
Howell, 2002). The operation of the LMC is based on the employment of dried-down 
fluorescently-labelled antibodies that dissolve into an aqueous-based liquid extract of a 
Martian regolith / crushed rock sample containing extracted organic molecules, 
initiating a multiplexed inhibition immunoassay before being flowed over a microarray 
composed of immobilised copies of the various multiplexed immunoassay targets. For a 
given antibody, if the corresponding target molecule is present in the liquid extract, the 
antibody binding site is occupied and thus inhibited from binding to the corresponding 
microarray spot which subsequently does not fluoresce. If the relevant target molecule 
is not present in the liquid extract, the antibody binding site is left vacant and therefore 
able to bind to the corresponding microarray spot which fluoresces.  
One of the key stages in the development of the LMC is the selection of antibodies that 
will be used in the flight instrument. The challenge in the acquisition of these antibodies 
lies in the nature of the molecules or classes of molecules that are currently under 
examination as potential LMC targets.  
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4.2 LMC Target selection and challenges 
The LMC will be part of the Pasteur payload on board the ExoMars rover and it will 
have the ability to detect up to 25 different molecular targets of different origins that are 
representative of ancient, preserved biomarkers of extinct life, biomarkers of extant life, 
those representing meteoritic input and other abiotic organic molecules as well as 
organic molecular markers of rover / instrument borne Earth contamination (Table 4-1, 
taken from Cullen and Sims, 2007).  
 
Table 4-1: Categories of molecular biomarkers and other relevant targets for biosensor-based Life detection 
(taken from Cullen and Sims, 2007) 
Category Context Typical Properties 
Molecular biomarkers of ancient 
extinct life 
Stable breakdown/preservation 
products of Life, typically membrane 
derived 
Low molecular weight, apolar 
Molecular biomarkers of 
extant/recent life 
Full range of molecules from 
metabolites to macromolecules 
Low to high molecular weight, polar 
Molecular biomarkers of 
microbial spacecraft 
contamination 
Species-specific targets, antigens or 
nucleic acid sequences 
High molecular weight 
macromolecules 
Abiotic organics Meteoritic in-fall 
Low molecular weight, polar and 
apolar 
Other targets 
Man-made synthetic molecules as 
positive controls 
Non-biological contamination 
Various 
Various (cleaning materials, 
spacecraft exhaust products) 
 
 
The need to select and prioritise the molecules that will represent the four major classes 
of LMC targets mentioned above, became clear at a very early stage of the LMC 
development, and a list of over sixty biomarker candidate compounds (both specific 
molecules and generic structures) was proposed, as a result of a 2006 international 
workshop focused on biomarkers for Life detection (Parnell et al., 2007). The search 
for, and even the understanding of what constitutes a biomarker is heavily influenced 
and directed by Earth biology (i.e. the assumption of ―Earth-like‖ life on Mars), and this 
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has been the case with the list of potential LMC targets; nevertheless, an effort was 
made to keep it as wide-ranging as possible. 
From Table 4-1 it is obvious that the LMC targets vary greatly in their physical 
properties and for some, if not most, of these molecules, acquiring high-affinity 
antibodies against them is not a simple procedure. ―Off the shelf‖ antibodies can be 
obtained for molecules with commercial applications (medical, environmental, etc.), but 
the LMC-relevant molecules that also have such applications are mainly in the 
contamination/control categories of targets. On the other hand, in order to obtain 
antibodies via the traditional methods for producing polyclonal and monoclonal 
antibodies, the antigens that will be employed should ideally present a level of structural 
and compositional complexity that most LMC targets lack, especially the markers for 
extinct Life, that are mostly small apolar molecules (haptens). 
Additionally, the antibodies that will be part of the LMC platform will be required to 
resist deactivation due to all factors related to a planetary exploration mission (primarily 
space radiation) and remain functional in the LMC solvent mixture that will be used – a 
combination of water, methanol and surfactant (Court et al., 2010) – in the extraction of 
organics from the regolith/crushed rock sample. Both the nature of the LMC target 
molecules and the harsh environment that are anticipated during the ExoMars mission 
suggest that the optimal option would be custom-made antibodies that would be 
engineered to recognise small haptens with high affinity, without being affected by the 
presence of unfavourable reaction conditions and phage display technology offers the 
potential to generate such molecules. 
 
4.3 Phage display Technology 
4.3.1.1 History and Principle 
Since the first description of phage display by George Smith (Smith, 1985), the display 
of proteins or small peptides on filamentous phage has become one of the leading 
approaches in the identification of peptides with novel properties and the isolation of 
desired peptides from large ―phage peptide libraries‖. The principle behind the method 
is that a foreign protein sequence (gene of interest) can be fused to the gene of one of 
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the coat proteins of filamentous phage, resulting to the creation of a fusion protein that 
is incorporated into the virion (the virus particle) (Parmley and Smith, 1989). The 
resulting virions (fusion phage) both display the foreign protein on their surface (phage 
display) and contain its encoding gene, providing a direct link between phenotype and 
genotype.  
Among the many applications of phage display technology, the ability to generate high 
sensitivity antibodies against challenging targets is the focus of the present work. 
Display does not necessarily involve entire immunoglobulin molecules; antibody 
fragments have also proven extremely efficient (Figure 4-1). The most popular formats 
are the single-chain fragments composed of the antigen-binding variable domains of the 
IgG heavy (VH) and light (VL) chain regions connected by a flexible peptide linker 
(scFv), and fragments described as Fab, that consist of the variable domains plus the 
first part of the constant domains. Additionally, F(ab‘)2 fragments consist of two 
disulfide-connected Fab fragments. The entire scFv is encoded by a single gene, 
facilitating the construction of fusion proteins and subsequent expression. The term 
―recombinant antibodies‖ which is employed extensively in this chapter refers to these 
single-chain antibody fragments. 
 
 
Figure 4-1: Structure of intact IgG molecule (left) and a variety of antibody fragments (right) (Image taken 
from Peterson et al., 2006) 
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4.3.1.2 Filamentous phage: characteristics and biology 
Filamentous phage are a large family of bacterial viruses that infect gram-negative 
bacteria, but unlike most bacteriophage, their production and secretion does not involve 
cell lysis (destruction). The most well-studied filamentous phage are E.coli-infecting 
phage f1, fd and M13 (which was used in the present work) (Figure 4-2), often grouped 
as Ff phage. Phage particles have a cylindrical shape with a diameter of 6.5 nm 
containing the 6400-nucleotide, circular ssDNA genome. The tubular virions are 
composed of thousands of copies of a major coat protein (pVIII), with a few copies (3-
5) of the minor coat proteins (pIII, pVI, pVII, pIX) at the two tips of the particle (Russel 
et al., 2004).   
 
Figure 4-2: Structure of the filamentous bacteriophage M13 (Image taken from Arap, 2005) 
 
All the Ff phage infect E.coli cells displaying F pili, which are the most visible feature 
of the F-plasmid mediated conjugation system in E.coli and is believed to allow stable 
DNA transfer between cells (Harrington and Rogerson, 1990). The amino-terminal 
domain of the minor protein pIII is exposed on the virion surface and binds to the F 
pilus (during the logarithmic phase of bacterial growth) in order to initiate the host cell 
infection.  
Once inside the host cell, the viral DNA uses host resources (RNA and DNA 
polymerases, topoisomerase) in its replication and phage gene expression, which is 
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assisted by additional phage proteins (pII, pV and pX). All phage proteins are 
synthesised simultaneously, but their production rate is strictly moderated.  
The distinctive feature of filamentous phage assembly is that it is a secretory process, 
with assembly occurring in the cytoplasmic membrane and new phage particles being 
secreted from the host cell as they are assembled.  
Filamentous phage are considered ideal candidates for phage display for a number of 
reasons, including the stability of the phage particles to a wide range of selection 
conditions, the small size of their genome which allows insertions into non-essential 
regions and the facilitation of library construction by the ability to isolate both single- 
and double stranded DNA and the availability of phagemid vectors. Additionally, since 
filamentous phage are not lytic phage, high titres of phage can be accumulated from 
infected cells and the modification of the coat proteins does not induce functionality 
loss (Russel et al., 2004).   
4.3.1.3 The minor coat protein pIII 
The Ff phage genome contains nine closely packed genes (I to IX) plus one major non-
coding region which contains the replication origins for the + and – DNA strand 
synthesis and the packaging sequence (PS). Gene III encodes the minor coat protein pIII 
which, as mentioned earlier, initiates host cell infection via its amino-terminal half (the 
carboxyl-terminal region remains buried in the virion and plays a part in 
morphogenesis). The foreign sequence can be inserted between the amino- and 
carboxyl-end of pIII without disrupting pIII‘s functionality (Smith, 1985). The protein 
pIII, which is present in five copies on one end of the phage particle, is the protein of 
choice for most phage display fusions; this is due to its tolerance for large insertions, its 
compatibility with monovalent display (see section 4.3.1.4) and the wide availability of 
suitable vectors (Russel et al., 2004).  
 
4.3.1.4 Phage and phagemid vectors for peptide display 
The vectors that can be employed in the display of peptides on the phage surface can 
either be based on the natural Ff phage sequence (phage vectors) or be plasmid-based 
vectors (phagemids) that only contain the fusion protein gene without other phage genes 
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(Lowman, 1997). When using phage vectors, the foreign sequence is inserted directly 
into the pIII sequence (or another coat protein); upon introduction to E.coli, phage 
particles will have all copies of the coat protein displaying the foreign peptide 
(polyvalent display).  
Phagemids were used in the present work; when phagemid vectors are used, the fusion 
gene is cloned into a plasmid under the control of a weak promoter. The phagemid 
vector has a plasmid origin of replication and an Ff origin, to allow phage genome 
replication and subsequent assembly. An overview of phage display via phagemid 
vectors can be seen in Figure 4-3 (image taken from Sidhu, 2001). 
 
Figure 4-3: Phage display using a phagemid vector. The vector contains a double-stranded DNA origin of 
replication (322 ori) and a selectable marker (ampicillin resistance, Ampr) to replicate and maintain the vector 
as a double-stranded plasmid in E. coli. (Image taken from Sidhu, 2001) 
 
When using phagemid vectors, the host cells are superinfected with a helper phage 
(M13KO7 was used in the present work), which belongs to the same family (Ff) but has 
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undergone mutations to reduce its packing efficiency and ensure that phagemid 
genomes are preferentially packaged during phage assembly and secretion. The helper 
phage also carries a gene that offers kanamycin resistance, which allows antibiotic 
selection of superinfected cells.  
The resulting phage population in phagemid systems display between zero and five 
copies of the desired peptide, with the majority of particles displaying no copy followed 
by particles displaying one copy (monovalent display) (O‘ Connell et al., 2002).  
Phagemid vectors present a number of advantages in the display of antibody fragments 
on filamentous phage, including their small size and ease of cloning (compared to phage 
vectors, where the structure of genes, promoters and terminators must not be disrupted) 
(Russel et al., 2004). This results to the construction of antibody libraries of much 
bigger sizes when using a phagemid system rather than a phage vector (this problem 
was noted by Parmley and Smith when describing using phage vectors – Parmley and 
Smith, 1989). Additionally, the monovalent display of antibody fragments on the phage 
surface facilitates the isolation of high-affinity binders, as opposed to multivalent 
display, which is based on avidity rather than pure affinity of binder to target on a one-
to-one basis. 
  
4.4 Phage antibody libraries  
4.4.1.1 Mimicking the immune system 
The success of phage display technology in the generation of sensitive antibodies 
against targets of interest is greatly dependent on the phage antibody library that will be 
used in the selection process. A library of poor quality (small size, low diversity of 
clones) could prove detrimental to the isolation of high-quality antibodies.  
The antigen-binding site of an antibody is composed of six complementarity-
determining regions (CDRs) or hypervariable regions; three within the light-chain 
variable domain (VL) and three within the heavy-chain domain (VH). In the immune 
system of living organisms, a great variety of antibody binding sites can be generated, 
via the combinatorial assembly of germline-encoded fragments. 
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In phage display technology, diverse libraries of immunoglobulin heavy (VH) and light 
(Vκ and Vλ) chain variable genes can be prepared from peripheral blood lymphocytes 
via polymerase chain reaction (PCR) amplification. It is believed that with a library size 
of ≥108 clones all possible VH/VL pairings can be included (even the pairs originating 
from B cells selected by the immune system) (Winter and Milstein, 1991). 
 The genes encoding the scFv fragments are generated by random recombination of 
heavy and light chains and the resulting library of recombinant clones is displayed on 
the surface of a population of phage. The construction and subsequent screening of a 
combinatorial phage display library mimics the immune system of living organisms 
(Figure 4-4); in the immune system, diverse combinatorial libraries of antibodies are 
displayed on the surface of B-cells. Exposure to a certain antigen triggers cell 
proliferation and differentiation (antibody generation or memory pathways). A phage 
display library is displayed on the surface of the virions (equivalent of the B cells) and 
selection is performed via exposure of the entire library to the target of interest, 
followed by amplification of the relevant clones.  
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Figure 4-4: Generation of antibodies in the immune system (top) and via phage display technology (bottom). 
The steps include rearrangement or assembly of germline V genes (1), surface display of antibody (or antibody 
fragment) (2) antigen-driven or affinity selection (3) affinity maturation (4) and production of soluble antibody 
(5) (Image taken from Winter et al., 1994) 
 
 
4.4.1.2 Naïve and immunised phage antibody libraries 
Phage antibody libraries are heterogeneous mixtures of recombinant DNA fragments, 
the expression of which is a population of fusion phage particles, each carrying a 
different recombinant DNA insert and displaying the corresponding antibody on its 
surface.  
Naïve phage antibody libraries are composed of antibody fragments from a pool of 
genes that are not explicitly biased to contain clones that bind to a certain antigen. The 
lack of bias makes naïve libraries appropriate for selection for a wide variety of antigens 
(including self, non-immunogenic or even slightly toxic molecules). In the construction 
of naïve libraries, V genes are amplified from B-cell cDNA, and heavy and light chains 
are randomly recombined and cloned in appropriate vectors, in order to encode a 
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combinatorial scFv or Fab library of fragments (Hoogenboom et al., 1998). The use of a 
naïve library in the search for binders against particular antigens offers access to some 
of the germline gene antibodies (non-recombinant molecules), but it is understood that 
their occurrence in the library is extremely rare. The affinity of antibodies isolated from 
a naïve library is proportional to its size (Hoogenboom et al., 1998), but a library of 
efficient size and diversity can yield antibodies against a great number of targets. 
Immunised phage antibody libraries are collections of immune antibody fragments, 
showing a bias for certain specificities as a result of coming from an immunised donor 
organism (Hoogenboom, 2005). Immunisation leads to an increase in the number of 
cells producing an immune response, especially in the levels of mRNA produced. 
Spleen, lymph nodes, tonsils, and bone marrow provide a rich source of plasma cells 
and Ig mRNA. Repertoires of VH or VL genes amplified from the mRNA of spleen 
cells of an immunised organism are therefore greatly enriched in V genes encoding part 
of an antigen binding site (Winter et al., 1994). Similarly to the naïve libraries, the 
random recombination of VH and VL gene repertoires leads to a loss of the original 
pairings, but this recombination, combined with the bias created by the immunisation, 
leads to the isolation of antibodies with extremely high affinities for the targets of 
interest.  
As far as the donor organisms for the construction of immunised libraries are 
concerned, immunised libraries of mouse (Clarckson et al., 1991), rabbit (Lang et al., 
1996), chicken (Davies et al., 1995), camel (Ghahroudi et al., 1997) and human (Barbas 
et al., 1993) origin have been reported. Immunised libraries from sheep are also 
promising, as studies have revealed high diversity in the antibody repertoire, despite a 
smaller overall gene pool size than humans or mice (Charlton et al., 2000). A large 
number of immunoassays and biosensors make use of polyclonal antisera (Wust and 
Hock, 1992), and it has been shown that the affinity of sheep antibodies for their targets 
is high, with slow dissociation rates from antigen, explaining their success as diagnostic 
molecules (Li et al., 2000). Both the naïve and the immunised library used in the present 
work were derived from sheep.  
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4.4.1.3 Selection of antibodies from a phage display library - Biopanning 
The step that follows the decision of the library type to use (naïve/immunised) is the 
screening process, which will isolate the antibodies with desired properties from the 
pool of displayed fragments. The selection procedure focuses on obtaining a 
subpopulation of phage-borne peptides with desired properties, from a heterogeneous 
starting population. In most cases, the first round of selection begins with a very large 
initial library and the selected subpopulation is a small fraction of the original 
population, within which the fitter clones are being overrepresented. This population 
can be ―amplified‖ by infecting fresh bacterial host cells, so that each individual phage 
in the subpopulation is represented by millions of copies in the amplified stock. The 
amplified population can then be subjected to further rounds of selection to obtain an 
ever-fitter subset of the starting peptides (Figure 4-5).  
 
 
Figure 4-5: Screening of a phage display library for binders of interest (biopanning) (Image taken from 
http://ymbc.ym.edu.tw/proteome/interact/phage_display.htm) 
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In a review of phage display technology, Smith and Petrenko highlight two parameters 
of selection which can be manipulated to some extent in order to enhance the efficiency 
of selection process. These parameters are stringency, which is defined as the degree to 
which peptides with higher ―fitness‖ are favoured over peptides with lower fitness; 
yield is the fraction of particles with a given fitness that survive selection. The ultimate 
goal of selection is to isolate peptides with high fitness, but this does not mean that 
stringency should be increased without bound, as increases in stringency result in 
reduced yield (Smith and Petrenko, 1997). 
The most common selection pressure imposed on phage-displayed peptide populations 
is affinity for a target receptor, a procedure known as ―biopanning‖ (Figure 4-5). In this 
method, the antigenic target is immobilised on a solid support, and the phage library is 
passed over the immobilised receptor. The phage particles from the library whose 
displayed peptides bind the receptor are captured on the surface; unbound phage 
particles are then washed away. Finally, the bound phage are eluted in a solution that 
loosens receptor-peptide bonds, yielding an ―eluate‖ population of phage that is greatly 
enriched (often a million fold or more) for receptor-binding clones. The eluted phage 
particles are still infective and are propagated by infecting fresh bacterial host cells, 
yielding an ―amplified‖ eluate that can serve as input to another round of affinity 
selection. Phage clones from the final eluate (typically after 2-3 rounds of selection) are 
propagated and characterised individually. The amino acid sequences of the peptides 
responsible for binding the target receptor are determined simply by determining the 
corresponding coding sequence in the phage DNA. In general, high stringency is 
favoured by low densities of the target receptor and by monovalent display of the 
foreign peptide; high stringency is almost invariably accompanied by relatively low 
yield (Smith and Petrenko, 1997). 
 
4.5 Application of phage display technology in the generation of anti-hapten 
antibodies 
The production of sensitive monoclonal antibodies via hybridoma technology against 
compounds that are poor immunogens (viral coat proteins, carbohydrates, small organic 
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molecules) is a very difficult procedure. However, the use of antibody libraries (naïve, 
immunised or synthetic) in combination with phage display technology offers an 
efficient alternative.  
Haptens are defined as low molecular weight (<1000Da) compounds that are not 
immunogenic by themselves, but are able to elicit an immune response when they are 
conjugated to much larger carrier proteins (Kuby, 1997). Haptens include a number of 
molecules with everyday applications, like dyes, pesticides and antibiotics; therefore, 
the acquisition of antibodies that would allow the rapid detection of potentially harmful 
haptens in the environment has always had commercial interest. Most anti-hapten 
immunoassays have been developed for environmental contaminants and utilise 
polyclonal antibodies, rather than monoclonal or recombinant molecules (Charlton et 
al., 2001). Conversely, the vast majority of recombinant antibodies used in biosensor 
and diagnostics technology have been raised against large molecules, like proteins and 
peptides (Charlton et al., 2001).  
In recent years, the generation of high-affinity antibodies against hapten targets has seen 
an impressive increase, as noted in a 2007 review by Sheedy and colleagues (Sheedy et 
al., 2007), greatly due to the parallel advances in phage display technology. Naïve, 
immunised and synthetic (built artificially via in vitro assembly of antibody gene 
fragments) antibody libraries have been employed in the production of anti-hapten 
antibodies, with various degrees of success, depending on the target and library used. 
The employment of phage display in the isolation of anti-hapten antibodies offers 
flexibility through the potential to modify the screening strategy (biopanning) to fit the 
requirements of different hapten targets. 
In addition to using certain libraries to screen for binders against certain haptens, the 
ability to construct a focused ―anti-hapten‖ library which is biased for the recognition of 
a variety of antigens of pre-defined size has been reported (Persson et al., 2006, Persson 
et al., 2008). A library of this kind is constructed using a hapten template, but has the 
ability to produce antibodies against a range of other haptens, closely related to the 
template in size.  
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4.6 Phytane and β-Carotane 
The two proposed LMC targets that were used for the generation of recombinant 
antibodies in the present work are phytane (2, 6, 10, 14 - tetramethylhexadecane) and β-
carotane (3, 7 – dimethyl-9-2, 2, 6 trimethylcyclohexylnonan) both of them belong to 
the category of fossil biomarkers (markers of extinct Life) and are stable breakdown 
products of more complex precursor molecules.  
Phytane (C20H42) (Figure 4-6) is a diterpenoid alkane which is a component of archeal 
membranes and is believed to be characterised by high stability over long periods of 
time; phytane and the closely related pristane (C19H40) have been found in ancient 
sedimentary deposits containing fossil organic matter (Brocks et al., 1997).  
 
 
Figure 4-6: The structure of phytane 
 
A number of precursor molecules can become modified to form phytane, with a 
possible diterpenoid intermediate, like phytol. Chlorophyll and the tetraether lipids that 
are cell membrane components in archea may both yield phytol during the breakdown 
process (Parnell et al., 2007); phytane can derive from phytol after structural 
modifications. The high stability and the wide range of biomolecules that can have 
phytane as their final breakdown product make the latter a high priority LMC target 
molecule. 
The second LMC target which was used in the generation of recombinant antibodies 
described in the present chapter was β-carotane (Figure 4-7). β-Carotane is a shorter 
chain, fossil derivative of the carotenoid class of large isoprenoid molecules (> C40). 
While certain fossil carotenoids are specific to particular kingdoms, β-β carotane (the 
dimer structure of the hapten used in this work) is produced by a number of different 
microorganisms, making it another promising LMC target. 
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Figure 4-7: Structure of β-carotane 
 
4.7 Aims and Objectives 
The objective of the present work has been to generate recombinant antibodies against 
the two potential LMC targets (phytane and β-carotane) with the employment of phage 
display technology. The outcome of this work, which was done in parallel for six LMC 
targets in total (the two targets reported here and four other targets), was viewed as a 
means to determine whether phage display can be the main method of acquiring 
antibodies against high priority LMC target haptens.  
Constrictions in time and resources are a major issue in the development of the LMC; 
given that one of the main advantages of phage display technology is its efficiency in 
terms of both cost and time, this was viewed as an opportunity to test this efficiency and 
determine whether phage display would be the optimal method of LMC antibody 
generation. 
By using both a naïve and an immunised phage antibody library, their potential could be 
directly compared; the use of naïve libraries does not involve the construction cost and 
time delay of obtaining an immunised library, and could therefore prove more resource-
efficient if successful. Additionally, the naïve library which was used had been 
constructed as an immunised library against another mixture of small molecules 
(lactone-type haptens), and this was seen as a chance to examine whether there would 
be any kind of positive bias in acquiring binders against our own haptens. 
Given that this was the first time that phage display technology was to be used in the 
context of the LMC development, the present work was also an opportunity to adjust 
119 
 
and optimise the protocols related to the screening of the libraries to fit the requirements 
of specific targets, in order to isolate high-quality binders against them. 
 
 
Materials and Methodology  
4.8 Culture media – Buffers – Other reagents 
The main culture media that were used throughout the screening of the phage antibody 
libraries were TYE, 2xTY and LB broth. All media are standard E.coli cultivation 
mixtures of similar ingredients that promote bacterial growth via the provision of 
elements that are necessary for crucial metabolic processes. Detailed descriptions of all 
three media can be seen in Table 4-. In order to prepare the media, the amounts of all 
their respective components were weighed out, dH2O was added to a final volume of 
500 ml and the medium was autoclaved prior to use. In the case of TYE where agar is 
present, the medium will quickly solidify in room temperature; in order to avoid this, 
the bottles of TYE medium were kept in a 40
o 
C waterbath after being autoclaved and 
prior to being used.  
Table 4-2: Details of the culture media used during phage antibody library rescue and panning (all component 
weights correspond to 500 ml final volume of medium in dH2O) 
Component 
Details 
Component 
Function 
 
TYE 
(500 ml) 
2xTY 
(500 ml) 
LB broth 
(500 ml) 
Bacto-tryptone 
(Oxoid – cat. no. LP0042) 
Provision of peptides, amino 
acids and peptones 
4g 8g 5g 
Bacto-yeast extract 
(Oxoid – cat. no. LP0021) 
Provision of vitamins, trace 
elements, various organics 
2.5g 5g 2.5g 
Sodium Chloride (NaCl) 
(Fisher – cat. no. BP358-1) 
Provision of sodium ions for 
transport and osmotic balance 
2.5g 2.5g 10g 
Agar Bacteriological 
(Oxoid – cat. no. LP0011) 
Solid culture substrate 7.5g -  
 
The 2xTY medium was generally used wherever liquid culture growth was the 
objective, while TYE was used in the preparation of solid media for colony analysis (i.e. 
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for counting and selecting colonies for further work). Three main categories of solid 
colonies were prepared and used in the form of solid medium in Petri dishes, with the 
addition of antibiotics to prevent culture contamination; TYEAG (500 ml TYE, 10 ml 
glucose 50%, 500 μl ampicillin, the latter from Sigma Aldrich – cat. no. A5354), 
TYEAKG (500 ml TYE, 10 ml glucose 50%, 500 μl ampicillin, 500 μl kanamycin, the 
latter from Sigma Aldrich – cat. no. K0254) and TYEKG (500 ml TYE, 10 ml glucose 
50% and 500 μl kanamycin). The 50% glucose mixture that was used was prepared with 
the addition of dH2O to 100 g glucose (Sigma Aldrich – cat. no. G5767) for a final 
solution volume of 200 ml and autoclavation prior to use. Ampicillin is an antibiotic 
that functions as a competitive inhibitor of the enzyme transpeptidase, an essential 
component of bacterial cell walls. The gene for ampicillin resistance is inserted to all 
the phage library antibody sequences during the construction of the libraries. 
Kanamycin is an antibiotic that indirectly inhibits protein synthesis in bacteria via 
interactions with the 30S subunit in prokaryotic ribosomes. Kanamycin resistance 
comes from the helper phage, helping library cells superinfected with helper phage 
survive over cells without the helper. Finally, the LB (Lysogeny Broth) medium is one 
of the best media for the growth and preservation of recombinant E.coli strains, and it is 
used during library rescue and plasmid preparations for sequencing or long-term 
storage. 
The soft agar that was required for plaque purification of the helper phage M13KO7 
was prepared by mixing 6.4 g of bacto-tryptone, 4 g of bacto-yeast extract, 4 g of NaCl 
and 6 g of agar bacteriological (for suppliers, see Table 4-) and adding dH2O to a final 
volume of 500 ml. Soft agar was autoclaved prior to use and after autoclavation it was 
kept at a 42
o
C waterbath before using it in the production of helper phage.  
As far as the common buffer solutions were concerned, phosphate buffer saline (PBS) 
was prepared from PBS tablets (Sigma Aldrich – cat. no. P4417) and a 0.1% solution of 
PBS-Tween 20 (PBST) was prepared via the addition of 500 ml Tween 20 (Sigma 
Aldrich – cat. no. P1379) to 500 ml PBS. Finally, TRIS buffer was used during the 
small scale expression (Severn Biotech – cat. no. 20-7901-10). All the buffer solutions 
were autoclaved prior to use.  
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Phage precipitation was facilitated by the use of a mixture of 20% PEG 6000/2.5M 
NaCl. 80g of PEG (polyethylene glycol) 6000 (Fisher Scientific – cat. no. P/3681/53) 
were mixed with 58.44g NaCl (Fisher Scientific – cat. no. BP358-1) and dH2O was 
added, to a final volume of 400 ml. The solution was autoclaved prior to use. 
 
4.9 Naïve phage antibody library  
The naïve phage antibody library which was used in the first attempt to acquire 
recombinant antibodies against β-carotane and phytane was provided by Grampian 
Bioconsultants and had been constructed a few months earlier as an immunised library 
against lactone-type molecules. The library comprised κ and λ light chains 
(approximately 2 x 10
7 clones each). The κ and λ libraries were pooled together and 
used in the panning procedure. 
 
4.10 Immunised phage antibody library construction 
The animal immunisation and the subsequent construction of the immunised library 
were carried out by Immunosolv Ltd. At the first stages, the phytane-KLH conjugate 
that had been synthesised earlier was used by Immunosolv Ltd. to immunise two 
Norfolk sheep (CF68 and CF69) on the 3
rd
 February 2009. The sheep were immunised 
initially with 100 µg /ml of a mixture of the phytane-KLH conjugate with four 
additional LMC target molecules conjugated to KLH. The carotane-KLH conjugate was 
not available at the time, so immunisation with carotane took place during the final one 
of four additional boosts that took place every 4 weeks with 50 µg /ml of the same 
mixed antigen.  Binding ELISA were performed on each test bleed (taken 2 weeks after 
the sheep were boosted {week 6, 10 and 14}) to determine whether an antibody 
response was occurring to the target antigens. The ELISA plates were coated with 2 
µg/ml antigen conjugated to BSA (bovine serum albumin) or BSA alone to rule out for 
any effect seen for binding to the carrier protein alone. Four days after the final of the 
four additional boosts, a production bleed was carried out, and B lymphocytes from this 
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bleed were used for the isolation of RNA, the library starting material. Following RNA 
collection, the immunised library was constructed by Immunosolv Ltd. 
 
4.11 Phage antibody library rescue  
4.11.1.1 Production of helper phage M13KO7 
The production of a high-titre helper phage M13KO7 stock is an essential first step to 
the screening of phage antibody libraries, as it is M13KO7 that provides the ―building 
blocks‖ for the production of phage particles displaying the library antibodies. In order 
to produce large amounts of a high-titre M13KO7 stock, a commercially available stock 
of M13KO7 (New England Biolabs – cat. no. NO315S) at a titre of 1011 phage/ml was 
used, and dilutions of this stock in PBS buffer (10
-2
 to 10
-12) were prepared. 50 μl of 
each dilution were used to infect 500 μl E.coli cells, TG1 strain (Stratagene – cat.no. 
200123) at logarithmic phase (log phase) of growth (OD600 = 0.4). In order to grow the 
cells to log phase, a small inoculum of the stock material was added to an autoclaved 
250 ml baffled flask containing 2xTY medium and incubated in a 37
o
C shaking 
incubator (IKA KS4000i) at 280 rpm until OD600 reached a value of 0.4 (approximately 
2 hours). The OD600 values were measured using a portable cell density meter (WPA – 
cat. no. CO8000). Infection of the TG1 cells with the helper phage was allowed to 
develop over a 30-minute period in a 37
o
C Clifton waterbath (Fisher Scientific). After 
this period, the infected TG1 cells of each helper phage dilution were added to 3 ml of 
soft agar (see section 4.8) and poured over TYE plates, without the addition of glucose 
or antibiotics. The plates were incubated overnight in a 37
o
C static incubator.  
The following day, plaque purification of the helper phage took place; one plaque of 
M13KO7 from the dilution plates from the day before was inoculated into 10 ml of TG1 
cells (OD600 = 0.4) in a sterile 50 ml plastic tube (Fisherbrand – cat. no FB55957). The 
contents of the tube were incubated for 2 hours in a 37
o
C shaking incubator at 280 rpm. 
After this incubation period, the contents of the tube were transferred to an autoclaved 
2l baffled flask with 500 ml of 2xTY medium and incubated for 1 hour in a 37
o
C 
shaking incubator at 280 rpm. At the end of the hour, kanamycin was added, to a final 
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concentration of 50 μg/ml, and overnight incubation followed, in a 30oC shaking 
incubator, at 280 rpm.  
On the third day of the M13KO7 production, the newly-formed helper phage particles 
were concentrated and collected in order to be used in the subsequent screening process, 
via a ―PEG precipitation‖ method involving polyethylene glycol 6000 (PEG 6000). 
PEG precipitation is a well-established method of phage concentration from crude 
bacterial lysates (Yamamoto et al., 1970). For the PEG precipitation, the culture that 
was incubated overnight was centrifuged using a Heraeus Megafuge 11R centrifuge 
(Thermo Fisher Scientific) at 8000 rpm for 15 minutes and 400 ml of the resulting 
supernatant were transferred to a new 2l baffled flask. 100 ml of a 20%PEG/2.5M NaCl 
solution were added to the supernatant and the flask was placed in a plastic container 
filled with ice for 1 hour. After this period, the contents of the flask were split between 
two autoclaved 330 ml plastic centrifuge tubes (Fisher Scientific) and centrifuged at 
8000 rpm for 30 minutes using a Sorvall centrifuge (model no. RC5C). After 
centrifugation, the supernatants were discarded and the pellets were resuspended in 8 ml 
of PBS buffer. The two suspensions were pooled together into a sterile 50 ml plastic 
tube, where 2 ml of the same PEG/NaCl solution were added, before placing the tube in 
ice for 20 minutes.  
Another centrifugation step followed, at 8000 rpm for 30 minutes and the supernatant 
was discarded. The pellet was resuspended in 5 ml PBS buffer and split into 1 ml 
volumes in sterile 1.5 ml Eppendorf tubes. The tubes were placed in a bench top 
minifuge and centrifuged at 12000 rpm for 10 minutes to remove any traces of bacterial 
debris. After centrifugation, the supernatants were moved to sterile cryo-vials 
(Fisherbrand – cat. no. 10-500-26) and 10 μl of material was removed to be used in the 
titration of the newly-made stock. The remaining volume of M13KO7 stock was stored 
at -80
o
C in the form of 15% glycerol (Sigma Aldrich – cat. no. G5516) stocks.  
In order to titrate the M13KO7 stock, the 10 μl volume that was taken before storing the 
stock was used to prepare a set of serial hundred-fold dilutions in PBS (10
-6
 to 10
-18
). 50 
μl of each of these dilutions were transferred to sterile 10 ml plastic tubes and 450 μl of 
TG1 cells in log phase of growth (OD600 = 0.4) were added. Infection of the TG1 cells 
was allowed to take place over a 30-minute period in a 37
o
C waterbath, followed by a 
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second 30-minute period in a 37
o
C shaking incubator, at 280 rpm. After infection, two 
volumes of 50 μl of each dilution were spread onto TYEKG plates (TYE medium with 
glucose and kanamycin) (duplicate plates) and the plates were incubated overnight in a 
30
o
C static incubator. The helper phage M13KO7 has a gene that offers kanamycin 
resistance, so it is expected that the cells that grow on the TYEKG plates are cells 
infected with M13KO7. The following day, colonies were counted and titres were 
obtained. Titres of 10
12-13 
or higher are considered satisfactory. In our case, application 
of this protocol resulted in a helper phage stock with a titre of 2.8 x 10
13
 phage/ml. 
 
4.11.1.2 Naïve phage antibody library 
The process that is used in order to ―rescue‖ the phage antibody libraries prior to 
screening them for binders against the desired targets presented some variations 
between the naïve  and immunised libraries. In the case of the naïve phage antibody 
library, 500 μl of library stock (see section 4.9) were spread onto TYEAG bioassay 
dishes (140 mm diameter – Sterilin, cat. no. 501V) and incubated overnight in a static 
30
o
C incubator (Thermo Fisher Scientific Heraeus Incubator). The following day, 3 ml 
of 2xTY medium were used to scrape the cell colonies from the dishes and the resulting 
cell suspensions were transferred to autoclaved 250 ml baffled flasks where 100 ml of 
LB broth, 1 ml of 50% glucose in dH2O and 50 μl of ampicillin (100 μg/ml) were 
added. The contents of the flasks were incubated for 1 hour in a shaking 37
o
C incubator 
at 280 rpm.  
After this incubation period, the optical density of the cell suspensions at 600 nm 
(OD600) was measured using a Varioskan Flash reader from Thermoscientific. A high 
OD600 (>2) means there is sufficient number of cells to use for the subsequent screening 
process, the preparation of ―back-up‖ cultures for future use and the DNA preparations 
(clean-up) for long-term library storage.  
 
4.11.1.3 Rescuing library material for immediate use 
Once the OD600 of the library culture had reached the desired value (>2), an appropriate 
volume of the culture was transferred to a sterile 50ml plastic tube containing 40 ml 
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2xTY medium for a starting OD600 value of 0.1 (approx. 1ml of library culture). 2xTY 
was added for a final volume of 50 ml and 1 ml of 50% glucose in dH2O and 50 μl (100 
μg/ml) ampicillin were added to the tube. The contents of the tube were transferred to 
an autoclaved 250 ml baffled flask and incubated for in a 37
o
C shaking incubator at 280 
rpm until OD600 reached 0.4 (corresponding to the log phase of cell growth).  
Once the OD600 reached 0.4, the culture was transferred to a sterile 50 ml plastic tube 
and infected with the helper phage M13KO7 at a cell to helper phage ratio of 1:20. The 
culture was incubated for 30 minutes in a 37
o
C waterbath to allow infection. At the end 
of this period, 100 μl of the infected library were removed in order to be serially diluted 
in 2xTY medium (ten-fold 10
-1
 to 10
-7
 dilutions of the starting material in 2xTY) and 
used for cell titrations. Two volumes of 50 μl of each dilution were spread onto TYEAKG 
plates (duplicates) and all plates were incubated overnight in a 30
o
C static incubator. 
Control TYEAKG plates without cells and with M13KO7-uninfected library cells were 
also prepared to allow possible contamination detection. These titrations provide a 
means of measuring the number of library cells successfully infected with M13KO7, as 
kanamycin resistance comes from the helper phage. Titration results of 10
8
 to 10
10
 
cells/ml of culture are generally considered satisfactory, while lower titres suggest that 
repetition of library rescue and infection with the helper phage is necessary.  
After having removed the material for titration, the remaining culture volume was 
centrifuged at 6000 rpm for 20 minutes. The resulting supernatant was discarded and 
the pellet was reconstituted in 50 ml 2xTY with the addition of 50 μl of ampicillin (100 
μg/ml). This solution was transferred to an autoclaved 250 ml baffled flask and 
incubated for 1 hour in a 37
o
C shaking incubator. This incubation period allowed the 
M13KO7-infected cells to fully develop their resistance to kanamycin, and at the end of 
the hour 50 μl (50 μg/ml) of kanamycin were added to the flask. The contents of the 
flask were incubated overnight in a 30
o
C shaking incubator at 250 rpm. 
The following day, the library phage particles were concentrated using the PEG-
precipitation method which was also used in the production of helper phage M13KO7 
(see section 4.11.1.1). After the overnight shaking incubation at 30
o
C, the library culture 
was transferred to a 50 ml sterile plastic tube and centrifuged at 6000 rpm for 20 
minutes. After centrifugation, the supernatant was split between new 50 ml tubes in 
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order to facilitate further handling of the material, and 1/5 volume of 20%PEG/2.5M 
NaCl  were added to each tube (each tube had 25 ml of culture, so 5 ml of 
20%PEG/2.5M NaCl were added). The tubes were left in polystyrene box filled with ice 
for 1 hour to allow phage precipitation. At the end of the hour, ―clouds‖ of phage should 
be visible in the tubes upon manual shaking. Another centrifugation step followed, at 
8000 rpm for 30 minutes.  
The tubes were removed from the centrifuge under careful handling to avoid 
resuspending the ―soft‖ pellet that was created. The supernatants were discarded and the 
pellets containing the phage particles were each resuspended in 10 ml autoclaved dH2O 
and pooled together in a new sterile 50 ml tube. The contents of the tube were 
centrifuged for 10 minutes at 6000 rpm as a further clean-up step. After the 
centrifugation, the supernatants were moved to a new tube and once more, 1/5 volume 
of 20%PEG/2.5M NaCl (approximately 5 ml) was added. The tube was placed in ice for 
20 minutes and then centrifuged at 8000 rpm for 30 minutes. The supernatant was 
discarded and the pellet was reconstituted in 2 ml PBS buffer.  
10 μl of this phage particle suspension, which had now been cleaned of cellular debris, 
were used for titrations in order to quantify the amount of phage in the resulting stock. 
The 10 μl volume was serially diluted (hundred-fold dilutions in 2xTY medium, 10-2 to 
10
-12
 of the starting material) and used to infect TG1 strain E.coli host cells. 100 μl of 
each dilution were transferred to sterile 1.5 ml Eppendorf tubes and were used to infect 
900 μl TG1 cell culture in 2xTY medium (OD600 = 0.4). The infection was allowed to 
take place over a 30-minute period in a 37
o
 C waterbath. At the end of this incubation 
period, two volumes of 100 μl of each dilution were spread onto TYEAG plates 
(duplicates) and all plates were incubated overnight in a 30
o
 C static incubator. Titres of 
10
12
 cells/ml or higher are considered satisfactory at this stage. 
After removing material for the titrations, the remaining volume was split between two 
1.5 ml sterile Eppendorf tubes (Eppendorf – cat. no. 05-402-25) and centrifuged using a 
bench top minifuge (Heraeus Fresco 17 from ThermoScientific) at maximum speed 
(13000 rpm for the specific model) for 5 minutes. The pure phage supernatant was 
transferred to sterile cryo-vials and stored at -80
o
C in the form of 20% glycerol stocks 
until the time came to use it in the panning process. 
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4.11.1.3.1 Preparation of “back-up” cultures (B cultures) 
After removing 1 ml of library material from the growing culture in order to rescue it 
for immediate use, another 1 ml of library culture was inoculated in an autoclaved 250 
ml baffled flask containing 50 ml 2xTY medium, 1 ml 50% glucose and 100 μg/ml 
ampicillin. The contents of the flask were incubated overnight in a 37
o
C shaking 
incubator at 280 rpm.  
The following day, the culture was transferred to a sterile 50 ml plastic tube and 
centrifuged at 6000 rpm for approximately 30 minutes until a solid pellet was formed. 
The supernatant was discarded and the pellet was resuspended in 10 ml 2xTY medium 
with 1 ml 50% glucose and 1.5 ml glycerol (for a 5% glucose, 15% glycerol stock 
solution). These B culture stocks were moved to sterile cryo-vials and stored at -80
o
C as 
bacterial backup material in case any problems or contaminations appeared during the 
library screening.  
 
4.11.1.3.2 DNA preparations for long term library storage 
In order to store the phage antibody library for long periods of time, the corresponding 
DNA sequences are isolated from the E.coli cells and stored separately, as it has been 
observed that stored library cells have a tendency to reject the DNA inserts after a 
certain period of time. In order to do this, the remaining library volume (after the 
removal of 2 ml for rescue of material for immediate use and the preparation of B 
cultures) was further incubated in a 37
o
C shaking incubator for approximately 40 
minutes. The library culture was then moved to sterile 50 ml plastic tubes and 
centrifuged at 6000 rpm for 20 minutes.  
The isolation of DNA was performed using a plasmid preparation kit from Qiagen 
(HiSpeed Plasmid Maxi Kit – cat. no. 12663), following the kit instructions. The 
method is a modified alkaline lysis procedure followed by DNA binding to an anion-
exchanging resin for the isolation of supercoiled plasmid DNA. After clean-up, plasmid 
DNA was stored at -20
o
C. 
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4.11.1.4 Immunised phage antibody library 
The protocol used in the rescue of the immunised phage antibody library followed the 
same overall principle as the one used in the naïve library rescue; the library cells were 
grown and infected with the helper phage M13KO7 in order to induce library phage 
production. The procedure used library stock material (see section 0), 1 ml of which was 
inoculated into 300 ml of 2xTY medium (1% glucose and 100 μg/ml ampicillin) inside 
a 2l autoclaved baffled flask. The contents of the flask were incubated in a 37
o
 C 
shaking incubator at 280 rpm until OD600 reached 0.4 (logarithmic phase of cell 
growth). When OD600 reached 0.4, 50 ml of culture were transferred to a sterile 50 ml 
plastic tube and infected with the helper phage M13KO7 at a cell to helper phage ratio 
of 1:20. The tube was placed in a 37
o
C waterbath for 30 minutes to facilitate helper 
phage infection of the library cells, and the infection was completed via an additional 
30-minute incubation in a 37
o
C shaking incubator at 280 rpm.  
At the end of the infection time, 100 μl of culture were removed to be used in titrations 
that would determine the number of successfully infected library cells. Serial ten-fold 
dilutions of culture in 2xTYmedium (10
-2
 to 10
-10
) were prepared and two volumes of 
50 μl of each dilution were spread on TYEAKG plates (duplicates), which were incubated 
overnight in a 30
o
C static incubator. Control TYEAKG plates without cells and with 
uninfected library cells were prepared in parallel in order to monitor contamination. 
Similarly to the naïve library rescue titrations, titres of 10
10
 to 10
11
 cells/ml of culture 
are generally considered satisfactory for further work, while lower cell counts suggest 
that repetition of the rescue process is needed.  
After removing material for the titrations, the remaining library volume was centrifuged 
at 4000 rpm for 10 minutes at 20
o
C and the supernatant was discarded. The pellet was 
resuspended in 100 ml 2xTY medium (100 μg/ml ampicillin), moved to an autoclaved 
250 ml baffled flask and incubated for 1 hour at a 30
o
C shaking incubator at 280 rpm. 
At the end of the hour, 100 μl kanamycin (50 μg/ml) were added to the culture and it 
was incubated overnight in the 30
o
C shaking incubator. 
The following day, PEG-precipitation of the library phage took place, in a very similar 
protocol to the one used for the naïve library. After the overnight incubation of the 
infected library cells, the culture was transferred to sterile 50 ml plastic tubes and 
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centrifuged at 6000 rpm for 30 minutes. The supernatant was moved to a new 50 ml 
tube and 1/5 volume of 20%PEG/2.5M NaCl (approximately 10 ml) was added to the 
tube. The tube was put in ice for 2 hours, at the end of which ―clouds‖ of phage were 
visible in the tube. Another centrifugation step followed, at 8000 rpm for 30 minutes. 
The supernatant was discarded and the pellet containing the library phage particles was 
resuspended in 40 ml of autoclaved dH2O. This suspension was centrifuged at 6000 rpm 
for 10 minutes. The supernatant after this centrifugation step was transferred to a new 
50 ml plastic tube and once more, 1/5 volume of 20%PEG/2.5M NaCl (8 ml) was 
added. The tube was placed in ice for 20 minutes before another round of centrifugation 
at 8000 rpm for 30 minutes. The supernatant was discarded and the pellet containing the 
phage was resuspended in 2 ml PBS.  
10 μl of this phage particle suspension, free of cellular debris, were used for titrations in 
order to quantify the amount of phage in the resulting stock. The 10 μl volume was 
serially diluted (hundred-fold dilutions in 2xTY medium, 10
-2
 to 10
-12
 of the starting 
material) and used to infect TG1 strain E.coli host cells. 100 μl of each dilution were 
transferred to sterile 1.5 ml Eppendorf tubes and were used to infect 900 μl TG1 cell 
culture in 2xTY medium (OD600 = 0.4). The infection was allowed to take place over a 
30-minute period in a 37
o
 C waterbath. At the end of this incubation period, two 
volumes of 100 μl of each dilution were spread onto TYEAG plates (duplicates) and all 
plates were incubated overnight in a 30
o
 C static incubator. Titres of 10
12
 cells/ml or 
higher are considered satisfactory at this stage. 
The remaining volume of phage in PBS buffer was split between sterile 1.5 ml 
Eppendorf tubes and centrifuged in a bench top minifuge at maximum speed (in this 
case 13000 rpm) for 5 minutes. The supernatant was transferred to sterile cryo-vials and 
stored at a -80
o
 C freezer in the form of 20% glycerol stocks until the time came to be 
used in the panning process. The eight different libraries were rescued and stored 
separately, and were only pooled together immediately before being used in the 
screening. The pooling of the κ and λ libraries took into consideration the representation 
of κ and λ chains in the active immune system of sheep (approx. 90% λ and 10% 
presence of κ). 
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4.11.1.4.1 Preparation of “back-up” cultures (B cultures) 
The preparation of backup cultures (B cultures) from the immunised libraries was very 
similar to the procedure used for the naïve library. After removing 50 ml of library 
material from the growing culture in order to infect with the helper phage M13KO7, the 
remaining 250 ml of material were incubated for an additional 2-hour period in a 37
o
C 
shaking incubator at 280 rpm. The culture was transferred to sterile 50 ml plastic tubes 
and centrifuged at 6000 rpm for 30 minutes. The supernatant was discarded and the 
pellet was resuspended in 10 ml 2xTY medium (total volume) (5% glucose and 15% 
glycerol). This library stock was split between sterile cryo-vials and stored at -80
o
C. 
 
4.12 Library Panning 
The principle for panning the libraries for binders against targets of interest (in this case 
phytane and carotane) is the same regardless of whether the naïve or the immunised 
library is being used.  
A plastic immunotube (Fisher Scientific – cat. no. 444202) was coated with the target of 
interest (phytane, in the form of phytanic acid, or carotane) in its conjugated form to a 
carrier protein (BSA or KLH, although generally the BSA conjugate was used in the 
first round of panning). In order to coat the immunotube, 4 ml of a 10 μg/ml solution of 
the target conjugate in PBS buffer were added to the immunotube, which was placed at 
4
o
C overnight to allow binding of the conjugate to the inner surface of the tube. The 
following day, the coating solution was discarded and the immunotube was washed 3 
times using 10 ml PBS buffer, in a sequential filling and emptying procedure. Then the 
immunotube was filled with 4 ml of a ―blocking‖ buffer aiming to coat any parts of the 
inner surface that had not been covered by the target conjugate. The blocking buffer 
consisted of Marvel skimmed milk powder in PBS buffer (MPBS - 2% solution). The 
coated immunotube was incubated at 37
o
C in a static incubator for 2 hours. At the end 
of this period, another washing step followed, identical to the previous one, with 3 
washes with PBS buffer. The tube was tap-dried carefully before the addition of the 
library material. 
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After the immunotube was dried off, the naïve or immunised library was added, in a 
mixture of MPBS buffer (4%) and BSA in PBS buffer (2 mg/ml). 1 ml of library 
material was mixed with 2 ml MPBS 4% and 1 ml BSA solution. The immunotube was 
sealed with parafilm and its contents were incubated rotating, by placing it on a rotating 
plate base (Stuart SB3) for 30 minutes. A static incubation step followed, at ambient 
temperature for 90 minutes (standing on the laboratory bench). At the end of this step, 
the contents of the tube were discarded along with unbound phage particles and the 
immunotube was washed with a washing buffer consisting of 0.1% Tween 20 in PBS 
buffer (PBST), in 10 washes of 10 ml volumes. Another 10 washes of 10 ml volumes of 
PBS buffer followed, and the immunotube was tap-dried carefully.  
In order to elute the phage particles bound to the surface of the immunotube, 
triethylamine (TEA) was used. This elution procedure is based on altering the pH value 
of the interior of the immunotube (alkaline elution), causing the detachment of the 
phage particles. 1 ml of 100 mM TEA (Sigma Aldrich – cat. no. T0886) solution in 
dH2O was added to the tube and the latter was mounted on the rotating plate base and 
rotated for 10 minutes exactly. In the meantime, two volumes of 0.5 ml Tris buffer (see 
section 4.8) were added to two sterile 1.5 ml Eppendorf tubes and at the end of the 10-
minute rotation the contents of the immunotube were immediately transferred to the 
Eppendorf tubes, in order to neutralise the TEA solution. An additional volume of 200 
μl of Tris buffer was added to the immunotube in order to neutralise any remaining 
TEA/phage mixture. 
0.75 ml of the eluted phage solution was used in order to infect 9.25 ml of TG1 strain 
E.coli cells (OD600 of 0.4) in a sterile 50 ml plastic tube. An additional volume of 4 ml 
TG1 cells was added to the immunotube and both tubes were placed in a 37
o
C 
waterbath for 30 minutes to allow infection of the host TG1 cells with the eluted phage 
particles. The remaining volume of eluted phage suspension was stored at -80
o
C in the 
form of a 15% glycerol stock. After 30 minutes in the waterbath, the contents of the 
immunotube and the 50 ml plastic tube were pooled together and 10 μl of material was 
removed in order to be used in titrations.  
The titration procedure consisted of the dilution of this starting material in 2xTY 
medium (serial ten-fold dilutions from 10
-2
 to 10
-7) and spreading of two 100 μl 
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volumes of each dilution onto TYEAG plates. The plates were incubated at 30
o
C (static 
incubation) overnight. This titration is a means of measuring the number of eluted 
phage particles and even low titres of 10
3
-10
4
 cells/ml are considered acceptable.  
After removing the 10 μl of material of the titrations, the remaining volume of infected 
cells was centrifuged at 4000 rpm for 10 minutes, the supernatant was discarded and the 
pellet was resuspended in 0.5 ml 2xTY medium. This suspension was spread on TYEAG 
large bioassay dishes and incubated overnight at 30
o
C (static incubation).  
The following day, 4 ml of 2xTY medium were used in order to scrape the grown cell 
colonies off the surface of the bioassay dishes and the cell suspension was collected in 
sterile 1.5 ml Eppendorf tubes. 100 μl of this suspension were used to inoculate 100 ml 
2xTY medium (1% glucose, 100 μg/ml ampicillin) in an autoclaved 250 ml baffled 
flask, while the remaining material was stored at -80
o
C as a 5% glucose, 15% glycerol 
stock. The contents of the baffled flask were incubated in a 37
o
C shaking incubator at 
280 rpm until OD600 reached 0.4.  
Once OD600 reached 0.4 (after approximately 90 minutes), 50 ml of the cell culture were 
transferred to a sterile 50 ml plastic tube and infected with helper phage M13KO7 at a 
cell to helper phage ratio of 1:20. The tube was placed in a 37
o
C waterbath to allow 
infection, followed by an additional infection period of 30 minutes in a 37
o
C shaking 
incubator at 280 rpm. At the end of the infection time, 10 μl of culture were removed to 
be used in titrations that would determine the number of successfully infected library 
cells. Serial ten-fold dilutions of culture in 2xTYmedium (10
-2
 to 10
-10
) were prepared 
and two volumes of 50 μl of each dilution were spread on TYEAKG plates (duplicates), 
which were incubated overnight in a 30
o
C static incubator. Control TYEAKG plates 
without cells and with uninfected library cells were prepared in parallel in order to 
monitor contamination. At this stage of eluted phage rescue, titres of 10
8
 to 10
10
 cells/ml 
of culture are generally considered satisfactory for further work, while lower cell counts 
suggest that repetition of the rescue procedure is needed. 
After removing material for the titrations, the remaining library volume was centrifuged 
at 4000 rpm for 10 minutes at 20
o
C and the supernatant was discarded. The pellet was 
resuspended in 50 ml 2xTY medium (100 μg/ml ampicillin), moved to an autoclaved 
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250 ml baffled flask and incubated for 1 hour at a 30
o
C shaking incubator at 280 rpm. 
At the end of the hour, 50 μl kanamycin (50 μg/ml) were added to the culture and it was 
incubated overnight in the 30
o
C shaking incubator. 
The following day, PEG-precipitation of the rescued phage took place. After the 
overnight incubation of the infected cells, the culture was transferred to sterile 50 ml 
plastic tubes and centrifuged at 6000 rpm for 30 minutes. The supernatant was moved to 
a new 50 ml tube and 1/5 volume of 20%PEG/2.5M NaCl (approximately 5 ml) was 
added to the tube. The tube was put in ice for 1 hour, at the end of which ―clouds‖ of 
phage were visible in the tube. Another centrifugation step followed, at 8000 rpm for 30 
minutes. The supernatant was discarded and the pellet containing the library phage 
particles was resuspended in 10 ml of autoclaved dH2O. This suspension was 
centrifuged at 6000 rpm for 10 minutes. The supernatant after this centrifugation step 
was transferred to a new 50 ml plastic tube and once more, 1/5 volume of 
20%PEG/2.5M NaCl (5 ml) was added. The tube was placed in ice for 20 minutes 
before another round of centrifugation at 8000 rpm for 30 minutes. The supernatant was 
discarded and the pellet containing the phage was resuspended in 2 ml PBS.  
10 μl of this phage particle suspension were used for titrations in order to quantify the 
amount of phage in the resulting stock material. The 10 μl volume was serially diluted 
(hundred-fold dilutions in 2xTY medium, 10
-2
 to 10
-12
 of the starting material) and used 
to infect TG1 strain E.coli host cells. 100 μl of each dilution were transferred to sterile 
1.5 ml Eppendorf tubes and were used to infect 900 μl TG1 cell culture in 2xTY 
medium (OD600 = 0.4). The infection was allowed to take place over a 30-minute period 
in a 37
o
 C waterbath. At the end of this incubation period, two volumes of 100 μl of 
each dilution were spread onto TYEAG plates (duplicates) and all plates were incubated 
overnight in a 30
o
 C static incubator. Titres of 10
12
 cells/ml or higher are considered 
satisfactory at this stage.  
The remaining volume of phage in PBS buffer was split between sterile 1.5 ml 
Eppendorf tubes and centrifuged in a bench top minifuge at maximum speed (in this 
case 13000 rpm) for 5 minutes. The supernatant was transferred to sterile cryo-vials and 
stored at a -80
o
 C freezer in the form of 20% glycerol stocks before being used in the 
second round of panning.  
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The PEG precipitation concluded the first round of panning of the phage antibody 
library; an additional 2 rounds of panning were performed in order to obtain specific 
and sensitive binders. Between panning rounds, the conjugate used to coat the 
immunotube was altered between the BSA- and KLH-bound format and the 
concentration of coating conjugate was lowered (from 10 μg/ml in the first panning 
round to 1 μg/ml for the subsequent rounds) in order to ensure the capture of sensitive 
binders. Representative plates from the phage titrations after the PEG precipitation step 
in each round of panning were stored at 4
o
C and were used to select colonies for the 
monoclonal ELISA (see section 4.13.1.2).  
 After 3 rounds of panning using TEA in order to elute the phage bound to the target 
conjugate on the surface of the immunotube, free antigen elution was the next phase in 
the library screening. In our case, free antigen elution only took place during the 
screening of the immunised library, using phytane and carotane (10 μM solutions in 
PBS buffer, using phytane from Sigma Aldrich –cat. no. 80165 and an appropriate β-
carotane derivative supplied by Dr. Manisha Sathe, see Figure 4-).  
 
Figure 4-8: Structure of the carotane derivative used in the free antigen elution round of panning of the 
immunised phage antibody library 
 
The derivatives that are used in the free antigen elution should ideally be identical to the 
molecules that antibodies will be raised against; in this case this was true for phytane, 
but the carotane derivative available at the time of studies (Figure 4-) had a carboxyl 
group on one end of the molecule, making it different to the LMC target carotane 
molecule (Figure 4-).  
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Figure 4-9: Structure of carotane (LMC target) 
 
Panning using free antigen was identical to the previous rounds with the exception of 
the elution step where, instead of 1 ml of 100 mM TEA solution, 4 ml of the 10 μM 
antigen solution in PBS buffer were added to the immunotube. After addition of the free 
antigen solution, the immunotube was rotated for 30 minutes and 2 ml of the contents 
were removed and split between two sterile 1.5 ml Eppendorf tubes. The immunotube 
was kept static on the laboratory bench for another 30 minutes, and the remaining 2 ml 
volume of its contents was transferred to two new Eppendorf tubes. The 30-minute and 
60-minute eluted material was used separately to infect two batches of TG1 E.coli cells, 
and the rest of the protocol was the same as for a normal round of panning. The two-
step elution separates binders with a high disassociation constant (quick but potentially 
loose binding to their target) from binders with a lower disassociation constant (slower 
and potentially stronger binding to their target), allowing the choice of the most 
appropriate antibodies at later stages of the selection process. 
 
4.13 Enzyme-linked immunosorbent assays (ELISA) 
After all panning rounds were complete, enzyme-linked immunosorbent assays 
(ELISA) were performed, in order to determine whether an enrichment in relevant 
binders has occurred through the sequential rounds of panning. These diagnostic ELISA 
are divided into ―polyclonal‖ and ―monoclonal‖ phage assays, based on whether the 
material used in the assay comes from a mixture of different phage clones or a unique 
clone.  
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4.13.1.1 Polyclonal phage ELISA 
Polyclonal ELISA were the first assays to employ, and came right after the completion 
of the three rounds of the library panning process. The material used in these assays was 
the suspension of phage that resulted from the PEG precipitation. This suspension was a 
mixture of different phage clones displaying different antibody fragments, so this assay 
is by no means conclusive about the quality of individual antibodies, but more of a 
method to acquire an idea of the results from the library panning. 
For the polyclonal ELISA, separate rows of wells in a 96-well microtitre plate (Fisher 
Scientific – cat. no.442404) were coated with 1 μg/ml solutions of the target molecules 
(carotane and phytane) in their BSA and KLH conjugate format and the carrier proteins 
(BSA and KLH) alone and incubated overnight at 4
o
C. All the solutions were in PBS 
buffer and 100 μl of solution were added to each well. Two rows of wells were coated 
with each solution, with columns corresponding to the number of panning rounds that 
had been performed (3 rounds for the naïve library panning and 4 rounds for the 
immunised library panning). The layout of the coated wells in the microtitre plate for 
the polyclonal ELISA can be seen in Figure 4-. 
 
Figure 4-10: Polyclonal ELISA well layout 
 
The next day, the plates were washed two times with PBS buffer (200 μl/well) and tap-
dried, before a blocking buffer was added to all wells, consisting of 2% Marvel 
skimmed milk powder in PBS buffer (2% MPBS). 200 μl of the blocking buffer were 
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added to each well and the plates were incubated at 37
o
C for 2 hours. At the end of this 
incubation period, the plates were washed two times with 0.1% PBST buffer and two 
times with PBS buffer (200 μl/well) and dried.  
The phage suspension was added next, in a mixture of 50 μl 4% MPBS blocking buffer 
and 50 μl of phage suspension from panning rounds 0-3 (―panning round 0‖ was the 
PEG precipitated phage suspension that resulted from the library rescue, before any 
actual screening for binders). The phage were allowed to bind to the coated wells over 1 
hour at room temperature. After this period, the plates were washed as before (2x PBST 
buffer and 2x PBS buffer) and dried, before the addition of the secondary antibody. 
100 μl of an HRP-labelled, anti- bacteriophage M13 antibody (GE Healthcare – cat. no 
27-9421-01), at a dilution of 1:1000 of the stock material were added to all wells and 
incubated for 1 hour at room temperature. After this incubation step, the plates were 
washed 4x PBST buffer and 2x PBS buffer and dried off.  
The addition of the HRP substrate solution followed, where 100 μl of substrate solution 
of 1 TMB tablet (Sigma Aldrich – cat. no. T3405) in 100 ml of a phosphate-citrate 
buffer with sodium perborate (Sigma Aldrich – cat. no. P4922) were added to all wells 
and incubated at room temperature for 1 hour. Blue colour from the reaction of the 
enzyme and its substrate was allowed to develop over 5-10 minutes, before the reaction 
was stopped with the addition of 50 μl of a 1M sulphuric acid solution (Fisher Scientific 
– cat. no. J/8420/17) to all wells. The optical density of the samples at 450 nm was 
measured using a VarioSkan Flash reader from Thermoscientific.  
 
4.13.1.2 Monoclonal phage ELISA 
The TYEAG plates that corresponded to the highest dilutions of phage material from the 
post-PEG precipitation titrations were stored at 4
o
C after colonies were counted, and 
were used to select colonies for the next stage in the antibody development, which is 
based on individual ―phage clones‖. In order to select clones displaying antibodies that 
bind to their target with high sensitivity and specificity, unique clones are randomly 
selected from the last rounds of panning and used in monoclonal ELISA, which is the 
decisive factor in the choice of clones that are taken forward to antibody production. 
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In our case, the selection process using the naïve library stopped after the polyclonal 
ELISA results and monoclonal ELISA data are only available for the immunised library 
panning. 
4.13.1.2.1 Growing individual clones for monoclonal phage ELISA 
The first step in the monoclonal ELISA was the picking of 95 different clones (leaving 
one of the 96 wells in a standard microplate empty to use as a control) from the titration 
plates using sterile pipette tips to scrape the cells from the solid medium and inoculate 
them into individual microtitre plate wells (Nunclon 96-well sterile plates from 
ThermoScientific – cat. no. TKT – 180 – 070U) with 100 μl 2xTY medium (1% glucose 
and 100 μg/ml ampicillin). The colonies were incubated overnight in a 37oC shaking 
incubator, at 280 rpm. The following day, a transfer device (VWR – cat. no. 738-0252) 
was used to transfer a small inoculum from the overnight plate to a new 96-well plate 
containing 200 μl 2XTY medium (1% glucose and 100 μg/ml ampicillin) in each well. 
The new plate was incubated in a 37
o
C shaking incubator, at 280 rpm for 2 hours, while 
the overnight plate was stored at -80
o
C after addition of glycerol to a final concentration 
of 15% in each well.  
After the incubation step, 25 μl of 2xTY medium (1% glucose and 100 μg/ml 
ampicillin) containing 10
9
 pfu helper phage M13KO7 were added to all wells and helper 
phage infection was allowed to take place during a 30-minute incubation in a 37
o
C 
static incubator, followed by 1 hour in a 37
o
C shaking incubator, at 280 rpm. After 
infection, the plates were centrifuged at 2500 rpm for 10 minutes, the supernatants from 
each well were discarded and the pellets were resuspended in 150 μl of 2xTY medium 
(100 μg/ml ampicillin and 50 μg/ml kanamycin). The plates were incubated overnight in 
a 30
o
C shaking incubator at 280 rpm. 
The following day, the contents of the microtitre plates were centrifuged at 2500 rpm 
for 10 minutes and the resulting supernatants were transferred to new microtitre plates 
and stored at -20
o
C before being used in the monoclonal ELISA.  
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4.13.1.2.2 Monoclonal phage ELISA protocol 
96-well microtitre plates (Fisher Scientific – cat. no. DIS 971 030J) were coated with 1 
μg/ml solution of target/BSA conjugate and BSA alone (one full plate of each coating 
solution), both in PBS buffer. 100 μl of solution were added to each well and the plates 
were incubated at 4
o
C overnight. The following day, the plates were washed three times 
with 0.1% PBST washing buffer (200 μl/well) followed by three washes with PBS 
buffer (200 μl/well) and tap-dried. The wells were blocked using 200 μl/well of 2% 
MPBS blocking buffer and incubated at 37
o
C for 2 hours (static incubation).  
The plates were washed as before (3x PBST and x PBS buffer) and dried, before a 
mixture of 50 μl 4% MPBS and 50 μl of phage supernatant was added to all wells. The 
plates were incubated for 1 hour at room temperature, then washed as before and dried. 
100 μl of the HRP-labelled, anti- bacteriophage M13 antibody, at a dilution of 1:1000 of 
the stock material were added to all wells and incubated for 1 hour at room temperature. 
After this incubation step, the plates were washed as before and dried off.  
The addition of the HRP substrate solution followed and incubation took place at room 
temperature for 1 hour. Blue colour from the reaction of the enzyme and its substrate 
was allowed to develop over 5-10 minutes, before the reaction was stopped with the 
addition of 50 μl of a 1M sulphuric acid solution  to all wells. The optical density of the 
samples at 450 nm and 650 nm was measured using a VarioSkan Flash reader from 
Thermoscientific.  
The monoclonal phage ELISA was repeated using the KLH conjugates of both targets, 
before conclusions could be drawn concerning the quality of the selected clones. 
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Results 
4.14 Immunisation ELISA (polyclonal sera)  
During the immunisation period, serum samples from blood collected from the two 
sheep (CF68 and CF69) at regular intervals (test bleeds) were used in binding ELISA, in 
order to determine the progress of the immunisation (all ELISA performed by 
Immunosolv Ltd.). During these ―test bleeds‖, both sheep showed an increase in 
antibody response with increase in number of boosts but sheep CF68 showed a higher 
antibody response than sheep CF69, therefore sera from sheep CF68 were the ones that 
were taken forward and were used in the library construction. The ELISA results can be 
seen in Figure 4- for phytane (which had been present in the immunisation mixture from 
the beginning) (Figure taken from Immunosolv Ltd.). As β-carotane was only added at 
the final immunisation boost, its immunogenic potential only became apparent in later 
stages, during the screening of the immunised library. 
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Figure 4-11: Progress of the antibody binding response of sheep CF68 blood sera to phytanic acid conjugated 
to BSA from week 6 to week 14 of the immunisation process (Figure provided by Immunosolv Ltd.) 
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As far as the immunogenic potential of phytane is concerned, it is apparent from Figure 
4- that the antibody response to it was increasing between boosts.  
 
4.15 Naïve phage antibody library  
In the rescue and screening of the naïve phage antibody library, it was deemed 
necessary to grow the κ and λ light chains separately. This decision aimed to increase 
the chances of selecting relevant binders from the library later in the panning process, 
although it is generally accepted that λ light chains present more utility potential than 
the κ light chains (Charlton personal communication).  
4.15.1.1 Titration results: library rescue and pan rounds 1-3 
The titrations that were carried out during the rescue and panning process allowed the 
quality monitoring of the procedure and the control of contaminations. The titration 
results from the library rescue can be seen in Table 4- and the titrations from the 
panning for binders against carotane and phytane can be seen in Table 4-.  
 
Table 4-3: Naïve phage antibody library rescue titration results 
 Library rescue 
Pre- PEG titration Post-PEG titration 
κ 5.8 x 107 4.29 x 1012 
λ 3 x 107 5 x 1012 
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Table 4-4: Titrations from the naïve library panning for binders against carotane and phytane 
 Pan 1 Pan 2 Pan 3 
Pre-
PEG 
titration 
M13KO7 
infection 
Post-
PEG 
titration 
Pre-
PEG 
titration 
M13KO7 
infection 
Post-
PEG 
titration 
Pre-
PEG 
titration 
M13KO7 
infection 
Post-
PEG 
titration 
CAROTANE 3 x 10
3 3.5 x 106 
3.2 x 
1011 
5 x 103 2 x 107 
Confluent 
growth 
1.27 x 
108 
1.68 x 
108 
Confluent 
growth 
PHYTANE 6 x 10
3 7.1 x 106 
3.3 x 
1011 
5 x 104 1.7 x 107 
Confluent 
growth 
1.5 x 
108 
1.9 x 108 
Confluent 
growth 
 
The titration results for the library rescue were reasonable, considering the library‘s 
initial size (2 x 10
7
 clones for both the κ and λ component of the library). It is generally 
acceptable that in the beginning of each round of panning – especially for the first 
rounds – the titration results from the eluted phage are low, followed by an increase in 
the number of colonies in the subsequent steps of a panning round, i.e. amplification 
and concentration. As far as the panning process was concerned, titrations from pan 1 
are within the values normally expected for a first round of screening, with a low 
number of binders binding to the immunotube and being amplified in the next steps of 
the panning round, and the same could be said for pan 2 and pan 3 results, with the 
exception of the post-PEG precipitation titration plates which showed confluent 
bacterial colony growth. Confluent growth is not the result of a successful PEG-
precipitation, but usually the result of contamination. It may also be an indication of a 
failed round of panning, as excessive stringency in the selection process can result to the 
suppression of the clones containing the inserts of interest and the domination of more 
resistant clones with different inserts.    
 
4.15.1.2 Polyclonal phage ELISA results 
At the end of the three rounds of panning, polyclonal ELISA was performed, in 
accordance with the procedure described in section 4.13.1.1. The ELISA results from 
panning for binders against phytane can be seen in Figure 4-A, while Figure 4-B shows 
the results obtained from panning for binders against carotane.  
143 
 
 
Figure 4-12: Polyclonal phage ELISA results from the panning of the naïve phage library for binders against 
phytane (A) and β-carotane (B) 
 
It is obvious from the polyclonal ELISA results that the panning of the naïve library did 
not result in the isolation of binders against either one of the two targets.  
 
4.16 Immunised phage antibody library  
4.16.1.1 Library rescue 
Similarly to the rescue of the naïve phage antibody library, the immunised library was 
rescued not as a whole, but the 8 sub-libraries were grown and stored separately, only to 
be pooled together immediately before the first round of panning. This practice is 
designed around preserving the diversity of the sub-libraries, despite the higher utility 
potential of the λ families. The titration results from the rescue of the 8 sub-libraries can 
be seen in Table 4-.  
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Table 4-5: Immunised library rescue titration results 
 Library rescue 
Pre- PEG titration Post-PEG titration 
MuVH1-Vλ 4 x 108 1.7 x 10
13 
MuVH1-Vκ 2.7 x 108 2.5 x 10
13 
Hu4a-Vλ 3 x 108 2.6 x 1013 
Hu4a-Vκ 6 x 108 8 x 1012 
VH1-Vλ 3.3 x 108 5 x 1013 
VH1-Vκ 1.03 x 108 1.9 x 1013 
VH2-Vλ 4 x 108 8.4 x 1013 
VH2-Vκ 1.7 x 108 6.2 x 1013 
 
The library rescue titres were considered reasonable and the 8 sub-libraries were pooled 
together in order to be screened for binders against carotane and phytane. The 
representation ratio of λ to κ libraries in the mixture that was used in the panning was 
9:1, corresponding to the κ/λ ratios in the active immune system of sheep. The titration 
results from the immunised library panning can be seen in Table 4-6.  
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Table 4-6: Titrations from the immunised library panning for binders against carotane and phytane (results in 
Pan 4 are presented for both free antigen elution periods; the upper line corresponds to the 30-minute elution 
and the lower line to the 60-minute elution period) 
 Pan 1 Pan 2 
Pre-PEG 
titration 
M13KO7 
infection 
Post-PEG 
titration 
Pre-PEG 
titration 
M13KO7 
infection 
Post-PEG 
titration 
CAROTANE 7 x 10
3
 5.3 x 10
8
 1 x 10
12
 2 x 10
5
 7 x 10
7
 4.3 x 10
13
 
PHYTANE 4.5 x 10
3
 6 x 10
7
 8.2 x 10
13
 5 x 10
3
 1.1 x 10
8
 4.8 x 10
13
 
 Pan 3 Pan 4 
Pre-PEG 
titration 
M13KO7 
infection 
Post-PEG 
titration 
Pre-PEG 
titration 
M13KO7 
infection 
Post-PEG 
titration 
CAROTANE 3 x 10
7
 1 x 10
7
 
Confluent 
growth 
2 x 10
7
 
1.5 x 10
8
 
5 x 10
8
 
1 x 10
10
 
4.8 x 10
9
 
3.1 x 10
9
 
PHYTANE 2.5 x 10
3
 4 x 10
7
 
Confluent 
growth 
2.5 x 10
6
 
1.3 x 10
7
 
3.5 x 10
9
 
5 x 10
9
 
1 x 10
12
 
8 x 10
8
 
 
 
The overall conclusion from Table 4-6 is that the titration results generally followed a 
reasonable trend according to what would be expected from panning an immunised 
library against similar targets (gradual enrichment in clones of interest between Pan 1 
and Pan 4) with the exception of the post-PEG precipitation titrations in Pan 3, where 
confluent bacterial growth was observed (for possible explanations of confluent 
bacterial colony growth, see section 4.15.1.1).  
 
4.16.1.2 Library Panning  
4.16.1.2.1 Polyclonal phage ELISA 
Similarly to the steps that followed the panning of the naïve phage antibody library, at 
the end of the three rounds of the immunised library panning, polyclonal ELISA were 
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performed, in accordance with the procedure described in section 4.13.1.1. The ELISA 
results from panning for binders against phytane can be seen in Figure 4-8A, while 
Figure 4-8B shows the results obtained from panning for binders against carotane.  
 
 
Figure 4-8: Polyclonal phage ELISA results from the immunised library panning for binders against phytane 
(A) and carotane (B) 
 
From the polyclonal ELISA results it is obvious that enrichment for relative binders has 
occurred for both targets between Pan 1 and Pan 3, with carotane being recognised in 
both its BSA- and KLH-conjugate form, while phytane is only recognised in its KLH-
conjugate form. The recognition of free carrier proteins is very low for both targets and 
both carriers used (BSA and KLH). The polyclonal ELISA was performed before Pan 4 
(free antigen elution), and after Pan 4 had been completed, to confirm the recognition of 
the target conjugates, and the results from Pan 4 confirmed the results from Pan1-3. The 
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phage suspension from Pan 4 recognised carotane in its conjugated form (both the BSA- 
and KLH-conjugate) but not free BSA or KLH. As far as phytane was concerned, Pan 4 
phage recognised phytane-KLH, didn‘t appear to recognise phytane-BSA and did not 
recognise free BSA or KLH (results not shown).  
 
4.16.1.2.2 Monoclonal phage ELISA  
After the completion of the polyclonal ELISA, individual ―phage clones‖ were selected 
to be taken forward in the selection process, and the quality of the binders they were 
displaying was examined via monoclonal phage ELISA (see section 4.13.1.2.2). The 
detailed results from the monoclonal ELISA can be seen in Figure 4-9 to Figure 4-11. 
These results are presented in table format as this is a screening assay and not a 
complete curve for each clone. For carotane, where polyclonal phage ELISA had shown 
recognition of both conjugates (BSA- and KLH-based), monoclonal ELISA were 
performed using both conjugates and both carrier proteins (Figure 4-10 for carotane-
KLH and Figure 4-11 for carotane-BSA). In the case of phytane, where only phytane-
KLH appeared to be recognised by the library phage, monoclonal phage ELISA was 
performed using only the KLH conjugate (Figure 4-9). 
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Figure 4-9: Monoclonal phage ELISA data for phytane (phytane-KLH). The data in green colour correspond 
to OD measurements between 0.05 and 0.3, the data in orange colour correspond to OD measurements 
between 0.3 and 0.5 and the data in red colour correspond to OD measurements >0.5 (4i/4ii correspond to the 
two free antigen incubation periods of 30 and 60 min respectively) 
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Figure 4-10: Monoclonal phage ELISA data for carotane (carotane-KLH). The data in green colour 
correspond to OD measurements between 0.05 and 0.3, the data in orange colour correspond to OD 
measurements between 0.3 and 0.5 and the data in red colour correspond to OD measurements >0.5 (4i/4ii 
correspond to the two free antigen incubation periods of 30 and 60 min respectively) 
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Figure 4-11: Monoclonal phage ELISA data for carotane (carotane-BSA). The data in green colour 
correspond to OD measurements between 0.05 and 0.3, the data in orange colour correspond to OD 
measurements between 0.3 and 0.5 and the data in red colour correspond to OD measurements >0.5 (4i/4ii 
correspond to the two free antigen incubation periods of 30 and 60 min respectively) 
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It is evident from Figure 4-9, Figure 4-10 and Figure 4-11 that for both phytane and 
carotane, there appear to be individual clones that bind to the hapten-carrier protein 
conjugate, but not the carrier protein alone, suggesting recognition of the hapten (target) 
end of the conjugate. More specifically, in the ELISA screening for clones that could 
recognise phytane-KLH approximately 10% of clones recognised it with low affinity 
(signal between 0.05 and 0.3), another 7% recognised it with medium affinity (signal 
between 0.3 and 0.5) and a 9% of clones recognised it with high affinity (signal over 
0.5). In the case of the recognition of carotane-KLH, approximately 9% of clones 
recognised it with low affinity, 24% with medium affinity and approximately 6% 
recognised it with high affinity. For carotane-BSA the results were similar, with 4% of 
clones recognising it with low affinity, 39% of clones with medium affinity and 
approximately 3% with high affinity. In all ELISAs, it was observed that the clones that 
were isolated after the 60-minute incubation with free antigen presented an overall 
increased recognition of their respective conjugates. 
Due to time restrictions, none of the clones that were shown to recognise their 
respective conjugate were taken forward to competition ELISA to determine whether 
they were able to recognise free antigen. Nevertheless, these studies showed that clones 
that were isolated from the use of an immunised library were able to recognise the 
conjugated forms of their antigens, while the use of a naïve library failed to give such 
clones. 
 
 
Discussion 
4.17 Limitations of recombinant antibody technology for hapten targets 
4.17.1.1 The design and quality of libraries 
Library quality is paramount to the isolation of high affinity antibodies. A library of 
insufficient size or diversity is likely to lack the potential to produce the best quality 
binders against a certain target. This is especially true for naïve libraries, particularly 
when they are used for hapten target antigens. In naïve libraries, the affinity of the 
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antibodies that can come from it is proportional to the size of the library, and this fact 
combined with the structural and compositional nature of haptens, suggests that only a 
library of significant size/diversity of clones could yield acceptable results. 
In the case of immunised libraries, the design of the immunogens that will be used in 
the immunisation of the donor organism will greatly influence the quality of the 
resulting library of clones. Conjugates using the wrong carrier protein, conjugates 
bearing spacers of insufficient or excessive length or unfavourable structure, and 
conjugates where hapten exposure is not optimal can all result to a collection of 
antibody fragments that lack the ability to recognise the hapten end of the conjugate.  
Where anti-hapten antibodies are concerned, it is quite usual that the antibodies 
developed are able to recognise a combination of the hapten and carrier protein 
molecule (‗interface binders‖), or other parts of the conjugate (spacer etc.), but not the 
free hapten in the absence of the carrier protein. In many cases, a low molecular weight 
target will not occupy the entire binding site on the surface of an antibody. The hapten 
will insert itself into a cavity formed by the antigen-binding site, leaving room for more 
contacts to be made between the carrier and the residues of the binding site. As a 
consequence, the affinity for the free hapten is lower than that of the hapten-carrier 
conjugate (Persson et al., 2006). These issues can be overcome by designing -wherever 
possible- conjugates to be used as immunogens where everything is taken into 
consideration, from the optimal carrier protein to be used, to the choice of the spacer 
and the orientation/position of the hapten. Some problems arising from the use of non-
ideal immunogens can be overcome during the selection process, especially if 
alternative versions of the hapten conjugate (different carrier protein, different spacer, 
different connection to the hapten) are available for the screening.  
 
4.17.1.2 pIII as an insertion frame 
The insertion frame that was used in the present studies was the minor coat protein pIII. 
In library design and construction, the use of pIII as the insertion frame for the foreign 
peptides may cause certain problems. Although pIII is more tolerant to insertions than 
other phage proteins (pVIII for instance), this may lead to infectivity reduction of the 
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resulting phage (Russel et al., 2004). The use of phagemid vectors, which results to the 
production of phage particles which also have wild-type protein pIII, helps to overcome 
this issue. These hybrid virions do not rely on the infectivity of the fusion pIII protein, 
and this allows the fusion to be designed around the specifications of the foreign 
peptide.  
 
4.17.1.3 Issues with the use of phagemid vectors/monovalent display 
The display system that was used in the present work was based on monovalent display 
of the antibody fragments on the surface of the virions. Despite the advantages of 
monovalent display, especially for LMC-type targets where the production of high 
affinity antibodies is crucial, it has been reported that it may lead to the selection of 
clones with unexpected structures (e.g. internal duplications resulting to bivalency, 
weak affinity clones present in high numbers) (Russel et al., 2004). This is the result of 
over-selection within the library, via many rounds of selection for instance, past the 
point where the clones of desired properties were dominant in the library population. 
Issues like these can be overcome by careful design (number of rounds, stringency of 
each round) and strict monitoring of the selection process, as well as collection of 
samples from each round of selection that can be analysed as a means of tracing the 
beginning of the problem.  
 
4.17.1.4 Expression editing  
Another issue to consider when using a library for phage display is that all library 
clones will not be displayed with equal efficiency. The fitness of the library clones is by 
no means identical, and some sequences will not be represented at all. This could mean 
that for a given target, the optimal (highest affinity) antibody could not be displayed at 
all and subsequently never isolated. Other sequences could be toxic to the host cells or 
obstruct phage assembly or be sensitive to digestion from bacterial proteases. These 
issues with clone (and subsequent antibody) representation in a library are collectively 
referred to as ―expression editing‖ by Russel and colleagues (Russel et al., 2004), and it 
must be taken into consideration in the evaluation of the results from a given library, 
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even more so when the library screening is against small molecules like the LMC 
targets examined in the present studies, which present the challenges discussed above. 
 
4.18 Screening the libraries for antibodies against phytane and β-carotane 
4.18.1.1 Naïve library screening 
The screening of the naïve  library for binders against phytane and β-carotane was 
composed of three panning rounds of increasing stringency, in the form of lowered 
concentration of coating antigen from round to round. At the end of the three rounds, 
binding ELISA were performed, and the unsatisfactory results that were obtained for 
both targets (Figure 4-), lead to no further rounds of panning. The titration results from 
each round of selection (Table 4-) did not appear unreasonable, but it became apparent 
from the Pan 3 titration results that they were by no means optimal. The titration results 
are viewed as a rough quality control of each step of the procedure, rather than a true 
indication of the success of the process, which can only be acquired from the binding 
ELISA data. The confluent growth which was observed in the post-PEG concentration 
titration plates in Pan 3 for both targets was also pointing at a possible over-selection 
pressure on the library, with the desired clones being overtaken by irrelevant clones of 
increased fitness. 
These results were not unexpected; the initial small library size (10
7
 clones) and the fact 
that it had not been raised against our particular target mixture lowered the chances of 
success. The fact that the library had been raised against different but similar size 
molecules did not cause a positive bias in the isolation of high-affinity clones against 
our own targets.  
The outcome of the screening of the naïve library was an indication that, in the context 
of the development of the LMC instrument, with all the limitations in time and 
resources it involved, the use of naïve libraries is not recommended. 
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4.18.1.2 Immunised library screening 
The immunised library which was used to generate antibodies against a mixture of LMC 
targets (including phytane from the beginning, with β-carotane being added at the final 
round of immunisation) was raised against own-synthesised conjugates of these hapten 
targets. This offered the possibility to design the immunogens based on a set of criteria 
for optimal target presentation to the immune system, using a carrier protein (KLH) and 
spacer structure and length that were considered appropriate. The polyclonal sera 
samples taken from the immunised sheep and analysed for recognition of phytane 
conjugate to BSA showed a definite increase in response between immunisation boosts 
(Figure 4-), and while it was not possible to examine the progress of the response to β-
carotane due to its late addition, the results (titrations and post-screening binding 
ELISA) showed that this delay in its addition did not result to the absence of phage 
clones that could recognise it. A possible explanation for this result could be that the 
structural similarities between phytane and carotane meant that the early addition of 
phytane created a positive bias for carotane recognition. 
More specifically, in the course of three panning rounds using the conjugated forms of 
both targets (increasing the selection stringency by lowering the concentration of the 
coating antigen) and one additional round with free antigen elution, it became possible 
to isolate a phage subpopulation that were displaying antibodies against the conjugated 
forms of phytane and β-carotane. This was obvious from the titration results during the 
biopanning procedure (Table 4-6), and even more so from the polyclonal binding 
ELISA performed upon completion of the screening (Figure 4-8). Both targets gave 
similar results; a notable difference was that the polyclonal ELISA for β-carotane 
showed recognition of both conjugates (BSA and KLH conjugate), while in the case of 
phytane there was no recognition of the BSA conjugate. The clones‘ ability to recognise 
one conjugate but not the other and none of the carriers alone may indicate that what 
they are actually binding to is an area composed of parts of KLH and the antigen 
(interface binders).  
At a further step of the selection process, monoclonal ELISA was run for the two targets 
(the phytane-BSA conjugate was not used, as there was no recognition of it), and it was 
shown that a number of individual clones were able to recognise the conjugates but not 
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the carriers alone, providing an encouraging indication that the clones – especially 
where carotane was concerned - were recognising the hapten end of the conjugates, 
rather than the carrier end.  
The matter of the clones‘ exact binding site within the conjugates was not resolved 
within the present studies, due to time restrictions. This means that there is no way to 
confirm that any of the clones that recognise the conjugated forms of phytane and 
carotane are indeed able to recognise free antigen. A number of experiments on 
different LMC targets that were run by other members of the LMC group after the 
completion of the present work did not lead to the isolation of clones that were able to 
recognise free antigen, so this issue remains to be clarified. 
Although there is a need to advance this work by moving from the ―phage level‖ to a 
soluble single-chain antibody (scAb) level, it appears that the use of immunised libraries 
can lead to the isolation of antibodies against LMC-relevant targets and in the context of 
recombinant antibody development within the time and resource constraints of the LMC 
programme it should be preferred over the use of naïve libraries. 
 
4.19 Future work 
4.19.1.1 Isolation of scAb against phytane and β-carotane 
The phage clones that were shown to recognise the conjugated forms of phytane and β-
carotane (but not the carrier proteins alone) with considerable sensitivity (Figure 4-9 to 
Figure 4-11) must be taken forward to competition ELISA, where recognition of free 
antigen can be confirmed, before moving ahead with the cloning of their responding 
display peptide sequences into appropriate vectors and expression of soluble antibody.   
The results from the monoclonal phage ELISA are by no means final as to whether high 
affinity antibodies against phytane and β- carotane will be isolated from this library. It is 
possible that the phage clones identified are recognising the interface between carrier 
and hapten, and this will be determined by the competition ELISA using free antigen. 
Additionally, it is possible that a peptide displayed on the virion surface shows a strong 
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recognition of the target, but when ―packaged‖ in a scAb format it shows less 
sensitivity.  
 
4.19.1.2 Modification of the screening process 
If the clones isolated at the end of the present work prove to be defective in the 
recognition of free target, there is always the option of screening the same immunised 
library once more, modifying the biopanning procedure. For instance, there is potential 
to remove interface binders by introducing free antigen elution earlier in the screening 
process, but the increase of stringency will result to reduced yield. This is not 
necessarily detrimental to the selection process, as long as every round is strictly 
monitored, preventing diversity loss from round to round.  
In a different practice, it would be possible to maintain library diversity during the first 
rounds of panning by maintaining the concentration of the coating antigen high in the 
first rounds, but this would probably result to a screening process composed of many 
rounds of selection, and it would have the potential of leading to the amplification of 
interface or other irrelevant binders in the phage population.  
Regardless of the modifications chosen and applied, the possibility to alter the selection 
process according to the requirements of a given project offers great flexibility and 
increases the chances of isolating high-affinity antibodies. 
Another factor that can be introduced in the selection process before moving to the 
soluble scAb level is the affinity maturation of the relevant binders. In the context of the 
LMC, there is a requirement for antibodies that remain functional in harsh solvent 
mixtures. Additional rounds of panning, where particular solvent mixtures could be 
integrated into the phage elution step could lead to the isolation of clones whose 
performance would not be affected by the solvents.   
As far as the use of naïve libraries is concerned, despite the poor results it gave in the 
present experiments, there is a possibility to modify the panning protocol and introduce 
different panning routes, in order to confirm whether the inability to isolate clones of 
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interest was due to the fact that they were not present in the library to begin with, or 
were present initially but unable to survive the selection stress.  
 
4.19.1.3 The future of recombinant antibody generation within the LMC development  
If the employment of immunised libraries results to the generation of high-affinity 
antibodies against the first set of targets, the method will be expanded to produce 
antibodies against more LMC-relevant molecules. The information collected at every 
step of the design, planning and screening of the present library can lead to a next round 
of antibody development which will be more time- and resource-efficient. That said, the 
need to approach every target (or set of similar targets) individually and modify the 
methods used accordingly will always be necessary.  Additionally, the ability to 
produce antibodies against a group of haptens as extensive as the potential targets for 
the LMC instrument is a step forward in anti-hapten antibody development that could 
prove to have applications outside the development of the LMC. 
 
Summary and Conclusions 
Overall, the attempt to employ phage display technology for the generation of LMC 
candidate antibodies lead to interesting conclusions about the method‘s efficiency and 
limitations.  
The first thing to note is the performance comparison between the naïve and the 
immunised phage antibody library; it was apparent that the former did not lead to the 
isolation of clones that were able to recognise the free or conjugated forms of phytane 
and β-carotane, while the latter resulted to a number of clones that can recognise the 
conjugated forms of both targets. 
The naïve library‘s inability to produce clones of interest could be a result of the 
library‘s size and/or quality, or an indication that the panning route that was followed 
requires modifications in order to allow the enrichment in clones displaying antibodies 
against the two targets. 
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The immunised library responded well to the panning route that was followed and a 
number of clones that can recognise the conjugated forms of the two targets and not the 
carrier proteins alone were collected from it. The studies ended at this point and further 
analysis (competition ELISA) is required in order to determine whether they can 
recognise free antigen.  
The clones that were isolated from the immunised library and were recognising the 
phytane-KLH conjugate were not recognising the phytane-BSA conjugate. This could 
mean that the clones are displaying interface binders, recognising a part of the 
conjugation site rather than the hapten end of the conjugate. Further analysis of said 
clones will be able to clarify this matter. 
Similarly to the naïve library, should further analysis show that the clones isolated from 
the immunised library are not able to recognise free antigen, the panning protocols can 
be modified (less stringency/additional rounds of panning/earlier introduction of free 
antigen elution) to determine the library‘s potential to generate clones of interest. 
In conclusion, phage display technology is undoubtedly a promising method of antibody 
production within the context of the development of the LMC instrument. It has proven 
quicker, more cost-efficient and more flexible than the traditional methods of antibody 
generation that had been employed in the past and had given low quality results. 
Whether it will be established as the standard method of LMC candidate antibody 
generation remains to be determined, after all the possibilities have been examined. 
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5 . 
Final discussion, conclusions and Future work 
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The results obtained from the experimental work that comprised the present thesis lead 
to useful conclusions about the use of antibodies in the core of biosensors like the Life 
Marker Chip instrument. Among the critical areas of the development of the LMC is the 
acquisition of antibodies against high-priority signatures of Life and the use of 
antibodies that can resist inactivation due to the combination of conditions associated 
with a planetary exploration mission like ExoMars. The research that was carried out 
within the present project helped clarify some aspects of these issues, although it was 
generally concluded that there is no ―template‖, i.e. all antibodies tested do not behave 
identically, in the development and resistance behaviour of antibodies for the LMC; 
each potential target should be approached individually in order to obtain sensitive 
antibodies against it and each antibody‘s ability to remain active in extreme conditions 
should ideally be assessed prior to integration to the final instrument platform. 
  
5.1  Ground-based radiation studies 
Overall, the ground-based irradiations of antibodies at simulated radiation levels 
envisaged for the ExoMars mission to Mars, and also at much higher levels, have given 
valuable information and data input for the LMC development. It is apparent that the 
dominant effect on the loss of activity of five representative antibodies studied was the 
processing and packaging of the antibodies as freeze-dried preparations in glass fibre 
pads and their subsequent retrieval from the pads for use in ELISAs. The subsequent 
steps of international shipping of the samples to an irradiation facility and their 
irradiation typically contribute far less to the loss of antibody activity. Therefore, it is 
apparent that further studies of the freeze-drying, packaging and sample recovery 
process are required. Initial studies of varying the solutes co-freeze dried with the 
antibodies have displayed promise in improving the recovery efficiency. For the 
radiation effects, the important observation is that at a representative Mars mission 
dose, none of the antibodies studied exhibit any evidence of loss of activity due to the 
radiation. This therefore achieves a key de-risking step for the LMC instrument 
development process of demonstrating that the core antibody reagents will survived the 
radiation environment to be encountered on the ExoMars mission. Whilst this study de-
risks the use of antibody-based assays in the exploration of the Red Planet, the 
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noticeable loss of antibody activity at higher radiation levels (x250 Mars mission dose) 
does suggest that further shielding or alterative radiation protection approaches will 
need to be considered for some other astrobiology targets such as future Europa 
missions. 
 
5.2 Studies of the effect of space radiation in Low Earth Orbit (BIOPAN-6) 
The experiment that was designed in order to be part of the BIOPAN-6 platform on 
board the FOTON-M3 mission lead to a number of conclusions concerning the ability 
of antibodies to form components of an instrument on a planetary exploration mission. 
Using this mission in LEO as an analogue of a mission to another planet, a variety of 
factors that could have a detrimental effect on antibody functionality were examined, 
including sample preparation, principally the lyophilisation of the antibodies into glass 
fibre pads, ground handling of the samples, orbital flight and sample recovery. The 
analysis that took place at the end of the mission revealed that, aside from the effect that 
lyophilisation has on the ability of antibodies to recognise and bind to their respective 
targets, the effect of all physical conditions during the mission and exposure to LEO 
level of radiation are not destructive to these antibodies.   
Within the context of the development of the LMC, it is important to note that the 
radiation levels measured for the Foton M3 mission were considerably lower than the 
radiation levels envisaged for an actual mission to Mars; the radiation environment was 
also different (more heterogeneous) than the radiation used in the ground-based studies 
(composed exclusively of proton and neutron radiation). Nevertheless, the results from 
the BIOPAN-6 experiment agreed with the results of the ground-based experiments in 
that they showed that antibodies did not undergo inactivation due to exposure to 
radiation, even after exposure to a broad spectrum of radiation like the one expected in 
LEO. Additionally, the BIOPAN-6 results showed that the antibodies used in this 
experiment remained functional after exposure to the combination of physical factors 
associated with a space mission (launch and re-entry conditions), which is another 
encouraging step in their use within a planetary exploration mission context. 
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5.3 Development of recombinant antibodies for potential LMC targets via phage 
display technology 
The screening of the naive library for binders against phytane and β-carotane was 
composed of three panning rounds of increasing stringency, with unsatisfactory results 
for both targets. These results were not unexpected; the initial library size (10
7
 clones) 
and the fact that it had not been raised against our particular target mixture lowered the 
chances of success; additionally it was deemed that although the library had been raised 
against different but similar size molecules, there was no positive bias in the isolation of 
high-affinity clones against our own targets.  
The outcome of the screening of the naive library was an indication that, in the context 
of the development of the LMC instrument, with all the limitations in time and 
resources it involves, the use of naive libraries is not recommended. 
The immunised library which was used to generate antibodies against a mixture of LMC 
targets (including phytane from the beginning, with β-carotane being added at the final 
round of immunisation) was raised against synthesised conjugates of these hapten 
targets. In the course of three panning rounds using the conjugated forms of both targets 
(increasing the selection stringency by lowering the concentration of the coating 
antigen) and one additional round with free antigen elution, it became possible to isolate 
a phage subpopulation that were displaying antibodies against the conjugated forms of 
phytane and β-carotane. Both targets gave similar results, regardless of their structural 
differences. 
Although there is a need to advance this work by moving from the ―phage level‖ to a 
soluble single-chain antibody (scAb) level, it appears that the use of immunised libraries 
can lead to the isolation of antibodies against LMC-relevant targets and in the context of 
recombinant antibody development it should be preferred over the use of naive libraries. 
If the employment of immunised libraries results to the generation of sensitive 
antibodies against the first set of targets, the method will be expanded to produce 
antibodies against more LMC-relevant molecules. The information collected at every 
step of the design, planning and screening of the present library can lead to a next round 
of antibody development which will be more time- and resource-efficient. That said, the 
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need to approach every target (or set of similar targets) individually and modify the 
methods used accordingly will always be necessary.  Additionally, the ability to 
produce antibodies against a group of haptens as extensive as the potential targets for 
the LMC instrument is a step forward in anti-hapten antibody development that could 
prove to have applications outside the development of the LMC. 
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Abstract 
The Life Marker Chip instrument (LMC) is currently part of the payload on the European Space 
Agency‘s (ESA) ExoMars rover that is scheduled for launch in 2018. The LMC will use antibody-based 
assays to detect molecular signatures of life in the shallow subsurface of Mars. For all the antibodies at 
the heart of the LMC, the ability to resist inactivation due to space radiation will therefore be a 
prerequisite. The objective of the present work has been to expose a number of LMC-relevant antibodies 
to simulated Mars mission radiation in the form of proton and neutron radiation produced via a cyclotron 
source. The proton and neutron components of the mission radiation environment are those that are 
expected to have the dominant effect on the operation of the LMC. After irradiation, the antibodies were 
assessed for any loss of functionality. Modelling of the radiation environment for a mission to Mars led to 
the calculation of nominal mission fluences for proton radiation during the cruise phase of the mission (4 
x 10
10 
protons/cm
2
)
 
and neutron radiation during Martian surface operations (2 x 10
7
 neutrons/cm
2
). 
Various combinations and multiples of these values have been used to demonstrate the effects of radiation 
on antibody activity both at the actual radiation levels envisaged for the ExoMars mission and at much 
higher levels (10x and 250x the mission dose).  In total, five antibodies were freeze-dried in a variety of 
protective molecular matrices and were exposed to the various radiation conditions. After exposure, the 
antibodies‘ ability to bind to their respective antigens was assessed. At radiation levels equal to 1x times 
the mission dose, four antibodies out of the five maintained the majority of their binding activity, while at 
10x and even 250x times the mission dose, the same four out of five antibodies maintained considerable 
amounts of their binding activity. It was also observed that the preparation and treatment 
(lyophilisation/rehydration) of the antibody samples had a detrimental impact on their performance, an 
effect that could be significantly reduced with the use of appropriate protective matrices and handling 
protocols. These experiments indicate that the expected radiation environment of a Mars mission does not 
pose a significant risk to antibodies packaged in the form anticipated for the LMC instrument. 
Keywords 
Immunoassay, antibodies, space radiation, Life detection, lyophilisation, ExoMars, Mars 
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Abstract 
The Life Marker Chip (LMC) instrument is an antibody assay-based sensor which will attempt to detect 
molecular signatures of Life in the Martian subsurface as part of the payload onboard the ESA ExoMars 
mission, currently scheduled for launch in 2018. The molecular reagents at the core of the LMC have no 
heritage of interplanetary mission use, therefore the design of such an instrument must take into account a 
number of risk factors, among which the radiation environment that will be encountered en route to, and 
on the surface of, Mars is a key factor. In order to study the effects of space radiation on lyophilised 
immunoassay reagents, primarily antibodies, a number of ground-based and space studies were 
undertaken, the latter in the form of ESA‘s 2007 BIOPAN-6 Low-Earth Orbit (LEO) space exposure 
platform. Two representative LMC antibodies were used in these studies in the form of lyophilised 
samples integrated in glass fibre pads, loaded into a custom-made sample holder unit which was mounted 
on the BIOPAN-6 platform. The BIOPAN mission went into orbit for 12 days, after which all samples 
were recovered and their binding performance was measured via ELISA. The factors expected to affect 
antibody performance were the physical conditions of a space mission and the exposure to space 
conditions (i.e. the radiation environment in LEO). Both antibodies survived complete inactivation due to 
these factors. The data from the LMC on BIOPAN-6 experiment, in combination with data from ground-
based irradiations of LMC components, are being used to de-risk the development of the LMC 
instrument. 
Keywords 
Antibodies, BIOPAN, Life Detection, lyophilisation, space radiation 
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Abstract 
The Life Marker Chip (LMC) instrument is an antibody assay-based system which will attempt to detect 
molecular signatures of Life in the Martian subsurface as part of the payload on board the ExoMars 
mission rover. One of the key stages in the development of the LMC is the selection of molecules that can 
serve as signatures of Life and the acquisition of high affinity antibodies against them. Phage display 
technology offers the possibility to generate high affinity recombinant antibodies against small molecules 
with poor immunogenic potential (haptens) which constitute a number of important prospective LMC 
target molecules. In this work, a naïve and an immunised phage antibody library have been employed in 
the production of recombinant antibodies against theexample LMC molecular targets phytane and β-
carotane. The naïve library, which had been constructed for a non-related family of haptens, gave 
extremely poor results for both targets, as the panning did not result to the isolation of clones that could 
recognise either of the two molecules. The immunised library had been constructed using lymphocytes 
from sheep immunised with a mixture of LMC targets, and resulted to the identification of phage clones 
that appeared able to recognise target conjugated to a carrier protein, without presenting cross-reactivity 
with the carrier proteins alone. The present work is concluded at this point, but further analysis is required 
in order to determine whether these clones are able to recognise free hapten and proceed with the 
purification of soluble antibodies. The selection process involved in phage display allows isolation of 
antibody clones that maintain their functionality in a variety of non-standard conditions required by the 
LMC instrument. Therefore we consider phage display technology with the use of immunised libraries an 
appropriate method for obtaining antibodies for the LMC instrument. 
 
Keywords 
Phage display, hapten, antibody library, Life detection, Life Marker Chip, ExoMars  
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DETECTING MOLECULAR SIGNATURES OF LIFE
ON MARS: THE LIFE MARKER CHIP (LMC) INSTRUMENT
Derveni, M. and the LMC Consortium*
1. Instrument & Mission Introduction
• The Life Marker Chip (LMC) instrument has
been commissioned for the European Space
Agency’s (ESA) ExoMars Rover.
• ExoMars is currently an ESA-NASA
programme for Mars exploration and is due
to launch the ExoMars Rover in 2018.
• The LMC is being developed by a UK-led
international consortium.
• The ExoMars Rover contains a drill for
collection of samples from 2m below the
surface – depth at which increased
preservation of organic molecules is
anticipated.
2. Instrument Principles
• The LMC instrument is based on antibody-assay
detection of specific organic molecules.
• The organic molecules targeted for Life detection
by the LMC are based on an assumption of “Earth-
like” Life on Mars – extinct and/or extant.
• The LMC instrument design enables the
simultaneous detection of up to 25 molecular
targets in a sample; four samples can be analysed
each using an independent sample analysis
module (see Box 3).
• The LMC incorporates integrated liquid sample-
extraction and processing for dry Martian samples.
4. Target Selection
• The molecular targets for the
LMC have been chosen to
represent markers of extinct
Life, extant Life, abiotic
chemistry (i.e. of meteoritic
origin) and mission-borne
Earth contamination.
• Development priority is given
to markers of extinct life (e.g.
preservation products of cell
membranes), molecules of
meteoritic origin (e.g.
polyaromatic hydrocarbons)
and Earth contamination
indicators (e.g. specific micro-
organisms found in spacecraft
AIV facilities).
5. Technology Description & Current 
Status (early 2010)
• The LMC employs a combination of optical evanescent
waveguides, micro-fluidics, immuno-microarrays with
fluorescent labels and CCD detector readout.
• The immunoassay reagents are integrated into the LMC
in pre-dosed amounts, freeze-dried into glass-fibre pads.
• A core component of LMC development is the use of
phage display recombinant antibody technology in order
to acquire antibodies against target molecules –
especially immunogenically difficult targets in a resource-
efficient manner.
• The LMC hardware is currently in a breadboard phase of
development. The recombinant antibody development
for LMC targets is an on-going project, and testing of
Earth-analogue Martian samples has been initiated.
Single module of the LMC unit
3. Current  design 
of the LMC - comprising 
of 4 individual sample 
analysis modules
*The LMC Consortium lead UK investigators: Cranfield University – Prof. David C. Cullen, University of Leicester – Prof. Mark Sims, Imperial College of London – Prof. Mark Sephton
Poster presentation contact: m.derveni.s06@cranfield.ac.uk
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Appendix 1: Representative Molecular Targets for the Life Marker Chip 
Instrument  
(Document developed by David C. Cullen, from original document produced by 
Catherine Rix, September 2010) 
Appendix 1 shows a list of representative LC target molecules in their ―free target‖ 
format, their derivatised forms and their synthesised (or envisaged) conjugated forms.  
Assay Name/ 
target 
Free Target Target derivative Structure for Immunisation 
Hopane 
Hopanoid 
biomarkers, 
derived from 
components of 
microbial cell 
walls 
17β(H),21β(H)-Hopane 
(Sigma 07562) 
 
MW = 412.73 
H
O
OH
 
KLH
 
5β-sterane 
Generic 
stearanes, 
derived from 
eukaryote and 
prokaryote 
membranes 
5β-coprostane 
(Sigma C2005) 
 
MW = 372.67 
H
H H
O
OH
 
 
5α-sterane 
Generic 
steranes, 
derived from 
eukaryote and 
prokaryote 
membranes 
5α-cholestane 
(Sigma C8003) 
 
MW = 372.67 
TBD TBD 
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Porphyrin 
Generic 
porphyrins 
derived from 
chlorophylls 
Etioporphyrin I 
(dihydrogenbromide) 
(Aldrich 252417) 
N
CH
NH
CH
NH
CH
N
CH
CH3 CH2
CH3
CH3
CH2
CH3
CH3CH2
CH3
CH3
CH2
CH3
 
 
MW = 478.68 (for non 
bromide form) 
NH
N
N
NH
O
OH
 
 
Carotane 
Fossil 
carotenoids 
from 
pigments 
β,β-carotane 
(Chiron, 0654.40-500-IO) 
CH3 CH3
CH3
CH3 CH3
CH3
CH3 CH3CH3CH3
 
MW = 559.07 
 
O
CH3 CH3
CH3
CH3 CH3
C
O
O
OH
 
MW = 396.60 
O
CH3 CH3
CH3
CH3 CH3
C
O
NH
O
PROTEIN
 
EDC/NHS conjugation 
Generic 
isoprenoid 
Phytane 
Marker of 
exctinct Life 
Phytane 
(Fluka 80165) 
 
CH3
CH3
CH3 CH3 CH3 CH3
 
 
MW = 282.55 
Phytanic acid (mixture of 
isomers) 
(Sigma P4060) 
 
CH3
COOH
CH3 CH3 CH3 CH3
 
 
MW = 312.53 
CH3
C
CH3 CH3 CH3 CH3 O
NH
PROTEIN
 
 
EDC/NHS conjugation 
Squalane / 
Squalene 
Marker of 
exctinct Life 
Squalane 
(Aldrich 234311) 
 
CH3
CH3
CH3 CH3 CH3
CH3CH3CH3
 
MW = 422.81 
 
Squalene 
(Sigma S3626) 
CH3
CH3
CH3 CH3 CH3
CH3CH3CH3
 
 
MW = 410.72 
2,3-Oxidosqualene 
(Sigma 41043) 
 
CH3
CH3
CH3 CH3 CH3
CH3
CH3CH3
O
 
MW = 426.72 
 
2,3-Oxidosqualene 
(with C6 carboxyl spacer) 
 
NH
CH3 C
CH3 CH3 CH3
CH3CH3
OH
CH3
CH3
H
COOH
 
 
MW = 557.89 
 
NH
CH3 C
CH3 CH3 CH3
CH3CH3
OH
CH3
CH3
H
C
O
NH
PROTEIN
 
 
EDC/NHS conjugation 
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Generic 
straight 
chain alkane 
(Stearic acid) 
straight chain 
alkane 
derived from 
fatty acids 
Octadecane 
(Sigma 74691) 
CH3
CH3
 
MW = 254.49 
Stearic acid (Octadecanoic acid) 
(Sigma S4751) 
CH3
C
OH
O
 
MW = 284.48 
CH3
C
NH
O
PROTEIN  
 
EDC/NHS conjugation 
Benzo[a]pyren
e 
Meteoritic 
origin 
Benzo[a]pyrene 
(Sigma, B1760) 
 
H
H H
H
H
H H
H
H
H
H
H
 
 
MW = 252.31 
4-(Benzo[a]pyren-6-yl)butanoic 
acid 
 
H
H H
H
H
H
H
H
H
H
H
HOOC  
MW = 338.40 
H
H H
H
H
H
H
H
H
H
H
C
O
NH
PROTEIN   
 
EDC/NHS conjugation 
Pyrene 
Meteoritic 
origin 
Pyrene 
(Aldrich 571245) 
H
H H
H
H
H
H
H H
H
 
MW = 202.25 
TBD TBD 
Anthracene 
Meteoritic 
origin 
Anthracene 
(Aldrich 141062) 
 
H
H
H
H H
H H
H
H
H
 
 
MW = 178.23 
Anthracene 
(with C4 carboxyl spacer) 
H
H
H
H H
H H
H
H
COOH
 
 
MW = 264.32 
H
H
H
H H
H H
H
H
C
O NH
PROTEIN
  
 
EDC/NHS conjugation 
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Fluorene 
Meteoritic 
origin 
Fluorene 
(Aldrich 46880) 
 
H
H
H
HH
H
H
H
H H
 
 
MW = 166.22 
Fluorene 
(with C4 carboxyl spacer) 
 
H
H
H
H H
H
H
HH
COOH
 
 
MW = 252.31 
H
H
H
H H
H
H
H H
C
O
NH PROTEIN
 
 
EDC/NHS conjugation 
cAMP 
Adenosine 3′,5′-cyclic 
monophosphate 
(Sigma A9501) 
 
MW = 329.21 
TBD TBD 
D-α amino 
acids (D-
cysteine) 
D-cysteine 
(Aldrich 30095) 
C
NH2
SH
HHOOC
 
MW = 121.16 
D-cysteine 
(with C6 ?? terminated spacer) 
C
NH2
O
HHOOC SH
  
MW = ?? 
TBD 
L-α amino 
acids (L-
cysteine) 
L-cysteine 
(Sigma C7352) 
C
HOOC
SH
HNH2
 
MW = 121.16 
TBD TBD 
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Dipicolinic 
acid 
Marker of 
extant Life 
Dipicolinic acid 
(2,6-pyridinedicarboxylic 
acid) 
(Aldrich P63808) 
N
OH
O
H
H H
O
OH
 
MW = 167.12 
Dipicolinic acid 
(with C6 thiol terminated 
spacer)
N
OH
O
O
H H
O
OH
SH   
MW = 299.34 
N
OH
O
O
H H
O
OH
S
N
O
O
O
NH
PROTEIN   
 
Conjugation to Sulfo-SMCC 
treated protein 
Isoalloxazine 
(flavin) 
Marker of 
extant Life 
Isoalloxazine (Alloxazine) 
(Aldrich A28651) 
N
N
N
N
O
O
H
H
H
H
H
H
 
MW = 214.18 
TBD TBD 
Ubiquinone-1 
(quinones) 
Marker of 
extant Life 
Ubiquinone-1 
(Coenzyme Q1) 
(Chemical Book ref) 
O
O
O
O
CH3
CH3
CH2
CH3
CH3
CH3
H
 
MW = 250.29 
TBD TBD 
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Phycocyanobil
in 
(phycobilins) 
Marker of 
extant Life 
Phycocyanobilin 
 
NH
NH
O
CH3
CH3
HOOC
CH3
N
NH
O
CH3HOOC
CH3
CH3
 
 
MW = 586.68 
Phycocyanobilin 
(with C6 thiol terminated 
spacer) 
 
NH
NH
O
CH3
CH3
HOOC
CH3
N
NH
O
CH3
CH3
CH3
O
NH
SH
 
 
MW = 701.92 
NH
NHO
CH3
CH3
HOOC
CH3
N
NH
O
CH3
CH3
CH3
O
NH
S
N
O
O
O
NH PROTEIN
  
 
Conjugation to Sulfo-SMCC 
treated protein 
Scytonemin 
(melanoidins) 
Marker of 
extant Life 
Scytonemin 
(Santa Cruz Biotechnology 
sc-202337) 
O
N
OH
O
N
OH
 
MW = 544.56 
Scytonemin 
(with C6 carboxyl terminated 
spacer) 
O
N
OH
O
N
O
COOH
 
MW = 658.70 
O
N
OH
O
N
O
C
O
NH
PROTEIN
 
EDC/NHS conjugation 
Atrazine; 
positive 
control for 
inhibition 
assay within 
LMC; 
positive 
control for 
scAb 
production 
Atrazine 
(Sigma, 45330) 
NH N
NN
NH
Cl
CH3
CH3
CH3  
MW = 215.68 
 
(with C6 carboxyl spacer) 
 
NH N
NN
NH
Cl
CH3
CH3
COOH
 
 
MW = 301.77 
NH N
NN
NH
Cl
CH3
CH3
O
NH
PROTEIN
  
 
EDC/NHS conjugation 
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Fluorescein 
positive 
control for 
inhibition 
assay within 
LMC; 
positive 
control for 
scAb 
production 
Fluorescein 
(Fluka 28803) 
O OOH
COOH
 
MW = 332.30 (free acid) 
TBD TBD 
 
 
